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Abstract 
 
 
Osteoarthritis (OA) is a degenerative joint disease and is the leading cause of physical 
disability in industrialised nations. Cartilage has received the most attention in the study of OA 
due to articular chondrocytes acting as potential instigators of disease. These cells are 
responsible for the anabolic-catabolic balance required for matrix maintenance due to their 
ability to synthesise the structural components of the extra-cellular matrix along with matrix-
degrading proteases. In order to better understand the mechanism by which this balance is 
shifted in OA, it would be useful to investigate the roles of the genes that are expressed in 
these cells. One of the most powerful tools to do this would be an inducible and chondrocyte-
specific system that utilises a cartilage-specific promoter, such as the aggrecan promoter.  
 
Aggrecan, one of the major structural components of cartilage, is a large aggregating 
chondroitin sulphate proteoglycan. This PhD set out to further our understanding of the 
transcriptional regulatory mechanisms that govern the chondrocyte-specific expression of the 
gene. A series of constructs containing various combinations of non-coding aggrecan DNA 
(mostly upstream of the transcriptional start site and including the first untranslated exon) were 
used to generate transgenic mouse embryos and an adult line in which the cartilage-specific 
expression of the transgene indicated the presence of cis-regulatory elements. These studies 
have identified three putatively important regions. One serves as a basal/core promoter at and 
around the transcriptional start site (TSS) (containing what could possibly be a non-essential 
92bp sequence depending on the developmental stage of the mouse). Another located 10kb 
upstream of the TSS can serve as an enhancer, and finally another located within a 7kb region 
further upstream. One or more of these elements seem to respond to injury as indicated by 
increased promoter activity in the OA-induced knees of the adult line containing all three 
regulatory regions.  
 
Using a combination of our data alongside published work (Han and Lefebvre, 2008), a 
cartilage-specific Cre recombinase line was generated and tested for specificity and continual 
gene expression under the induction of OA. The work presented in this thesis can now be used 
to contribute to knowledge on the pathogenesis of OA.  
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Introduction 
 
1 Transcription 
 
1.1 Introduction to transcription 
 
The regulation of the spatio-temporal expression of genes in eukaryotes is central to processes 
such as development and differentiation, as well as homeostasis. Eukaryotic genes are 
complex and are organised within genomes that are in turn organised within compact 
nucleoprotein structures (chromatin). Studies over the past 35 years have indicated that 
different genes are regulated through several mechanisms, primarily transcription (Roeder, 
2003).  
 
Although approximately 9 years have passed since the human genome sequence was first 
mapped (Lander et al., 2001), much of the genome still remains unannotated. A mere 1.5% of 
the human genome is responsible for protein coding while 45% is composed of repetitive DNA, 
which are mainly remnants of retrotransposons accumulated over thousands of years of 
evolution. The remaining "50% of the human genome, which is made up of non-coding 
sequences that were previously referred to as ‘junk’ DNA, is now thought to contain key 
regulatory elements that are crucial for the execution of the elaborate expression programs in 
the multiple cell types of the human body (Heintzman and Ren, 2009). Therefore, it is the DNA 
sequences in and around specific gene promoters that provide the important information which 
controls the time, location and level at which specific genes are transcribed. This information is 
generally thought to consist of three parts and can also be referred to as cis-regulatory DNA 
sequences: the core/basal promoter; the region proximal to this promoter; and finally the more 
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distal regulatory elements such as enhancer sequences; silencer elements and insulators. It is 
now widely accepted that tissue specific transcriptional activation of genes requires three 
distinct categories of transcription factors (trans-acting factors) to interact and assemble at the 
cis-regulatory DNA sequences of these genes. The first of these factors to be purified and 
characterised both biochemically and genetically were the transcriptional activators/repressors 
(also called transacting/transcription factors). Next came the ‘basal factors’ or the ‘general 
transcription factors’ (GTFs) and finally, the ‘coactivators’ (Meisterernst et al., 1991) or 
‘mediators’ (Flanagan et al., 1991).  
 
The ‘basal’ or ‘core’ transcriptional apparatus, independent of activators and coactivators, is 
sufficient for recognition of and low levels of accurate transcription from, common core 
promoter elements in vitro (basal transcription) (Roeder, 1996). However, the general 
consensus has always been that although this ‘basal’ transcriptional apparatus is nearly 
universal in its role as a highly conserved ‘driver’, it is the sequence-specific transacting factors 
(activators and repressors) that serve as the master switches in turning transcription of specific 
genes on or off in a cell- and gene- specific manner. This notion has always been accepted 
due to the high conservation of the components of the ‘core machinery’ amongst all species 
from yeast to humans. Transacting factors, on the other hand, can show major differences 
from organism to organism and their expression reflects cell-to-cell variation. It is now known 
that this model is overly simplified and that members of the ‘core transcriptional apparatus’ also 
serve as ‘engines’ that drive cell-specific gene expression too (Kuras et al., 2000), (Xiao et al., 
2006), (Yan et al., 2005). 
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1.2 Components of the eukaryotic transcriptional apparatus 
 
1.2.1 RNA Polymerases – RNA polymerase II transcription cycle 
 
Eukaryotes use three functionally distinct classes of nuclear RNA polymerases (Roeder and 
Rutter, 1969): RNA polymerase I (which transcribes large ribosomal RNA genes); RNA 
polymerase II (which transcribes protein-coding and small structural RNA genes) as well as 
RNA polymerase III (which transcribes tRNA, 5SRNA and other small structural RNA genes) 
(Weinmann and Roeder, 1974). Each polymerase contains its own distinct composition of 
subunits (14, 12 and 17 subunits in RNA polymerase I, II and III respectively).  
 
Eukaryotic RNA polymerase II typically has 12 subunits (RPB1-RPB12) and is incapable of 
specific promoter recognition (Myer and Young, 1998). RNA polymerase II transcribes mRNA, 
but that is only its most basic role. While transcribing mRNA, it also scans for damaged DNA 
and modifies the surrounding chromatin. It also acts, through its largest subunit, as a platform 
for several necessary mRNA processing factors.  
 
The largest subunit of eukaryotic RNA polymerase II, RPB1, contains an unusual C-terminal 
domain (CTD) that is made up of repeats of the heptapeptide consensus sequence N-Tyr 1 -
Ser 2 –Pro 3 –Thr 4 –Ser 5 –Pro 6 –Ser7 –C, of which there are 52 copies in mammals 
(Corden et al., 1985). The amino-acids in these repeats are subject to reversible post-
translational modifications (phosphorylation, glycosylation and cis-trans isomerisation) 
(Phatnani and Greenleaf, 2006), (Meinhart et al., 2005). These modifications control many 
aspects of the functional state of pol II. These include the assembly of a multisubunit enzyme, 
its transportation to the nucleus, its localisation within subnuclear domains or onto DNA 
templates and finally, its ultimate destruction.  It is also worth noting that lysine residues in the 
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several non-consensus CTD repeats that are also found in mammals can be ubiquitinated in 
response to DNA damage (Somesh et al., 2005).  
 
This CTD serves as a scaffold for the recruitment and interaction of a large number of nuclear 
factors. This recruitment of transcription and processing factors throughout different stages of 
the transcription cycle is closely linked to the modification state of the CTD, in particular the 
position of the phosphorylated serines.  RNA polymerase II is recruited to the promoters of 
active genes in a hypo-phosphorylated state. However, studies have shown that it is 
phosphorylated by TFIIH-mediated phosphorylation at Ser5 (Ser 5P) when it passes through 
the 5’ end of a gene whereas Ser2 phosphorylation is prominent when the enzyme reaches the 
3’ end of a gene (Komarnitsky et al., 2000). These phosphorylated repeats help recruit and 
bind capping factors and 3’ processing factors to the 5’ end of newly transcribed RNA and the 
poly(A) sites at the 3’ end respectively (Ho and Shuman, 1999). When pol II is in the middle of 
a gene, both Ser2 and Ser5 are phosphorylated.  
 
Other interacting partners include the mediator complex (to regulate the initiation of 
transcription) as well as several histone methytransferases. Rather than carrying all these 
factors throughout the transcription cycle, the CTD interacts differently with each factor at the 
correct time. The biological role of CTD phosphorylation remains to be fully elucidated but It is 
now thought that different phosphorylation patterns throughout the 52 repeats including 
additional phosphorylation of Ser7 in some of the repeats may allow for gene-specific 
regulation through the dynamic modification of DNA templates and processing of nascent RNA 
transcripts (Chapman et al., 2007).  
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1.2.2 Cis-regulatory sequences 
 
1.2.2.1 Core/basal promoters 
 
The core promoter lies at the heart of transcription and can be widely diverse in its structure 
and function. There are two known modes of transcription initiation – focused and dispersed 
(Juven-Gershon et al., 2006a), (Juven-Gershon et al., 2006b). In focused initiation, 
transcription starts at a single nucleotide or within a narrow region of multiple nucleotides. 
However, in dispersed initiation, there are multiple weak start sites that are found over a wider 
region of about 50-100 nucleotides. In complex organisms such as humans, around 70% of 
genes have dispersed core promoters which are typically found in CpG islands (genomic 
regions that contain a high frequency of CpG sites). It is generally thought that focused 
promoters are linked to inducible genes whereas dispersed promoters, are used for 
constitutively expressed genes.  
 
The study of focused core promoters has led to the discovery of a set of common DNA 
sequence elements/patterns that are associated with these promoters. The most commonly 
known sequence motifs are the TATA box, BREu (upstream TFIIB recognition element), Inr 
(initiator), MTE (motif ten element), DPE (downstream promoter element), DCE (downstream 
core element), and XCPE1 (X core promoter element 1). These elements have unique 
qualities, which are linked to the expression of downstream genes. They can co-exist in the 
same promoter.  However, specific combinations are more common than others with some 
patterns being complementary to one another. For example, a TATA-dependent core promoter 
with TATA+Inr motifs has different properties than a DPE-dependent core promoter with 
Inr+DPE motifs. In contrast to this, TATA, BRE, DPE and MTE motifs are not associated with 
dispersed promoters (Sandelin et al., 2007), (Carninci et al., 2006). Therefore, it is likely that 
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there are important and fundamental differences in the mechanisms of transcription between 
focused and dispersed promoters. 
 
The following are examples of core promoter motifs involved in RNA polymerase II 
transcription: 
1- The TATA box is probably the best-known transcription factor binding site and the first to be 
discovered. It is associated with strong tissue-specific promoters and often co-exists with 
initiator (Inr)-like sequences at the transcriptional initiation site. Although it is a well-known core 
promoter motif, it is only present in approximately 10-15% of mammalian core promoters (Kim 
et al., 2005), (Cooper et al., 2006); 
2- The BRE element, (TFIIB recognition element) can either increase or decrease transcription 
rates in eukaryotes. Two separate recognition sites have been found: The BREu element, 
which lies upstream of a subset of TATA boxes and the BREd element, which lies immediately 
downstream of the TATA box. (Deng and Roberts, 2005); 
3-The Inr is possibly the most common core promoter motif and encompasses the transcription 
start site (TSS). Although the initiator element can co-exist and act synergistically with the 
TATA box, it is in fact independent of it. The TATA and Inr motifs are the only known core 
promoter motifs that can alone recruit the pre-initiation complex  (described in Introduction 
section 1.2.3.1) and initiate transcription (Smale and Baltimore, 1989); 
4-The DPE (downstream promoter element) typically lies downstream of the TSS/Inr in TATA-
less promoters of Drosophila melanogaster. It is thought to have a similar function to the TATA 
box in directing the pre-initiation complex to a nearby TSS. In some cases, however, the TATA, 
Inr and DPE motifs can be found in the same core promoter (Burke and Kadonaga, 1997), 
(Kutach and Kadonaga, 2000); 
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5- The MTE (motif ten element) is located immediately upstream of the DPE and like it, is 
conserved from Drosophila to humans. The MTE functions together with the Inr but can act 
independently of the DPE as well as the TATA box. However, there is synergy between the 
MTE and DPE as well as between the MTE and TATA box (Lim et al., 2004).  Figure 1 shows 
details including the locations and consensus sequences of all the above-mentioned 
functionally cis-regulatory motifs. 
 
Figure 1: Some core promoter motifs for transcription by RNA polymerase II. This 
diagram is roughly to scale. The motifs are presented as IUPAC consensus symbols: N, any 
nucleotide; R, A or G (purine); S, C or G; V, A or C or T; W, A or T; Y, C or T (pyrimidine).  
 
 
 
1.2.2.2 Distant regulatory elements 
 
The other classes of cis-regulatory elements that are more distal to the core/basal promoters of 
genes include enhancers, silencers and insulators. Whereas enhancers act to recruit a 
complex array of transcription factors with chromatin-modifying functionalities that facilitate 
gene transcription (Lee and Young, 2000), silencing elements  (silencers) bind proteins 
and/or modify chromatin structure to inhibit the transcription of genes (Ogbourne and Antalis, 
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1998). Insulators , can provide further regulation by restricting the spread of heterochromatin 
and impeding transcriptional enhancers from activating unrelated nearby promoters (West et 
al., 2002).  
1.2.2.2.1 Enhancers 
 
DNA exists in cell nuclei in a highly ordered compact form called chromatin (Felsenfeld and 
Groudine, 2003). The structural units of chromatin are nucleosomes, which are composed of 
146 base pairs of DNA wrapped around a single histone octamer composed of two histone 
H2A-H2B dimers and one H3-H4 histone tetramer (Luger et al., 1997). In order for transcription 
to occur, the transcriptional machinery much first overcome the negative effects that chromatin 
has on the expression of genes namely, the inability of protein-DNA interactions required for 
transcription to occur because of the compaction of DNA. One of the main roles of enhancer 
elements is to recruit transcription factors that promote the decondensation of repressed 
chromatin. Another is to facilitate the assembly of the transcriptional machinery at gene 
promoters (Maston et al., 2006). Enhancer sequences can contribute to a gene’s overall 
spatiotemporal pattern of expression in an additive fashion (Visel et al., 2009). An example of a 
gene that is controlled by multiple enhancer sequences with different specificities is the 
mammalian !-globin gene (Bender et al., 2001). 
 
One of the most common features of enhancers is that they are scattered across large non-
coding intervals (Nobrega et al., 2003). Some can also drive gene expression independently of 
their orientation (Alley et al., 1995). There are also exceptional cases of enhancers that can 
function at a distance of over 1 Mb upstream or downstream of their gene promoter target. An 
example of this is the Sonic hedgehog (Shh) gene whereby mutations in a conserved non-
coding region in the 5th intron of the Lmbr1 locus, which is 1 Mb away, can lead to mouse and 
human preaxial polydactyly with mirror-image digit duplications (Sagai et al., 2005). Enhancers 
can even be located within their target gene (intronic sequences) (Krebsbach et al., 1996).  
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Each enhancer can integrate and initiate regulatory prompts and is generally believed to have 
a binary on/off output.  Genes can be regulated in a cell-specific manner due to enhancers 
containing binding sites for specialised sets of transcription factors (TFs) (Introduction section 
1.2.3.2), which include activators and repressors.  Therefore, a gene is only activated, or 
indeed repressed, in cell types where these factors reside. TFs bind to short regulatory 
consensus sequences (Stormo, 2000), which usually contain specified positions (base pairs) 
that are highly discriminative and some which are more dispensable.  
 
Although the main function of enhancers as binding platforms for transcription factors is widely 
accepted, the details of their structural necessities are less known.  Two models exist which 
embody two extremes of structural necessities: The first is that of the enhanceosome 
model. This model is based on the interferon-! enhancer, which functions as a specific 
assembly platform for precise protein complexes with rigid requirements on binding-site 
composition, order, orientation and spacing (Merika and Thanos, 2001).  Given all these 
qualities, enhanceosomes would display near-perfect conservation across their entire lengths 
amongst different species, which as discussed in Introduction section 1.4, isn’t always true for 
cis-regulatory sequences. The second model is that of the billboard enhancer . This type 
of enhancer can integrate regulatory output from individual trans-factors which can be bound in 
any order, orientation and spacing. As long as the sum of activating and repressing inputs 
remains constant, the individual factors could change. In reality, enhancers lie in between 
these two extremes.  
1.2.2.2.2 Silencers 
Silencers generally share most of the properties that are ascribed to enhancers. They are 
sequence-specific elements that confer a negative effect on the transcription of a gene. Most 
silencers can function independently of orientation and distance from the core promoter 
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sequence.   However, some have been identified to have position-dependence. In terms of 
their location, they can be within a proximal promoter, as part of a distal enhancer or as an 
independent distal regulatory module (situated upstream of the TSS, in an intron or in a 3’ 
untranslated region of a gene). They can act synergistically and cooperate in binding to DNA.  
 
In contrast to enhancers, which act as binding sites for activators, silencers are binding sites 
for the negative transcription factors called repressors. Repressor function may, in some 
cases, require the recruitment of negative cofactors (Introduction section 1.2.3.3) called 
corepressors. There are a number of models that have been suggested for repressor function. 
In the first model, repressors may function by blocking the binding of a neighboring activator or 
by directly competing for the same site. In the second model, a repressor may inhibit activators 
and/or general transcription factors (Introduction section 1.2.3.1) from accessing a promoter 
through the establishment of a repressive chromatin structure by the recruitment of histone 
modifying activities or chromatin-stabilizing factors. Finally, in the third model, a repressor may 
block transcriptional activation by preventing the assembly of the preinitiation complex 
(Introduction section 1.2.3.1) (Maston et al., 2006).  
1.2.2.2.3 Insulators/boundary elements 
The main function of an insulator is to block genes from being affected by the transcriptional 
activity of nearby genes. In this way, insulators can limit the action of transcriptional regulatory 
elements to defined regions and divide the genome into individual domains of expression. 
Insulators are typically approximately 0.5kb – 3kb in length and function in a position-
dependent, orientation-independent manner. They have two main characteristics: their ability 
to block enhancer-promoter communication, and their ability to stop the spread of repressive 
chromatin by acting as heterochromatin barriers. For some insulators, these characteristics 
can be separable (Recillas-Targa et al., 2002), (Maston et al., 2006).  
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The globin genes of vertaebrates are found clustered within the genome. Mapping studies in 
erythroid cells have defined an open chromatin domain that contains the entire cluster. Within 
this domain, there are globin enhancers that temporally regulate these genes without affecting 
the expression of independently regulated genes flanking the globin domain. At the 5’ end of 
the chicken globin domain is a folate receptor gene and its regulatory elements (HAS). 
Downstream of the globin cluster are the olfactory receptor genes (OR). The folate receptor 
genes are active when the globin genes are repressed and inactive when the globin genes 
become active during erythropoiesis. The OR genes, on the other hand, are not expressed in 
erythroid cells. Insulator elements are able to achieve this differential expression amongst the 
different genes within the cluster. The hypersensitive sites (5’HS4 and 3’HS1), which flank the 
active chicken globin domain, were proposed as candidate insulators due to their proximity 
between the differentially regulated promoters and regulatory elements. An element that 
resides within the human !-globin gene locus (Li et al., 1999a) is homologous to the chicken !-
globin insulator, 5’HS4, which is the most well characterised insulator element in vertebrates. 
Molecular analyses of the 5’HS4 insulator in transgenic assays indicated that it is proficient in 
enhancer blocking as well as in protection against position effects (Valenzuela and Kamakaka, 
2006).  
1.2.2.3 Locus control regions (LCRS) 
 
Other than basal/core promoter regions and the distal cis-regulatory elements described 
above, there are also locus control regions  that facilitate the activation of a cluster of 
genes. Locus control regions (LCRs) are groups of regulatory elements that can organise an 
entire locus or gene cluster and are operationally defined as elements that direct tissue-
specific, physiological expression of a linked trans-regulated gene. They work in a position-
independent and copy-number-dependent manner. LCRs typically consist of multiple cis-acting 
elements (such as enhancers, silencers, insulators and nuclear-matrix or chromosome 
scaffold-attachement regions (MARs or SARs)) that are bound by transcription factors (tissue-
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specific as well as ubiquitous), coactivators, repressors and/or chromatin modifiers. Although 
each of these components differentially affects the expression of a gene, it is their collective 
activity that functionally determines an LCR and dictates appropriate spatial/temporal gene 
expression. The most prominent characteristic of an LCR is its strong, specific enhancer 
activity. They frequently feature a cluster of nearby DNase I hypersensitive sites and are 
thought to provide an open chromatin domain for genes with which they are associated (Li et 
al., 2002).  
 
LCRs have been identified in a broad spectrum of mammalian loci. The first and most-studied 
LCR to date is the mammalian !-globin LCR (Chakalova et al., 2005). The human !-globin 
locus has five genes that are differentially expressed throughout development, and are 
organised in order of their developmental expression.  The !-globin LCR is located 
approximately 6-25kb upstream of the cluster of genes within the !-globin locus and drives 
high-level, erythrocyte lineage-specific expression of these genes. The activity of this LCR is 
orientation-dependent since inverting it destroys much of its function (Tanimoto et al., 1999).  
 
1.2.3  Trans-regulatory molecules 
1.2.3.1 General transcription factors (GTFs) 
The transcription of a gene by the enzyme RNA polymerase II (pol II) requires the assembly of 
a core promoter along with a group of GTFs into a complex called the preinitiation complex 
(PIC) (Buratowski et al., 1989). On its own, RNA polymerase II is unable to recognise target 
promoters and so needs these general factors to achieve this function. Each of the GTFs bring 
specific functions to the transcription complex and have been broadly characterised (Thomas 
and Chiang, 2006).  
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TFIID is a TF, which is composed of TATA-binding protein (TBP) in a complex with at least 10 
other TBP-associated factors (TAFs).  It plays a significant role in the recognition of promoters 
and binds to specific DNA elements that can be found within the core promoter such as the 
TATA box, the DPE, the Inr and the MTE motifs. It does this with the help of TBP and TAFs 
(Chen and Hampsey, 2002), (Juven-Gershon and Kadonaga).  Although TFIIA is not essential 
for the formation of the PIC, it can help stabilize the TFIID-promoter complex. TFIIB can bind 
the TFIID-promoter complex by DNA recognition as well as direct interaction with TFIID. Along 
with other factors such as mediator, it supports the stable binding of TBP to the TATA-box of 
an activated gene (Li et al., 1999b), (Kuras and Struhl, 1999). It is essential for the assembly of 
the PIC since it is needed for promoter recognition, the selection of the TSS as well as the 
recruitment of pol II. Pol II, in turn, enters the PIC pre-bound to TFIIF, which prevents its non-
specific binding to DNA. It does this by serving as an early ‘checkpoint’ for correct PIC 
assembly by the recognition of a correct TFIID-TFIIA-TFIIB complex at the TATA box. TFIIF 
interacts with the assembled TFIID-TFIIA-TFIIB complex through TFIIB. After all the above-
mentioned components of the PIC have bound, TFIIE and TFIIH enter and complete this 
complex. Structural experiments that were performed on pol II revealed the presence of a 
flexible ‘jaw’ which closes around the DNA when the enzyme is associated with DNA at an 
active promoter (Cramer et al., 2001),(Gnatt et al., 2001). TFIIE appears to bind directly to pol 
II at the position of this ‘jaw’ suggesting that it is involved in regulating its opening and closing 
(Leuther et al., 1996). TFIIH, on the other hand, is responsible for the phosphorylation of Ser 5 
on the CTD of pol II. Due to the complex array of protein-DNA and protein-protein interactions, 
the PIC is a very stable structure (Figure 2). 
 
It has been suggested that the assembly of the PIC possibly occurs in a single concerted 
recruitment event, which brings to the promoter a large preassembled ‘pol II holoenzyme’ 
consisting of the enzyme bound to the mediator complex as well as most, if not all, the GTFs. 
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However, previous in vivo and in vitro evidence have shown that the GTFs (such as TFIID, 
TFIIA and TFIIB) (Zawel et al., 1995) and the mediator complex (Svejstrup et al., 1997) 
actually stay behind at the promoter as pol II is engaging in transcript elongation. This would 
allow for the fast entry of new polymerases for re-initiation of the transcription of the gene. If 
the holoenzyme recruitment model were to hold true, it would be necessary to postulate 
different forms of the enzyme for ‘first time’ and ‘ongoing’ transcription of a gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Mechanism of preinitiation complex assembly. The promoter DNA (straight black 
line) is shown with a TATA sequence upstream of the TSS (arrow). TFIID binds to the TATA 
element, followed by TFIIB. TFIIF and RNA polymerase II enter the complex together. The C-
terminal domain (CTD) of RNA polymerase II (wavy line) binds to the mediator complex (Med) 
at this stage. TFIIE and TFIIH complete the complex. 
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1.2.3.2 Transcription factors 
 
The recognition of DNA response elements by transcription factors is a key step in 
transcription (Georges et al.). The response elements can be present within the core promoter 
near the TSS, in a stretch of regulatory DNA several base pairs away or within an 
enhancer/silencer sequence (Gondor and Ohlsson, 2009). Transcription factors are part of a 
large group of easily identifiable gene regulatory proteins and represent between 5 and 10 
percent of the coding capacity of human genomes. The relative ease with which these proteins 
can be characterised comes from early experiments, which delineated their modular structural 
architecture consisting of well-defined functional motifs. These include DNA binding, activation, 
oligomerization and regulatory domains (Babu et al., 2004). One primary function of the 
regulatory domain is to recruit cofactors (discussed in Introduction section 1.2.3.3) that carry 
chromatin-remodelling activities or can directly interact with pol II transcriptional machinery 
(Ptashne and Gann, 1997). 
 
The classification of TFs is based on a common structural framework of the DNA binding 
domain (Narlikar and Hartemink, 2006). They are organised hierarchically and the main types 
include homeodomain TFs, POU TFs, basic helix-loop-helix TFs, leucine zipper TFs, zinc 
finger TFs, nuclear hormone receptor TFs and finally HMG box-containing TFs. The 
Arabidopsis transcription factor database (AtTFDB, http://arabidopsis.med.ohio-
state.edu/AtTFDB/) lists 41 families. Each family consists of paralogous genes that encode 
structurally and functionally similar TFs that can recognize the same, or very similar, 
consensus DNA target sequences (Georges et al.). 
 
The organization of TFs can often occur in a dimeric or tetrameric manner, and because each 
of the monomers binds to similar sequences, the DNA response elements in general consist of 
two half-sites.  Although the half sites of a particular TF typically show high sequence similarity, 
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they can in fact have different sequences as well as different organization and spacers 
between them and can vary in their distances from TSS. It can thus be unclear what 
constitutes a specific TF target sequence. Examples of these TFs include the p53 (Menendez 
et al., 2009) and nuclear hormone receptor (Sandelin and Wasserman, 2005).  
 
The earliest transcription factors- for genes transcribed by pol II- to be identified were those 
that acted through core promoter-specific DNA response elements. These included Sp1 
(Dynan and Tjian, 1983), HSF (Parker and Topol, 1984) and USF (Sawadogo et al., 1988).  
Coupled with earlier experiments performed on the glucocorticoid receptor (Payvar et al., 
1981) as well as others performed in 1985 on genetically identified yeast regulatory factors, 
these studies provided strong evidence for factors that regulate the activity of pol II by binding 
and interacting with distal DNA control elements. The original in vitro mechanistic experiments 
implicated TFIID as an assumptive target for activators (Sawadogo and Roeder, 1985).  
 
1.2.3.3 Transcription co-factors 
Although the general transcription apparatus is structurally very complex and transcriptional 
activators have tissue and DNA binding site specificity, other factors are required for the 
transcriptional machinery to be functionally active in vivo. These factors are defined as those 
that are required for the function of DNA-binding activators and not for basal transcription per 
se and do not show any independent site-specific binding. They have been named the 
‘coactivators’ and are essential for ‘activator’ function. The coactivators fall into several 
nonmutually exclusive groups: 1- The factors intimately associated with the general 
transcriptional machinery, including the TFIIA, TAF components of TFIID, the SRB/MED 
components associated with RNA polymerase II, related complexes that catalyze nucleosomal 
histone acetylation, the SWI/SNF complex and related chromatin-remodeling complexes. 2- 
the general cofactors derived from the USA (upstream stimulatory activity) fraction in human 
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cells. In the early nineties, a crude fraction was isolated from human tissue that strongly 
enhanced stimulation of transcription by activators such as the E box-binding protein USF and 
the GC box-binding protein Spl in a purified transcription system. This co-factor fraction was 
termed USA and has been broken down into negative cofactors (termed NCs) as well as 
positive cofactors (termed PCs). Both act in concordance to selectively repress basal 
transcription while enabling activator-dependent transcription. 3- the factors that are either 
gene or cell type specific whose primary interactions are with DNA-bound activators, such as 
the B cell-specific OCA-B, the more pleiotropic CBP and p300 and nuclear hormone receptor-
interacting factors (Roeder, 1998), (Kaiser and Meisterernst, 1996), (Hampsey, 1998). Some of 
the above factors in Introduction sections 1.2.3.3.1, 1.2.3.3.2 and 1.2.3.3.3. 
1.2.3.3.1 The SRB/Mediator complex 
The most significant of the above-mentioned co-activators is the ‘mediator’ or SRB/mediator 
complex. The human mediator is a counterpart of the yeast mediator with which it has strong 
conservation structurally and functionally. Human mediator was first discovered through a 
stable intracellular thyroid hormone-dependent association with thyroid hormone receptor (TR). 
This approximately 25-subunit complex (which was named TRAP TR-associated protein) was 
experimentally shown to be necessary for TR-dependent transcription from DNA templates by 
pol II and GTFs (Fondell et al., 1996). Subsequently, a number of site-specific DNA-binding 
regulatory factors have been shown to function through direct interactions with distinct 
Mediator subunits (encoded by Srb and Med genes) and the large complex is seen as a 
multivalent control panel, which has been proven to be the main passage for communication 
and interaction between the general transcriptional machinery (including Pol II and the GTFs) 
and the DNA-bound activators/repressors (Malik and Roeder, 2000).  
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1.2.3.3.2 Chromatin-Remodelling Complexes 
Another group of cofactors are those that act through modifications of chromatin structure. 
Other than the DNA packaging functions of nucleosomal and higher order chromatin 
structures, there are other functions that are linked to gene regulation.  These include imposing 
a barrier to the general transcription machinery that otherwise exhibits intrinsic potential to 
transcribe histone-free DNA templates through interactions at core promoters (reviewed in 
(Clapier and Cairns, 2009)). They were discovered through earlier studies in which purified pol 
II and GTFs couldn’t interact with DNA templates that had assembled into chromatin, whereas 
the complete formation of a PIC or a TFIID-promoter complex prior to chromatin assembly 
actually enabled and facilitated subsequent transcription initiation (Workman and Roeder, 
1987), (Lorch et al., 1987).  Furthermore, histone depletion experiments that were performed in 
yeast confirmed a general repressive function for histones and demonstrated that some factors 
act mainly to overcome this repression, whereas others bring about a level of activation 
beyond that seen by histone depletion (anti-repression plus net activation) (Han and Grunstein, 
1988). The SWI/SNF complexes are one class of cofactor proteins that modify the chromatin 
structure non-covalently in an ATP-dependent fashion. Once recruited to enhancer elements, 
these proteins can reposition specific nucleosomes along the DNA which enables core 
promoters to be exposed (Kingston and Narlikar, 1999). 
1.2.3.3.3 Chromatin modifying enzymes 
Another class of cofactors remodels chromatin structure by introducing covalent modifications 
to the N-terminal tails of histones. It is now known that a wide variety of modifications that 
occur on the N-terminal tails of histones are coupled with, and presumably effect specific gene 
activations and repressions. These include acetylation, deacetylation, methylation, 
phosphorylation and ubiquitylation and are brought about by acetyltransferase, deacetylase, 
methyltransferase, phosphorylase and ubiquitin enzymes respectively. For example, the 
enzyme histone acetyltransferase (HAT) transfers an acetyl group onto specific lysine amino 
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acids on the histone tails. This addition diminishes the positive charge of the histone, which 
leads to the loosening and weakening of the electrostatic bonds between it and the DNA 
around it, opening the chromatin and enabling the transcriptional machinery to access 
regulatory sites. A number of HATs have been identified that catalyze the acetylation of 
histones at specific residues. The protein complexes that catalyze histone acetylation include 
PCAF, CBP, p300, GCN5, TR-RAP complex and others (Rosenfeld et al., 2006).  The 
functional antagonist of HATs are the histone deacetylases (HDACs), which in contrast, 
remove acetyl groups and prevent further acetylation, thus maintaining a closed chromatin 
structure (Strahl and Allis, 2000), (Lachner and Jenuwein, 2002), (Berger, 2002), (Vaquero et 
al., 2003). 
 
 It is important to note that a second level of regulation occurs not on the histone proteins, but 
rather directly on the DNA. The methylation of DNA, which is indeed the classic epigenetic 
alteration, involves the addition of a methyl group (CH3) onto the cytosine residues of DNA 
(Bird, 1986). This event is associated with the silencing of transcription. This inhibitory effect 
works in two ways. First, densely methylated DNA can interrupt transcription factor binding 
which automatically silences expression. The second way is a little less direct and more 
suitable to regions with more dynamic changes in gene expression. The presence of methyl 
groups on selected cytosine residues attracts a class of proteins known as methylated-DNA 
binding proteins, which can further go on to attract an entire cluster of proteins that form a 
repressor complex (HDACs present in this complex) (Bird, 2002), (Klose and Bird, 2006). 
 
Figure 3 illustrates the interactions that occur between the cis-regulatory and trans-regulatory 
elements discussed above in order to achieve efficient activation of a gene.  
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Figure 3: Eukaryotic transcription factors and activation mechanisms. The ultimate 
purpose of DNA-binding activators is to mediate Pol II recruitment and function. The effects of 
these activators on Pol II are mostly indirect and involve several interactions with diverse 
cofactors that modify chromatin structure and ease the recruitment of Pol II and general 
initiation factors. Chromatin remodelling and modifying factors including ATP-dependent 
factors, HATs and HMTs are shown in orange. Cofactors that act at the level of DNA are 
shown in shaded blue and include the Mediator, general positive cofactors such as PC3 and 
PC4, cell specific factors (X) such as OCA-B and OCA-S. The negative cofactor such as TBP-
interacting NC2 is shown in pink.  
 
1.3 The transcription cycle  
 
The synthesis of eukaryotic RNA proceeds through multiple stages. These include the 
assembly of the pre-initiation  complex, initiation , promoter clearance , elongation 
and finally termination of transcription. The pre-initiation  of transcription starts with a 
transcriptional activator recruiting co-factors that serve as nucleosome remodellers (such as 
the SWI/SNF complexes) as well as those that act as nucleosome-modifying enzymes (such 
as HATs) to the nucleosomes of promoters of genes to be transcribed. This allows GTFs and 
Pol II to access the promoter (Fuda et al., 2009). Approximately 11-15 base pairs around the 
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TSS are unwound to form an ‘open complex’ that allows the single-stranded DNA template to 
eventually enter the active site of Pol II (Cramer, 2004). 
 
During the initiation  phase of transcription, a second activator binds to the promoter, 
interacts with and encourages the binding of the GTFs (such as TBP, TFIID, TFIIA and TFIIB), 
which eventually leads to the assembly of the PIC and recruitment of hypophosphorylated Pol 
II. It also recruits other co-activators such as the mediator, which can interact with the GTFs 
and increase expression levels (Kim et al., 1994). The DNA template is aligned in the active 
site of Pol II where nucleotides are paired with the template and are joined progressively to 
form the RNA transcript. The first "8-15 nucleotides of RNA are formed within the pol II-
promoter complex as, at this point, the transcription complex is functionally unstable and pol II 
requires the active participation of auxiliary TFs. However, once these initial bonds have 
formed, pol II can escape the promoter (‘promoter escape’) and form an early pol II-DNA 
transcription elongation complex from which all the GTFs rapidly dissociate (Pokholok et al., 
2002). As opposed to ‘promoter escape’, ‘promoter clearance’ , which describes the 
availability of the promoter for binding of a new preinitiation complex, requires the physical exit 
of the enzyme and usually only occurs once the catalytic site has reached at least 60 base 
pairs downstream of the TSS. Only a fraction of initiation events lead to promoter 
escape/clearance, as there is often a tendency to release the transcribed RNA and produce 
truncated RNA transcripts since the polymerase is not yet committed to transcript elongation. 
This is called abortive initiation and commonly occurs in eukaryotes. Promoter clearance 
coincides with the phosphorylation of Ser 5 on the CTD of Pol II by TFIIH (Goldman et al., 
2009), (Dvir, 2002). Like most of the remaining stages of transcription, promoter 
escape/clearance is an energy-dependent process that requires the consumption of adenosine 
triphosphate (ATP). 
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Following promoter escape, the RNA transcript continues to be stably bound in the 
transcription complex, but there are still instabilities that are associated with the newly formed 
early elongation complex (EEC) that differentiate it from a fully mature elongation complex. 
The tendency for transcript slippage persists until it reaches approximately 23 nucleotides in 
length. So the EEC undergoes continued adjustments- often accompanied by transcriptional 
pausing near the promoter- before becoming a fully productive elongation complex.  Promoter-
proximal pausing occurs when Pol II pauses in the 5’ region of the transcription unit and only 
progresses efficiently into productive elongation upon stimulation by appropriate signals. This 
pausing is thought to function as a regulatory checkpoint that takes place before the EEC 
commits to productive elongation (Lis, 1998). DSIF (DRB sensitivity inducing factor (consisting 
of the elongation factors Spt4 and Spt5)) and NELF (Negative elongation factor) are negative 
factors that are thought to cooperate to repress transcription elongation and promote proximal 
pausing. Several other factors are required for the release of paused Pol II into productive 
elongation, after which Pol II continues through the rest of the gene. It is thought that the 
positive transcription-elongation complex (P-TEFb) phosphorylates DISF, NELF and Ser 2 of 
the pol II CTD, which in turn relieves the paused polymerase of the negative effects of 
hypophosphorylated DISF and NELF (Peterlin and Price, 2006). As pol II travels through the 
coding region, numerous factors (e.g FACT, Spt4, Paf1,TREX complexes, Spt6 and Swi/Snf) 
journey with it (Sims et al., 2004). FACT and Spt6 have been linked with histone disassembly 
and reassembly. FACT facilitates the displacement of H2A-H2B dimers throughout in vitro 
transcription and so promotes Pol II elongation through chromatin (Belotserkovskaya et al., 
2003). Spt6, on the other hand, can interact physically with histones in vitro (particularly H3 
and H4) and has histone chaperone activity (Bortvin and Winston, 1996). They both, however, 
are important for the elimination of false transcription initiation within the coding regions of the 
gene by promoting reassembly of histones. Paf1 might provide a platform for the association of 
complexes that modulate the structure of chromatin (Adelman et al., 2006). The multi-subunit 
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TREX complex is thought to ease transcription elongation by restricting the unsuitable pairing 
of the nascent RNA with the DNA template (Huertas and Aguilera, 2003). The Swi/Snf complex 
continues to remodel the chromatin of transcribed gene throughout elongation. 
 
CTD phosphorylation appears to play a crucial role in pairing Pol II elongation to post-
transcriptional steps such as mRNA capping, splicing, polyadenylation, export and chromatin 
modifications such as histone methylation. These processes are extremely important since the 
production of a mature messenger RNA (mRNA) involves the three main RNA processing 
events splicing, capping and polyadenylation. The process of splicing removes the non-coding 
introns from the transcribed RNA. Different protein isoforms can be translated by the selective 
inclusion of different coding sequences (called alternative splicing).  The process of capping 
requires the addition of a methylated guanosine to the 5’ end of the RNA through an 
unconvensional 5’ to 5’ triphosphate linkage. This usually occurs during transcription of the first 
40 nucleotides (Rasmussen and Lis, 1993). Polyadenylation, on the other hand, requires the 
addition of a string of adenines to the 3’ end of the RNA molecule subsequent to the cleavage 
of the transcript. The processes of capping and polyadenylation enhance the stability of the 
newly formed transcript.  
 
Cleavage and polyadenylation are referred to as the 3’ processing events and take place after 
the transcription of the poly(A) site at the 3’ end of a gene. The cleavage of the transcript 
coincides with the completion or termination of transcription. The termination of transcription 
involves the dissociation of the Pol II transcription complex from the DNA template. There are 
two models that have been proposed. They are not entirely mutually exclusive. The first is the 
allosteric model, which requires a conformational change to take place in the polymerase 
following transcription of the poly(A) sequence. This, in turn, makes the enzyme accessible to 
termination. PCF11 is a protein factor that has been found to trigger the break down of the Pol 
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II transcription complex in a CTD-dependent manner (Zhang and Gilmour, 2006). The second 
is the torpedo model, in which a 5’ to 3’ RNA exonuclease degrades any RNA that is still 
associated with Pol II following the cleavage and release of the RNA transcript. This leads to 
the termination of Pol II that has already served its purpose. In support of this model, there are 
certain genes in yeast and humans (Rat1 in yeast and XRN2 in humans) whereby their 
termination is dependent on a 5’ to 3’ exonuclease. Figure 4 illustrates the cycle of 
transcription.  
 
1.4 The evolution of transcriptional control across eukaryotic 
species 
Recently, the comparison of RNA expression levels between closely and distantly related 
vertebrate species has demonstrated tissue-specific conservation of gene expression. A recent 
study compared gene expression levels of over 3000 unambiguous gene orthologs from 10 
functionally equivalent vertebrate tissues of pufferfish, frog, chicken, mouse, and human  
(Chan et al., 2009). The profiles were more comparable and alike amongst homologous 
tissues of different species than amongst tissues of the same species.   
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Figure 4: Multistages of the transcription cycle . Step 1: chromatin opening. The 
repressed gene and regulatory region to be transcribed are entirely packaged as nucleosomes 
(green). An activator (orange oval) binds and recruits nucleosome remodellers (HATs/Swi/Snf 
complex) to clear the promoter. Step 2: PIC formation. A second activator (yellow diamond) 
binds, promotes the binding of GTFs (blue rectangle) and recruits more coactivators such as 
the mediator (green hexagon), facilitating Pol II (red rocket) entry to the PIC. Step 3: initiation. 
DNA is unwound (oval inside Pol II) at the TSS, which leads to the formation of an open 
complex. Step 4: promoter escape/clearance. Pol II breaks contacts with promoter-bound 
factors, transcribes approximately 25 base pairs downstream of the TSS, produces an RNA 
(purple line) and pauses, partially mediated by DSIF (Spt4 +Spt5) (pink pentagon) and 
negative elongation factor (NELF) complex (purple circle). The Ser residues at position 5 (Ser 
5) of the Pol II CTD repeats are phosphorylated (red P) during this step. Step 5: escape from 
pausing. P-TEFb (blue triangle) is recruited directly or indirectly by the activator and 
phosphorylates Ser 2 of the Pol II CTD repeats, SPT5 and the NELF subunits (blue Ps). NELF 
dissociates from the rest of the complex. Pol II escapes from the pause, either terminating or 
entering productive elongation. Step 6: productive elongation. Nucleosomes are disassembled 
and reassembled as the Pol II elongation complex transcribes through the gene due to the 
factors present within the elongation complex. Step 7: termination. After the Pol II complex 
transcribes the gene, it is removed from the DNA, and the RNA is released. Step 8: termination 
of Pol II by the allosteric or torpedo model or both. Taken from (Fuda et al., 2009). 
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It is important to note that although there is high conservation of gene expression across 
different species, this does not necessarily correlate with the amount of nearby conserved non-
exonic DNA. This underlines that tissue-specific expression patterns can be maintained in spite 
of wide sequence divergence in regulatory DNA (Fisher et al., 2006). In contrast to this, many 
powerful comparative computational approaches have used the fact that sequence constraint 
can correlate with experimentally validated regulatory regions in DNA in order to predict these 
regions (Wasserman and Sandelin, 2004). Ultraconserved (perfect sequence identity of at 
least 200bp) or extremely conserved elements in human vs pufferfish comparisons were 
shown to be sufficient to identify putative gene regulatory elements (Pennacchio et al., 2006). 
 
The controversy over conservation versus divergence of regulatory sequences could possibly 
be explained by the relevance that these sequences have to selectivity. Many of the cis-
regulatory elements detected by ChIP might be functional or biochemically active yet 
selectively neutral (do not confer a selective advantage or disadvantage to the organism) and 
thus lack evolutionary conservation. Relevant elements can possibly be identifiable due to their 
evolutionary conservation (Birney et al., 2007). 
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2 Skeletal development 
 
2.1 Introduction to skeletal development 
The vertebrate skeleton is a complex organ with more than 200 bones. There has been 
considerable progress in the genetic and molecular understanding of all aspects of skeletal 
development over the last 10-20 years. One of the main characteristics of the skeleton is that it 
is an organ made of two distinct types of tissue, cartilage and bone. The main cell types in 
bone are osteoblasts and osteoclasts whereas in cartilage, it is chondrocytes. Chondrocytes 
and osteoblasts are both of mesenchymal origin and share a common progenitor while 
osteoclasts are of haematopoietic origin (Ducy et al., 1997), (Karsenty, 2008). 
 
The formation of bone can be seen as the endpoint in skeletal development. The process is 
started with mesenchymal cells from three distinct embryonic lineages: The craniofacial 
skeleton is the product of cranial neural crest cells, the axial skeleton is derived from the 
paraxial mesoderm (somites) while lateral plate mesodermal cells form the limb or 
appendicular skeleton. The cells from these separate lineages migrate to their correct locations 
in the embryo where the appropriate future skeletal elements will develop. They develop due to 
all these mesenchymal cells aggregating to form mesenchymal condensations of high cell 
density (Hall and Miyake, 1992).  
 
The cells can then follow either one of the following pathways:  
The first, which comprises most of the vertebral bones such as the long bones of the limbs and 
elements of the axial skeleton, involves most embryonic mesenchymal condensations. In this 
case, they differentiate into cartilage cells (chondrocytes) that form the template, or anlagen, of 
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the future bone. Later on, through a process called endochondral ossification (described in 
Introduction section 2.2), this cartilaginous template is eventually replaced by bone. 
In the second case, which comprises fewer bones such as the flat bones of the skull and 
clavicle, the cells of the mesenchymal condensations bypass the cartilaginous intermediary 
step and differentiate directly into osteoblasts. This is called intramembranous ossification 
(Hall. 1988). 
 
2.2 Endochondral ossification- formation of the primary 
ossification centres (POCs).  
The first change indicative of beginning the process of endochondral ossification occurs 
around the centre of the future bone shaft. The process of endochondral ossification can be 
divided into 5 stages. The first is the commitment of mesenchymal cells to becoming cartilage 
cells, which is achieved by the expression of the two transcription factors Pax1 and Scleraxis 
(Cserjesi et al., 1995), (Sosic et al., 1997) 
 
During the second phase, these committed mesenchymal cells condense into compact 
nodules (or mesenchymal condensations) that eventually differentiate into chondrocytes. The 
formation of these nodules is initiated by N-cadherin (Oberlender and Tuan, 1994). N-CAM, 
however, seems to be critical for maintaining them (Hall and Miyake, 1995). These 
precartilaginous condensations express the transcription factor sox9, a high mobility group 
(HMG) box-containing DNA binding protein. It seems that mutations in this gene can cause 
camptomelic dysplasia, a rare disorder of skeletal development (Wright et al., 1995), (Kist et 
al., 2002). Additional proof of this transcription factor’s importance comes from an elegant 
mouse embryo chimera experiment. In this experiment, both copies of sox9 were inactivated in 
embryonic stem  (ES) cells. The mutant ES cells were then injected into blastocysts from wild-
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type females to generate chimeras. Further analysis of these chimeras demonstrated that 
sox9-/- cells were able to contribute to multiple cell lineages but always failed to differentiate 
into chondrocytes. This block occurred at the mesenchymal condensation stage, identifying 
sox9 as the earliest determinant of the chondrocyte cell fate (Bi et al., 1999), (Bi et al., 2001). 
 
In addition to this, two other HMG-containing proteins, L-sox5 and sox6, are co-expressed with 
sox9 in al precartilaginous condensations and continue to be expressed in the cartilages of 
mouse embryos. They bind to the chondrocyte-specific enhancer of #1 (II) collagen in vitro and 
induce its expression in non-chondrocytic cells. Together with sox9, they induce endogenous 
expression of chondrocyte differentiation marker genes such as #1 (II) collagen and aggrecan 
in vivo. Although L-sox5 and sox6 have a high degree of homology to each other, their only 
similarity to sox9 is their HMG box (Yang and Karsenty, 2002). 
 
Throughout the third stage of endochondral ossification, chondrocytes proliferate rapidly to 
form the cartilage model for the bone. During their division, they secrete a cartilage-specific 
extra-cellular matrix (ECM) and form two distinct subpopulations of cells that can be separated 
by morphological and biochemical characteristics into round, low-proliferating chondrocytes 
(distal chondrocytes) and high-proliferating chondrocytes that are organized into columns 
(columnar chondrocytes). The distal chondrocytes are found at the future distal joint surfaces 
of the developing bone while the columnar ones are present more towards the center (Long et 
al., 2001).  
 
 In the fourth phase, some of the columnar chondrocytes exit the cell cycle and no longer 
divide. They differentiate into prehypertrophic and hypertrophic chondrocytes increasing their 
volume dramatically thus contributing significantly to the elongation of the skeletal elements. 
The hypertrophic chondrocytes produce collagen X and fibronectin, which they release into the 
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ECM. This enables the ECM to become mineralized (calcified) by calcium phosphate. 
Hypertrophic chondrocytes also secrete VEGF, the pro-angiogenesis factor in order to 
transform mesodermal mesenchymal cells into blood cells and vascularise the region (Gerber 
et al., 1999).  
 
In the fifth phase, the cells that surround the cartilage model (fibroblast-like cells that form a 
layer called the perichondrium) differentiate into osteoblasts, forming the periost. Blood vessels 
from the periost, which were produced in the previous phase, invade the calcified matrix of 
hypertrophic chondrocytes, providing osteoclasts to degrade the mineralized cartilage matrix 
as well as osteoblasts and hematopoietic cells. This results in the formation of primary 
ossification centres. Within these centres, hypertrophic cartilage matrix is degraded, the 
hypertrophic chondrocytes undergo apoptosis (Hatori et al., 1995) and the osteoblasts replace 
chondrocytes with trabecular bone forming bone marrow. At the same time, the osteoblasts in 
the perichondrium begin to construct a bone collar of compact bone around the middle portion 
(diaphysis) of the dying cartilage resulting in the primary ossification centre being located 
inside a tube of bone (Wagner and Karsenty, 2001), (Hall and Miyake, 2000). Eventually, most 
of the cartilage is replaced by bone, leaving permanent hyaline cartilage only at joints or 
articular surfaces of bones. 
2.3 Synovial joint formation 
 
Synovial joints are necessary for skeletal function. They allow vertebrates to display a great 
range of motions by articulating bones with one another. They consist of several highly 
specialized tissues such as bone, articular cartilage, tendons, ligaments, synovium and joint 
capsule. The articular cartilage coats the surface of bones and enables pain-free and 
deformation-free movement. The tendons ensure articular motion by transmitting muscle force 
to bones. Ligaments, stabilize the joints by interconnecting bones. The synovium consists of a 
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synovial membrane that produces a lubricating synovial fluid rich in nutrients for the avascular 
articular cartilage and internally lines the joint capsule. This fibrous capsule, in turn, surrounds 
the joint and seals its cavity. The most complex synovial joint is the knee due to it featuring 
additional exclusive tissues. These include shock-absorbing menisci, cruciate ligaments as 
well as space-filler fat pads (Ralphs and Benjamin, 1994).  
 
As described earlier, skeletogenesis starts with the formation of uninterrupted mesenchymal 
condensations. Mechanisms must therefore exist to dictate the precise location at which these 
condensations become interrupted and eventually form joints and interzones. Thus, the 
development of a functional synovial joint is generally divided into two phases. The first is the 
formation of cartilaginous anlagen and the intervening zones in which the joints will develop, 
and the second is the formation of the joint cavity described above. During joint cavitation, the 
peripheral interzone is absorbed into each adjacent cartilaginous zone, evolving into the 
articular surface; this surface is destined to become a specialized cartilaginous structure that 
does not normally undergo vascularisation and ossification (Pacifici et al., 2005), (Pitsillides 
and Ashhurst, 2008). Figure 5 demonstrates the major steps in digital synovial joint formation.  
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Figure 5: Schematic diagram depicting the major steps in digital synovial joint 
formation. A: Mesenchymal prechondrogenic condensations are appearing in the early limb 
bud, exhibit no overt signs of joint formation and are therefore uninterrupted. B: Unknown 
upstream patterning mechanisms determine the exact location for joint initiation. C: the 
interzone forming at each future joint site represents the first overt morphological sign of joint 
formation. There is further gathering and condensation of cells at this site. In the meantime, 
mesenchymal cells constituting the bulk of the condensations differentiate into chondrocytes 
and establish the cartilaginous skeleton. D: A cavitation process begins that eventually leads to 
the physical separation of the adjacent skeletal anlagen and formation of a synovial cavity. E: 
The opposing sides of the joint begin to mold into reciprocally shaped and interlocking 
structures. F: Eventually, all the distinct component of a mature joint form and include articular 
cartilage, capsule and a full-fledged synovial cavity. All these processes are continuous and 
are presented here as distinct events for descriptive purposes. Adapted from (Pacifici et al., 
2005). 
 
2.4 Postnatal development of bones- development of secondary 
ossification centres (SOCs) 
A developing long bone has an epiphysis and metaphysis at each end and a diaphysis (shaft) 
in between. By the middle of the embryonic stage, these regions are established and go 
through proportional changes in size until skeletal maturity. The epiphyses are important 
structures that are responsible for the transverse and spherical growth of the ends of the bone, 
the shaping of the articular surfaces, and the longitudinal growth of the metaphyses and the 
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diaphysis. In addition to this, a small amount of longitudinal growth also occurs with interstitial 
expansion of the epiphyseal cartilage, including the undersurface of the articular cartilage. 
Each epiphysis, formed initially completely in cartilage, subsequently differentiates into three 
histologically distinct regions. These are: i) the cartilage at the outermost boundary of the 
epiphysis adjacent to the joint space that is the articular cartilage, ii) the cartilage adjacent to 
the metaphysis that forms the growth plate (physeal cartilage) and iii) the cartilage between the 
articular cartilage and the physeal cartilage referred to as the epiphyseal cartilage, which will 
form a secondary ossification center after vascular and osteoprogenitor cell invasion (Forriol 
and Shapiro, 2005), (Forriol and Shapiro, 2005). 
 
The formation of the POC and SOC is quite similar in that they both involve the mineralization 
and degradation of cartilage, angiogenesis, cartilage resorption associated with apoptosis of 
habitant cells and finally de novo synthesis of bone matrix by osteoblasts.  However, the 
development of the SOC differs in some fundamental aspects from that of the POC in that 
vascularization occurs prior to the formation of a bony collar, chondrocyte hypertrophy and 
cartilage matrix mineralization (Alvarez et al., 2005).  Furthermore, a primary and critical event 
that precedes the formation of the SOC is the early generation of vascularized cartilage canals 
(Blumer et al., 2005).  
 
The growth plate is a specialized structure comprising of columns of resting, proliferating and 
hypertrophic chondrocytes. The growth plate components go through a sequential process of 
cell proliferation, synthesis of extracellular matrix, cell hypertrophy, mineralization of the matrix, 
localized vascular invasion accompanied by osteoprogenitor cells, and apoptosis. These highly 
coordinated activities lead to longitudinal bone growth and bone formation at the physeal-
metaphyseal region by proliferation of chondrocytes as well as the expansion of the 
hypertrophic region. The mechanisms that govern their differentiation seem to encompass 
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those controlling differentation during embryonic development (endochondral ossification) 
(Pechak et al., 1986), (Olsen et al., 2000). Growth cartilage renews itself through the germinal 
zone and is constantly replaced with bone at the physeal- metaphyseal junction. Though these 
developmental mechanisms, the length of the entire bone increases, the epiphyses and 
metaphyses at either end are displaced progressively further away from the centre of the bone, 
and the growth plate itself maintains the same height throughout the growth period. 
Concurently, there is radial growth of the diaphysis and parts of the metaphysis by 
intramembranous bone formation with direct apposition of cortical bone by osteoblasts from the 
inner cambial layer of the periosteum. This is coordinated closely with resorption of bone by 
osteoclasts on the inner cortical endosteal surfaces and lateral metaphyseal surfaces to 
maintain the relative proportions of the marrow cavity to the cortices and the overall shape of 
the bone as it grows. Figure 6 and Table 1 show the complete histologic stages in long bone 
and epiphyseal development from an early embryonic stage to adulthood.  
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Figure 6 The major stages in the formation and development of long bones 
and epiphyses (as described in Table 1), from stage 1 to stage 16a. From 
(Rivas and Shapiro, 2002). 
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Table 1 Histologic stages in long bone and epiphyseal development. The 
substages labeled ‘a’ and ‘b’ refer to an event that is occurring at the same time but in a 
different part of the same bone or to a structurally important continuation of the same process 
at a slightly later time. From (Rivas and Shapiro, 2002) 
 
 
Stage Histologic events 
1 Limb-bud formation, uniform distribution of mesenchymal cells, and formation of 
apical ectodermal ridge 
 
2 Mesenchymal condensation 
Cartilage differentiation 
3a Interzone formation 
3b Chondrocyte hypertrophy in middle part of long-bone cartilage model 
 
4 Epiphyseal shaping 
4a Formation of intramembranous periosteal bone at mid-diaphysis (primary center 
of ossification) 
 
5 Resorption of joint interzone and formation of smooth articular cartilage surface 
 
5a Vascular invasion of hypertrophic chondrocyte area, endochondral bone 
formation (mid-diaphysis), and completion of formation of primary center of 
ossification 
6 Formation of the physis and of peripheral perichondrial groove tissue 
 
6a Farthest relative extent of epiphyseal/physeal position 
7 Vascularization of epiphyseal cartilage with formation of cartilage canals 
8 Central chondrocyte hypertrophy to form spherical mass, development of 
growth plate completely surrounding secondary ossification center 
 
9 Vascular invasion of developing secondary ossification center into hypertrophic 
chondrocytes adjacent to mineralized cartilage matrix 
10 Bone formation and marrow cavitation in secondary ossification center, 
formation of hematopoietic marrow 
11 Increase in size of secondary ossification center, decrease in size of epiphyseal 
cartilage 
 
12 Central chondrocyte hypertrophy and secondary-ossification-center growth-
plate change from spherical to hemi- spherical orientation 
13 Fat in marrow, hematopoietic marrow adjacent to secondary-ossification-center 
growth plate 
 
13a Epiphyseal bone-plate formation 
14  Fullest relative extent of secondary-ossification-center development in 
epiphyseal cartilage 
 
15 Thinning of physis 
 
15a Involution of secondary-ossification-center growth plate 
15b Subchondral bone-plate formation 
16 Resorption of physis with linkage of epiphyseal and metaphyseal circulations 
 
16a Calcification of lowest zone of articular cartilage, tidemark formation, and 
transformation of all marrow to fat 
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2.5 Cartilage 
The embryology of cartilage can be viewed in the following way: The mesenchymal cells that 
aggregate to produce cartilage form a blastema at 5 weeks of gestational age in humans. They 
are called chondroblasts when they begin to secrete cartilage matrix. With increasing 
development, the ECM that is formed steadily pushes the cells apart. These cells, which are 
encased in this tough and specialized matrix, are then called chondrocytes. It is the 
mesenchymal tissue that surrounds the blastema that gives rise to the perichondrium (Bhosale 
and Richardson, 2008).  
 
Cartilagenous tissues are present throughout the body and according to the composition of the 
ECM (based on the presence of collagen and elastic fibers) and on tissue morphology, are 
classified histologically into hyaline cartilage (Bhosale and Richardson, 2008), elastic 
cartilage (present in the outer ear, larynx and epiglottis), and finally fibrocartilage (found 
in the pubic symphysis, intervertebral discs, meniscus, TMJ and annulus fibrosus). Hyaline 
cartilage has unique and diverse characteristics. Like all cartilage, it is a specialized form of 
connective tissue that consists of cells and extracellular material. Chondrocytes are embedded 
in an ECM, and it is the matrix that endows cartilage with its unique characteristics. Hyaline 
cartilage is covered by a tough and fibrous sheath of dense, irregular connective tissue (the 
perichondrium). The perichondrium contains a graded series of cells caught at different stages 
of development. The cells at the periphery of the perichondrium are flat fibroblasts that, in time, 
differentiate to form the egg-shaped chondroblasts, which in turn develop into round, mature 
chondrocytes. The chondrocytes, which often contain large lipid droplets, are responsible for 
the synthesis, secretion, and maintenance of the ECM. Should the chondrocytes die or 
become damaged, the cartilage matrix degenerates and can undergo calcification. Although 
the perichondrium can act as a source of new chondrocytes to a limited extent, cartilage does 
not regenerate well unless the animal is quite young. The ECM of elastic cartilage is criss-
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crossed by numerous branched elastic fibers rich in the protein elastin. These elastic fibers 
lend a high degree of flexibility and resilience to the matrix. When bent, elastic cartilage will 
rapidly bounce back to its original form. The outer margins of elastic cartilage, like hyaline 
cartilage, are defined by a fibrous perichondrium made of dense connective tissue. This 
perichondrium contains collagen fibrils, fibroblasts as well as chondroblasts. The mature 
chondrocytes occupy spaces in the matrix called lacunae. Hyaline and elastic cartilage appear 
very similar when viewed with a light microscope but can be differentiated with an electron 
microscope due to the detection of elastic fibers in the elastic cartilage. Fibrocartilage , on 
the other hand, is a unique subtype of cartilage in that it lacks a true perichondrium, and often, 
as in the intervertebral disc, forms a structural and functional junction where cartilage and 
ligament meet. Also, collagen type I is the prominent structural element in fibrocartilage as 
opposed to collagen type II in hyaline cartilage. The variation in total proteoglycan and collagen 
content and localization pattern of minor collagens in the matrix of different subtypes of 
cartilage is either due to a response to the different physiological requirements and mechanical 
stresses that the cartilage tissues have at different anatomic sites or as a consequence of 
developmental events (Naumann et al., 2002), www.visualhistology.com.  
 
Nevertheless, hyaline cartilage is the predominant form of cartilage and is the type of 
cartilage that is most commonly associated with the skeletal system. It is this form of cartilage 
that generates the anlage for many bones in the embryo, the growth plate through which many 
bones increase their size during juvenile development and finally the bearing surface upon 
which bones articulate in movable joints (articular cartilage) (Roughley, 2006).  
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2.5.1 Articular Cartilage 
2.5.1.1 Basic overview 
In adults, articular cartilage is a relatively acellular tissue, with cell volume averaging 
approximately 2% of the total cartilage volume (Poole et al., 2001). Articular cartilage is a 
highly specialized connective tissue that covers the weight-bearing surfaces of diarthrodial 
joints. Cartilage layers cover bone ends and are principally responsible for permitting low-
friction, high velocity movement between bones, absorbing the transmitted forces associated 
with locomotion, and contributing to joint stability. The chondrocytes of mature articular 
cartilage are terminally differentiated cells and are mainly responsible for synthesizing and 
maintaining the highly specialized cartilage matrix macromolecules (see Table 2). This 
cartilage ECM is composed of an extensive network of collagen fibrils (mainly collagen II), 
which confers tensile strength, as well as an interlocking mesh of proteoglycans (mainly 
aggrecan), which themselves provide compressive stiffness in joints through their ability to 
absorb and extrude water (Harris et al., 2004).  
 
It is not clear whether articular cartilage can be defined as a distinct tissue in the juvenile, as it 
forms a continuum with the hyaline cartilage of the central epiphysis, which is destined to be 
resorbed (table 1 stage 16). Indeed, it is still somewhat of a mystery why articular cartilage 
survives at all and is not also replaced by bone. 
 
2.5.1.2 Structural organization 
The components of the articular cartilage ECM are highly ordered from the cartilage surface to 
the deepest layers. It is divided into four individual zones with separate functions: The 
superficial, middle or transitional, deep or radial and calcified zones. Unlike the deepest two 
zones, there is no sharp boundary between the first three zones (superficial, middle and deep). 
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The superficial zone is the thinnest of the four and consists of many fine collagen fibrils that are 
oriented in a tangential manner, low levels of proteoglycan as well as elongated chondrocytes 
that are aligned parallel to the surface (Venn, 1979). This zone is in contact with the synovial 
fluid of the joint and is accountable for most of the tensile properties of cartilage that enable it 
to withstand shearing as well as the tensile and compressive forces imposed on it by the 
movement of the articulation (Martel-Pelletier et al., 2008).  
 
The middle or transitional zone is composed of a higher content of proteoglycans (to resist 
compression) and thicker but less collagen fibrils that are organized into radial bundles or 
layers. The chondrocytes in this zone, which represents approximately 40-60% of the total 
cartilage height, are at low density and have a round shape (Schinagl et al., 1997).  In the deep 
zone, chondrocytes have the same shape as those in the middle zone. They are, however 
aligned perpendicular to the articular surface but with low density. Compared to the other 
zones, this zone contains the largest collagen fibrils in a radial disposition, which extend into 
the bone to reinforce tissue attachment.  Aggrecan (proteoglycan) content is at its highest 
(Venn, 1979), (Martel-Pelletier et al., 2008), (Hu and Athanasiou, 2006).  
 
The deepest calcified cartilage zone, which is divided from the other zones by the tidemark, 
mechanically and physically separates the hyaline cartilage from the subchondral bone. It 
mainly functions to anchor the cartilage to the bone since collagen fibrils from the deep zone 
penetrate into the calcified cartilage. Chondrocytes are very scarce and hypertrophic (Martel-
Pelletier et al., 2008). The structure of articular cartilage is shown in Figure 7.  
 
Throughout the four zones, the pericellular area that surrounds the chondrocytes is composed 
of a thin layer of non-fibrillar material. This most probably represents the products synthesized 
by the chondrocytes such as proteoglycans and glycoproteins. Immediately adjacent to the 
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pericellular region lies the territorial cartilage extra-cellular matrix. Here exists the dense 
meshwork of collagen fibers that form a capsule-like structure around the cells providing 
mechanical protection to the chondrocytes  (Martel-Pelletier et al., 2008), (Guilak et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  Representation of the general structure of adult human articular cartilage to 
show the zones, regions and relationship with subchondral bone. Particular important 
features of molecular content or properties are indicated. Also, shown are the relative 
diameters and organizations of collagen macrofibrills as well as large aggregating 
proteoglycans in the different zones. Adapted from (Poole et al., 2001). 
 
2.5.1.3 Composition 
Whereas most of the tissue wet weight of cartilage is composed of water and dissolved 
inorganic salts (including sodium, calcium and potassium chloride), the rest -approximately 
20%- is occupied by collagen, proteoglycans, as well as other proteins or glycoproteins. The 
water content in cartilage is mostly found in the extracellular matrix and is unevenly distributed 
with its concentration at its highest (80%) close to the articular surface. However, with 
increasing depth, the concentration of water decreases and reaches approximately 65% of the 
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total wet weight in the deep zone.  The water in the cartilage functions in maintaining the 
resilience of the tissue and contributes to the nutrition and lubrication system. More accurately, 
the diffusion of water through the cartilage aids the movement of nutrients from the synovial 
fluid through the tissue, contributing to the nutrition of the chondrocytes.  The proper 
maintenance and flow of water in the tissue relies on its interaction with the macromolecules 
found there (Bhosale and Richardson, 2008).  
 
Collagen represents approximately 50-60% of the cartilage dry weight. The collagen is 
organized in fibrils, which construct a network that dictates the shape and form of the tissue.  
The fibril diameters vary from 20nm in the superficial zone to 70-120 nm in the deep zone. The 
most abundantly found collagen is collagen type II, which is specific to articular cartilage and 
occupies 90-98% of the total tissue collagen. As mentioned earlier, these fibers give cartilage 
tensile stiffness and strength through their mechanical properties (Buckwalter and Mankin, 
1998), (Martel-Pelletier et al., 2008).  
 
Proteoglycans, on the other hand, constitute the second largest portion of the solid phase in 
articular cartilage occupying approximately 5-10% of the tissue wet weight. In articular 
cartilage, proteoglycans are complex supramolecular aggregates that consist of a central 
hyaluronic acid (HA) filament to which multiple monomers are non-covalently attached 
(Heinegard, 2009). In addition to HA (Holmes et al., 1988), other examples of articular cartilage 
specific proteoglycans include aggrecan (the most abundant proteoglycan), link protein 
(Neame and Barry, 1994), small leucine-rich repeat proteoglycans (SLRPs) such as decorin, 
biglycan, fibromodulin and lumican (Schaefer and Iozzo, 2008) and finally versican (Sztrolovics 
et al., 2002) and perlecan (Arikawa-Hirasawa et al., 1999).  
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In the extracellular matrix of cartilage, the proteoglycans are mainly of the large aggregating 
type (approximately 50-85%) and of the large nonaggregating type (approximately 10-40%). 
An aggregating proteoglycan consists of a monomer formed by the core protein, which acts as 
a protein backbone. From this core protein, numerous glycosaminoglycan side chains radiate 
at a 90° angle, extending stiffly. These side chains are composed of a long chain of 
polydimeric saccharide repeats including chondroitin-4-sulfate, chondroitin-6-sulfate and 
keratan sulfate, of which chondroitin sulfate is the most plentiful (approximately 60-90%). The 
average chondroitin sulfate chain has 25-30 disaccharide repeats while keratan sulfate chains 
only consist of around 5 or 6 repeating dimeric units (Heinegard, 2009), (Martel-Pelletier et al., 
2008).  
 
Table 2 shows a wide range of articular cartilage ECM components. 
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Table 2: Extracellular matrix components of cartilage. Abbreviations: HA = hyaluronic acid. 
HS = heparan sulphate. OA = osteoarthritis. PRELP = proline- and arginine-rich repeat protein. 
TGF-! = transforming growth factor-! (Harris, E et al. 2004). 
 
Molecule Function and location    
Collagens 
 
Type II Tensile strength, Major component of  collagen fibrils 
Type IX Tensile properties, Interfibrillar connections; cross-links to surface of collagen 
fibril, NC4 domain projects into matrix 
Type XI Nucleation/control of fibril formation; within collagen fibril 
Type VI Forms microfibrillar network, binds hyaluronan, biglycan, decorin; pericellular 
Type X Support for endochondral ossification; hypertrophic zone and calcified cartilage 
Type XII Associated with collagen I fibrils in perichondrium and articular surface 
Type XIV Associated with collagen fibrils throughout articular cartilage 
Proteoglycans 
Aggrecan Compressive stiffness through hydration of fixed charge density: binding 
through G1 domain to HA stabilized by link protein 
Versican Low levels in articular cartilage throughout life; calcium –binding and selectin-
like properties  
Perlecan Cell-matrix adhesion; pericellular 
Biglycan Binds collagen VI and TGF-!; pericellular 
Decorin Controls size/shape of collagen fibrils, binds collagen II and TGF-!; 
interterritorial 
Fibromodulin Same as decorin 
Lumican Same as decorin 
PRELP Mediates cell binding through HS sulfate in syndecan 
Chondroadherin Binding to cells via #2!1 intergrin 
Other Molecules 
Hylaluronic acid Retention of aggrecan within matrix 
Link protein Stabilizes attachment of aggrecan G1 domain to HA  
Cartilage 
oligomeric 
Interterritorial in articular cartilage; stabilizes collagen network or promotes 
collagen fibril assembly; calcium binding  
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matrix protein 
(COMP) 
Cartilage matrix 
protein (CMP) 
Tightly bound to aggrecan in immature cartilage 
Cartilage 
intermediate 
layer protein 
(CILP) 
Restricted to middle/deep zones of cartilage, increase in early and late OA 
Glycoprotein 
(gp)-39, or YKL-
40 
Marker of cartilage turnover; chondrocyte proliferation; superficial zone of 
cartilage 
Fibronectin Cell attachment and binding to collagen and proteoglycans; increase in OA 
cartilage 
Tenascin-c Binds syndecan-3 during chondrogenisis; angiogenesis 
Superficial zone 
protein (SZP) or 
lubricin 
Joint lubrication (superficial zone only) 
Membrane Proteins 
CD44  Cell-matrix interactions; binds HA 
Syndecan-3 Receptor for tenascin-c during cartilage development; cell-matrix interactions 
Anchorin CII Cell-surface attachment to type II collagen; calcium binding 
Integrins 
(#1,2,3,5,6,10; 
!1,3,5) 
Cell-matrix binding: #1!1/collagen 1 or VI, #2!1 or #3!1/ collagen II, #5!1/FN; 
intracellular signalling 
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3 Aggrecan 
 
3.1 Overview 
Aggrecan, the large aggregating chondroitin sulphate proteoglycan, is one of the major 
structural components of hyaline cartilage as it is the most abundantly established 
proteoglycan in the tissue. It is also present in significant concentrations in the extracellular 
matrices of other tissues such as meniscus, heart, brain and liver (Dudhia, 2005). 
 
 It does not exist in isolation within the extracellular matrix of cartilage. Instead, it is present in 
the form of proteoglycan aggregates (Hascall, 1988). Up to 100 individual monomers of 
aggrecan are non-covalently attached to a central filament of HA forming macromolecular 
aggregates of aggrecan (Figure 8) (Hardingham and Fosang, 1992). Each of these interactions 
is in turn stabilized by the presence of a link protein (Morgelin et al., 1988). The structure of the 
proteoglycan aggregate is therefore influenced by three parameters: the length of the HA, the 
proportion of link protein and finally the degree of aggrecan processing. To date, two molecular 
forms have been characterized for proteoglycan aggregates that have been derived directly 
from cartilage without the use of dissociative agents  (Manicourt et al., 1991). Apart from the 
apparent differing content of link protein across these two forms, they may also have different 
functional characteristics (Buckwalter et al., 1994). 
 
The aggregates of aggrecan (molecular mass of 108-109 Da) occupy a large hydrodynamic 
volume due to their high fixed negative charge resulting from the numerous attached 
polyanionic glycosaminoglycan chains (Horkay et al., 2008). This brings about a rise in osmotic 
pressure and subsequent swelling of the cartilage. This swelling pressure is counteracted by 
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the resistance of intact collagen fibres in cartilage. Collectively, these features enable joints to 
resist compressive force while maintaining a high tensile strength (Akizuki et al., 1987). 
 
 
Figure 8: Schematic representation of an aggregate of aggrecan, with detail of monomer 
in boxed region. Globular domains (G1-G3) and attached GAGs are depicted. Aggrecan 
binds via G1 domain to hyaluronic acid (HA). This binding is stabilised by link protein (LP). 
Adapted from www.cmb.lu.se/ctb/ photos/Aggrecan.gif. 
 
3.2 Aggrecan protein 
The aggrecan monomer consists of an extended multidomain protein core with a predicted size 
of approx. 220-250 kDa to which several chondroitin sulphate (CS) and keratan sulphate (KS) 
side chains are attached. There is a globular domain (G1) at the N-terminus of the protein 
core, which mediates specific interactions with the complex carbohydrate hyaluronan (HA)  
(Watanabe et al., 1997a) (Figure 8). These interactions are in turn stabilised by simultaneous 
binding to link protein (also bound with high affinity to HA). The G1 domain has a typical three-
looped structure. The first of these is the N-terminal A loop which has amino acid sequence 
similarity to the immunoglobulin superfamily. The 2 additional loops (B and B’) are named the 
proteoglycan tandem repeats (PTRs) and are homologous to each other. The G1 domain is 
separated from a second highly homologous domain (G2) by a linear interglobular domain 
(IGD). G2 is made up of a second pair of PTRs (loop B and B’) that do not appear to interact 
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with HA (Fosang and Hardingham, 1989). Although the exact function of this domain is still 
unknown, it appears to function by inhibiting aggrecan secretion prior to GAG modification in 
the Golgi (Luo et al., 1996), (Doege et al., 1991), (Yasumoto et al., 2003). 
 
The GAG-attachment region provides the high anionic charge density that is needed for the 
unique properties of aggrecan. It is composed of three domains that are responsible for 
attachment of keratan sulphate and chondroitin sulphate: The KS-attachment domain along 
with the neighbouring CS-attachment region, which is divided into two subdomains – the CS1 
and CS2 domains.  The KS-attachment domain resides adjacent to the G2 region and is 
composed mainly of repeat motifs that vary in number between species (Barry et al., 1994). 
Human aggrecan contains 30-60 keratan sulphate GAG chains per monomer, which are 
composed of shorter repeats of acetylgalactosamine and galactose. The 6- hydroxyl group of 
the N-acetly-galactosamine is sulphated.  
 
Like the KS-rich domain, the CS1 domain (which lies adjacent to it) is also composed largely of 
repeat motifs that vary in number across species.  Furthermore, the human aggrecan CS1 
domain displays size polymorphism across different individuals due to the flexible number of 
19 amino acid tandem repeats, each of which contains two serine residues that can act as an 
attachment site for chondroitin sulphate (Doege et al., 1997). On average, there are 100-150 
chondroitin sulphate glycosaminoglycan (GAG) chains per monomer of human aggrecan and 
each is made up of 40-50 repeating disaccharide units of N-acetylgalactosamine and 
glucuronic acid. In this case, the 4- and 6- hydroxyl groups of the N-acetyl-galactosamine are 
sulphated. Linkage to the protein occurs via a specific Ser-Xylose-Galactose-Galactose-
Glucuronate sequence. Irrespective of the varying numbers of CS chains that the aggrecan 
molecules of different individuals are able to bear, the structure of the CS chains can change 
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throughout life due to changes in length and sulphation pattern (Roughley and White, 1980),  
(Silbert and Sugumaran, 2002), (Funderburgh, 2000), (Watanabe et al., 1998). 
 
In addition to the KS and CS attachment sites, the GAG attachment region also possesses 
sites for the attachment of O-linked + N-linked oligosaccharides (Nilsson et al., 1982). With 
increasing age, these can become substituted with KS (Santer et al., 1982). Therefore, the 
location of KS may be expanded to the G1, the IGD and the G2 region where O-linked or N-
linked oligosaccharide attachment sites can reside (Barry et al., 1995).  Like the CS chains, the 
KS chains show age-related changes in structure (Brown et al., 1998). 
  
At the C-terminus of the protein core, there are two alternatively spliced epidermal growth 
factor-like regions (EGF1 and EGF2), a lectin (LEC)-like G3 domain, and an alternatively 
spliced domain which shows sequence homology to complement regulatory proteins (CRPs).  
The G3 domain appears to contribute to the intracellular trafficking of aggrecan (post-
translational processing of the core protein and subsequent aggrecan secretion) (Zheng et al., 
1998). Very little is known about the functions of the EGF-like domains although it is likely that 
they have high affinity to Ca2+ ions indicated by their functions in proteins such as human 
protein S and human coagulation factors IX and X. Thus, it is possible that the EGF-like 
domains of aggrecan bind Ca2+ and interact with the Ca2+-dependent LEC-like carbohydrate–
binding domain (Baldwin et al., 1989), (Valhmu et al., 1995). 
 
The LEC-like domain of aggrecan shows significant homology with several other known 
proteins such as the human leucocyte adhesion molecule 1 (LAM-1), the sea raven antifreeze 
protein and the human macrophage mannose receptor (Valhmu et al., 1995). 
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3.3 The Aggrecan Gene 
3.3.1 Intron/exon organisation of the human aggrecan gene 
The human aggrecan gene (AGC1) has been localized to chromosome 15q26.2 by in situ 
hybridization (Just et al., 1993), (Korenberg et al., 1993). The sequencing of genomic cosmids 
of the human aggrecan gene has revealed that the gene consists of 19 exons and 18 introns. 
The entire coding region (exons 2-19) is restricted to a 39.4kb segment of the overall ~70kb 
gene. The exons range in size from 77 to 4224bp (Table 3) (Valhmu et al., 1995). Although it’s 
not clear whether this is of any functional significance, the G3 region can give rise to different 
aggrecan transcripts due to alternative splicing (Fulop et al., 1993). 
 
The aggrecan gene has been characterised in several species including R. norvegicus (Doege 
et al., 1990), H. sapiens (Valhmu et al., 1995), M. musculus (Watanabe et al., 1995), and G. 
domesticus (Li and Schwartz, 1995). However, until the beginning of this work, little was 
understood about the transcriptional regulatory mechanisms that govern the expression 
(particularly the chondrocyte specific expression) of the gene in these different species. 
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Table 3 Some of the characteristics of the exons/introns of the human aggrecan gene. A 
protein domain is coded for by each exon or a combination of exons.  Intron sizes are accurate 
within ±0.1kb. In addition to the 3’UTR, exon 19 also codes for the 25-amino acid C-terminus of 
aggrecan. Adapted from (Valhmu et al., 1995). 
 
Exon Intron 
Protein domain 
No Size (bp) No Size (kb) 
5’UTR 1 375 1 >13 
SP 2 77 2 2.4 
G1-A 3 384 3 1.0 
4 175 4 1.6 
G1-B 
5 128 5 1.5 
G1-B’ 6 294 6 1.9 
IGD 7 378 7 1.5 
8 175 8 0.5 
G2-B 
9 128 9 1.4 
G2-B’ 10 294 10 2.1 
KS-1 11 240 11 2.9 
KS-2/CS 12 4224 12 0.9 
EGF-1 13 114 13 8.4 
EGF-2 14 114 14 3.2 
15 158 15 0.5 
16 83 16 0.8 LEC 
17 145 17 0.8 
CRP 18 183 18 0.5 
3’UTR 19 212 
 
- - 
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3.3.2 The expression of the aggrecan gene 
The aggrecan gene is mainly expressed in cartilaginous tissue. Unlike Col2a1, aggrecan is not 
expressed in skeletogenic mesenchymal cells, the perichondrium or presumptive joint cells 
(Shepard et al., 2007) and is mainly found in differentiatied chondrocytes such as the 
chondrocytes of the growth plate and articular cartilage embryonically and throughout 
adulthood. In the knee, in addition to its expression in the hyaline cartilage of the growth plate 
and the articular surfaces, aggrecan is expressed in the fibrocartilage of the menisci. A study 
performed on ovine cartilage showed that in 2-7-day old menisci, aggrecan is localized in the 
inner meniscal zone, which displays a hyaline cartilage-like character at this stage in meniscal 
development. At later age points (> 7 months), aggrecan was also shown to be widely 
distributed throughout the other meniscal zones and did not decline markedly with age 
(Melrose et al., 2005). 
 
It is important to note that although the expression of aggrecan is mainly found in differentiated 
chondrocytes, it has been detected before the appearance of cartilage matrix. In E14.5 mice, 
although no Col2a1 mRNA was observed, aggrecan mRNA was detected in the posterior 
region of the mesenchymal cell aggregation continuous with the ossifying mandibular bone 
anlage prior to chondrogenesis (Fukada et al., 1999). 
 
Even though high levels of aggrecan protein expression are found predominantly in cartilage, 
its mRNA has also been observed in the: 
1- Central nervous system (CNS) in which aggrecan glycoforms are major constituents of 
perineuronal nets in the brain of the adult rat. Matthews et al (2002) showed by in situ 
hybridization that aggrecan is found in the cerebral cortex, the deep cerebellar nuclei, 
the colliculi, the spinal core, the dentate gyrus as well as the CA1, CA2, and CA3 fields 
of the hippocampus. Also, they showed that neurons are the predominant cellular 
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source of aggrecan in the adult CNS. Finally, using in situ hybridization, RNase 
protection analysis, and antibody staining, they demonstrated that aggrecan mRNA is 
not expressed in the CNS until late in embryonic development, peaks in expression at 1 
month of age, and is maintained at relatively high levels into adulthood (Matthews et al., 
2002). Another group showed more recently that aggrecan regulates astrocyte 
development and is expressed by embryonic glial precursors (Domowicz et al., 2008).   
2- Notochord, which has its own extracellular matrix composed of several proteins 
including proteoglycans such as aggrecan (Sandell, 1994). The notochord has major 
roles in vertebral column formation by inducing sclerotome differentiation and by forming 
the nucleus pulposus of intervertebral discs. Within intervertebral discs, aggrecan is 
expressed in the nucleus pulposes as well as the inner annulus fibroses  (that is 
transitional in its composition between the nucleus pulposus and the outer annulus 
fibroses) (Le Maitre et al., 2007).  
3- Liver, where aggrecan mRNA has been shown by northern analysis and in situ 
hybridization to be expressed differentially during liver fibrogenesis (Krull and Gressner, 
1992). 
4- Heart, where aggrecan is specifically colocalized with several groups of migrating cells 
that include the endocardial cushion tissue cells, the epicardial cells, a mesenchymal 
cell population in the outflow tract that may be of neural crest origin, and a 
mesenchymal cell population in the inflow tract. This was shown by western blotting, 
immunohistochemical studies as well as RT-PCR of chicken embryo hearts at stages 
12-21 of development (Zanin et al., 1999).  
5- Carotid artery and the aorta. Using a proteomic-based approach, the extracellular 
proteoglycan core protein composition of intimal hyperplasia from both the internal 
carotid artery and the internal thoracic artery was shown to include aggrecan (Talusan 
et al., 2005). Also, by immunohistochemical studies, it was shown that aggrecan is 
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present at low levels in the cells arranged into lamellar and interlamellar cell layers 
within the embryonic chick aortic wall during development (Arciniegas et al., 2004).  
6- Adipose tissue. Voros et al showed that aggrecan mRNA is present in murine intra-
abdominal and inguinal subcutaneous fat pads. They suggested that aggrecan might 
contribute to the regulation of lipid uptake and obesity in mice (Voros et al., 2006). 
 
The aggrecan chondroitin sulphate proteoglycans (CSPG) that are expressed in different 
tissues such as cartilage, notochord and brain are all products of the same aggrecan gene. 
However, in each tissue the CSPG product exhibits significantly different chemical, structural, 
and immunological properties, indicating that although each is initiated on an identical core 
protein, they are processed differently, yielding distinct proteoglycans (Schwartz and 
Domowicz, 2004). 
 
3.3.3 The regulation of the aggrecan gene 
The basal promoter of the aggrecan gene has been defined by mapping the TSS in different 
species including H. sapiens (Valhmu et al., 1995) and R. norvegicus (Doege et al., 1994) and 
was shown to be active in different cell lines in the latter species. In humans, this preliminary 
promoter was shown to lack canonical TATA and CAAT boxes and contain several putative 
binding sites for ubiquitous transcription factors such as SP-1, AP-2, and AP-4 that are located 
in both the promoter and untranslated exon1. They may possibly mediate the basal activities of 
this promoter. The following are cis and trans-regulatory elements that have been identified by 
in vitro studies and have been shown to regulate the expression of aggrecan by directly 
driving/repressing promoter activity: 
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1- Exon sequences (cis-regulation): Using luciferase reporter constructs driven by the 
human aggrecan promoter (taken as -701bp - +52bp relative to the human aggrecan TSS, 
87,147,670 on chromosome 15, Assembly: March. 2006 NCBI36/hg18), the 5’ and 3’ 
untranslated regions of the human aggrecan gene were found to regulate gene expression 
transcriptionally in a cell-type specific manner. The 5’ untranslated region (+1 - +375bp) is also 
the 1st untranslated exon of the human aggrecan gene. It stimulated the activities of the human 
aggrecan promoter by about 8 fold in chondrocytes and 40 fold in NIH 3T3 cells. In contrast, 
the 3’ untranslated region inhibited the activities of the human aggrecan promoter by about 40-
70% in both cell types (Valhmu et al., 1998a). 
 
     Sequential deletions of a large portion of this so-called human aggrecan proximal promoter 
from -701bp - -52bp had very little effect on promoter activity when the 5’UTR was present. 
However, when the 5’UTR was removed, leaving a 5’ flanking sequence of -701bp - +25bp or -
52bp - +25bp, luciferase activity was reduced 85-100%. Thus, it seems that the 5’UTR/exon 1 
of the human aggrecan gene can act as the minimal promoter required to drive basal 
expression of the aggrecan gene. It is possible that sequences within this region bind to 
general transcription factors required for the assembly of the transcription initiation complex. 
Also, as mentioned above, this region contains several putative SP-1 binding sites 
characteristic of most TATA-less and CAAT-less promoters, and may be involved in recruiting 
the TFIID protein to the transcription initiation complex (Valhmu et al., 1998a). 
 
2- Silencing region (cis-regulation): A 1.8kb genomic fragment, containing 5’ non-coding 
chick aggrecan DNA as well as exon 1, was able to drive the expression of the pGL2-Basic 
reporter gene in a tissue-specific manner. Transient transfections of chick sternal chondrocytes 
and fibroblasts with pGL2-Basic plasmids bearing progressively reduced portions of this 1.8kb 
‘promoter fragment’ allowed mapping of chondrocyte-specific transcription enhancer and 
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silencer elements that are consistent with sequence analysis data. Positions -873 and -721, 
relative to the chick aggrecan TSS and in this 1.8kb fragment, are at the 5’ ends of two copies 
of the sequence CACCTCC (CIIS2) that has been suggested to be a silencer motif in the 
COL2A1 promoter (Savagner et al., 1990). Deletion of these two motifs reduced the cell type 
specificity of luciferase expression while the overall promoter acitivities increased (Pirok et al., 
1997). 
 
3- Sox9 (trans-regulation): The mouse aggrecan promoter is responsive to the sox9 
transcription factor in the cartilage derived cell line, TC6. Sox9 overexpression in TC6 cells 
enhanced the transcriptional activity of the AgCAT-8 construct (containing 8kb of promoter/ 1st 
exon/intron fragments of the aggrecan gene) by up to "3 fold. This enhancement was lost 
when a 4.5kb fragment from the 3’end of the 8kb construct (corresponding to intron 1) was 
deleted (Sekiya et al., 2000). 
 
Although Sekiya et al showed that a segment of Agc1  was responsive to Sox9, they did not 
show whether this gene segment binds Sox9 and is sufficient to drive cartilage expression in 
vivo. Han and Lefebvre (2008), however, showed a highly conserved enhancer within Agc1 
that is a direct target of the Sox trio (Sox9, 5 and 6). The binding of Sox9 to this enhancer 
occurs only in the presence of L-Sox5/Sox6. A similar mechanism applies to other cartilage 
enhancers (Han and Lefebvre, 2008). Furthermore, the ChIP hybridization experiment 
performed by Oh et al (2010) showed that rat aggrecan contained two separate Sox9 
interaction sites which possibly correspond to the findings of the two studies mentioned above 
(Oh et al.).  
 
Other than the regulatory elements/factor described above, there are regulators that are 
associated with altered expression of aggrecan that may or may not act directly on the 
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promoter.  Examples are: 
1- Biomechanical stimuli: The levels of aggrecan mRNA are affected by short and long 
term load-controlled compression. There is a transient upregulation of aggrecan mRNA 
synthesis in bovine articular cartilage explants when a compressive stress of 0.1 MPa is 
applied for 1,4,12 and 24 hours.  For example, at 1 hour, aggrecan mRNA levels in 
loaded explants were increased 3.2 fold compared to control explants (Valhmu et al., 
1998b). Also, more recently, aggrecan expression in the annulus fibrosus cells of the 
human intervertebral disc was shown to be significantly increased by mechanical load 
(Neidlinger-Wilke et al., 2009). 
 
2- Hyperosmotic loading: Osmotic loading, which is the process of incubating cells with 
solutions of different osmolarity for various time points, influenced the expression of the 
aggrecan gene (driven by the sequence -2368bp to +375bp relative to the TSS) 
particularly through the 1st exon/5’UTR. More specifically, aggrecan promoter activity 
and mRNA levels were suppressed approximately two-fold when bovine monolayer 
chondrocytes were subjected to 24 hours of hyperosmotic loading. There was no 
suppression, however, with the deletion of the 1st exon/5’UTR of the gene in the reporter 
construct. This osmotic regulation was time-dependent and found to correlate with cell 
shrinking and swelling (Palmer et al., 2001).  
 
3- Hif1# and Hif2#: The nucleus pulposus is an aggrecan-rich, avascular tissue that 
permits the intervertebral disk to resist compressive loads. Owing to this, the 
relationship between HIF-1# (Hypoxia-inducible-factor 1# - a transcription factor that 
responds to oxygen tension and regulates glycolysis) expression and aggrecan 
promoter activity was measured. It was shown that when HIF-1# was suppressed, 
irrespective of the oxemic state, there was a partial loss of aggrecan expression and 
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promoter activity. Moreover, when cells were treated with 2-DOG, a glycolytic inhibitor, 
there was inhibition in aggrecan promoter activity. Results of this study indicated that 
oxygen-independent stabilization of HIF-1# in nucleus pulposus cells is a metabolic 
adaptation that drives glycolysis and aggrecan expression (Agrawal et al., 2007). 
Furthermore, it has been shown that human chondrocytes from knee articular cartilage 
enhance the production of aggrecan in response to hypoxia specifically through HIF-2# 
(Hypoxia-inducible-factor 2#) (Thoms and Murphy). At least in articular chondrocytes, 
aggrecan is not a direct HIF-2# target, but is upregulated by hypoxia through the 
cartilage-specific transcription factor SOX9, which itself is upregulated in response to 
HIF-2# (Murphy et al., 2009). 
 
4- IL-1: The cytokine interleukin 1 (IL-1), which is considered to be the principal inducer of 
mediators of cartilage degradation in osteoarthritis (see Introduction section 4), can 
activate numerous signalling pathways involved in cartilage destruction and 
dedifferentiation of chondrocytes.  With respect to aggrecan, IL-1 was shown to induce 
the reduction in its expression. IL-6 has also been found to act synergistically in the IL-1 
induced suppression of aggrecan in chondrocytes. It seems that IL-1 induced IL-6 
secretion by chondrocytes can eventually downregulate the expression of aggrecan 
through the p38MAPK and/or the PI3K/JNK signalling pathways (Radons et al., 2006).  
 
5- TGF-!1: TGF-!1 has been observed to have profound effects on the initiation of 
mesenchymal cell condensation, which leads to chondrogenesis, and eventual 
production of ECM components. James et al (2009) showed that addition of TGF-!1 to 
chondrogenic medium of postero-frontal cranial suture-derived mesenchymal cells in 
vitro resulted in significant induction of aggrecan by 24 fold over baseline expression. 
The expression of SOX9 was increased by 30 fold as well. They did not, however, 
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confirm whether the regulation of aggrecan gene expression occured indirectly through 
the upregulation of SOX9 or by some other mechanism (James et al., 2009). 
. 
6- MicroRNA-140 (miR-140):  MicroRNA-140 has been shown to be a marker for 
chondrogenesis. In a study performed by Miyaki et al (2009), pellets of MSCs, which 
were strongly stained by Safranin O after chondrogenesis induction for 14 days, 
revealed a gradual increase in miR-140 expression in parallel with expression of sox9, 
aggrecan, and col2a1. This indicates that the expression of miR-140 increases during 
chondrocytic differentiation of MSCs, and this is consistent with its high expression in 
chondrocytes. Furthermore, the group performed experiments that potentially reveal that 
miR-140 may regulate the expression of aggrecan. Chondrocytes were stimulated with 
IL-1! with and without transfection of double stranded (ds)-miR-140.  Conversely, 
aggrecan expression with IL-1! stimulation was significantly increased by ds–miR-140. 
In the absence of IL-1!, the nonspecific dsRNA (dsNega) did not change the basal 
levels of aggrecan. These results demonstrated that miR-140 regulates aggrecan. 
However, the mechanism of this regulation is unknown. It is possible that IL-1! 
negatively regulates the expression of aggrecan through the downregulation of the 
positive aggrecan regulator miR-140 since in vitro treatment of chondrocytes with IL-1! 
suppresses miR-140 expression (Miyaki et al., 2009).  
 
Despite all the preliminary data on the various cis-regulatory factors that affect the activities of 
the aggrecan promoter, regulatory elements directing specific expression in cartilage has yet to 
be described in vivo. The first in vivo study to search for these regulatory elements involved the 
rat aggrecan gene. Initially, this search had focused primarily on the proximal promoter, a 922-
bp DNA fragment with 640-bp 5'-flanking DNA and 282-bp exon 1 sequence.  This sequence 
had showed higher promoter activity in transfected chondrocytes than in fibroblasts (Doege et 
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al., 1994). However, this was not reproducible in subsequent experiments which indicated that 
there may be additional regulatory sequences other than the proximal promoter that are 
responsible for expression of the rat aggrecan gene in chondrocytes. DNA fragments upstream 
of the TSS and throughout the first intron (30kb) along with flanking sequences at the 3’ end of 
the gene were analysed in cell transfection assays as well as transgenic mice. The results of 
the cell transfection experiments showed an upstream "5kb tissue specific enhancer/repressor 
at about -12kb – -7kb relative to the TSS (called P3) and a far downstream enhancer without 
tissue specificity. When fused to an elongated proximal promoter sequence ranging from -3400 
- +280bp (called P0), this upstream ‘enhancer’ also displayed its functionality in vivo. However, 
although both elements were active in cell culture experiments, the downstream ‘enhancer’ 
was not effective in vivo. The function of the downstream enhancer thus remains unresolved 
(Doege et al., 2002). 
 
The combination of the upstream sequence P3 fused to P0 seems to direct expression of 
aggrecan in the developing cartilages of the long bones of the fore and hind limbs, the ribs, the 
scapula and some craniofacial cartilages. However, it is not completely sufficient for all aspects 
of aggrecan regulation; there was no expression found in vertebral bodies at embryonic day 
14.5 of development, nor in the cartilage of the digits. Also, the expression was present only in 
hypertrophic chondrocytes. It is possible that other controlling sequences may remain outside 
these two described elements and/or silencer sequences may be present within them (Doege 
et al., 2002).  
 
The second and more recent in vivo study, which was published during the course of my work, 
and that was performed in search of aggrecan cis-regulatory elements involved the mouse 
aggrecan gene. A highly conserved and regulatory 359-bp sequence located approximately 
10Kb upstream of the mouse Agc1 TSS (corresponding to a sequence present within the rat 
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P3 sequence) was identified. When multimerised (x4), this sequence was able to direct 
expression of the Col2a1 minimal promoter (-309 bp - +308 bp relative to the TSS) in both 
embryonic and adult cartilage in transgenic mice, in a manner that matches aggrecan 
expression. When tested in transient transfection, this sequence was almost as active in RCS 
(rat chondrosarcoma) cells as a similar construct containing 4 copies of the Col2a1 enhancer 
fused to the Col2a1 minimal promoter (Han and Lefebvre, 2008).  
 
From these experiments, it has been concluded that aggrecan expression appears to be at 
least partially regulated by a combination of proximal promoter sequences and distant 
elements at the 5’ end of the promoter. 
 
3.4 The proteolysis of aggrecan 
The core aggrecan protein is subject to extracellular proteolytic processing and is rarely 
present in an intact form within the proteoglycan aggregates of the cartilage matrix. This leads 
to an accumulation of fragments that bear the G1 regions coupled with a loss of those that do 
not by diffusion from the tissue.  As a result of this, proteoglycan aggregates become enriched 
with aggrecan G1 regions as opposed to the more intact molecules. These G1 regions can 
accumulate in the cartilage ECM with age, thereby competing for binding sites on HA with 
newly synthesised proteoglycan during turnover and remodelling of the cartilage ECM 
(Maroudas et al., 1998). 
 
Alterations in cartilage with normal aging are independent of the changes that take place in 
degenerative joint disease or injury, in which pathology-related changes in the cartilage ECM 
and cells can accumulate over 2-3 decades. A prominent feature of joint disease is the 
increased proteolytic cleavage of aggrecan, which considerably reduces the levels of the 
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protein. The proteolysis of aggrecan is mediated by aggrecanases and matrix 
metalloproteinases (MMPs) (Sztrolovics et al., 1997). It is now well recognized that the 
principal proteinases responsible for aggrecan degradation in situ in articular cartilage are the 
aggrecanases (Sandy, 2006). Two aggrecanase isoforms have been identified recently and 
are members of the ‘A Disintegrin and Metalloproteinase with Thrombospondin motifs’ 
(ADAMTS) gene family – ADAMTS-4 and ADAMTS-5. The five aggrecanase cleavage sites 
that have been identified in aggrecan include one residing in the IGD and four in the CS2 
domain (Tortorella et al., 2000). Within the IGD, in addition to the known aggrecanase 
cleavage site at TEGE373374ARGS and the MMP cleavage site at DIPEN341342FFGV, a new 
cleavage site VQTV356357TWPD (located between the aggrecanase and MMP sites) has 
been identified recently and is cleaved by the protease HtrA1 (Chamberland et al., 2009). 
 
 The IGD has been the focus of intense research due to its susceptibility to proteolytic 
cleavage in experimental systems that study proteoglycan catabolism and cartilage 
degenerative disease.  Altered glycosylation patterns within this domain during aging or in 
degenerative changes may further influence this susceptibility (Pratta et al., 2000).  
 
The remodelling and turnover of articular cartilage components such as aggrecan has to be 
carefully regulated so as to maintain the biomechanical properties of the tissue. Normal 
cartilage function depends on a high aggrecan content, high GAG substitution and large 
aggregate size. The loss of cartilage integrity in arthritis is associated with the impaired 
function of the aggrecan core protein due either to its proteolytic cleavage  (decreases the 
overall negative charge) or the proteolytic cleavage of HA (decreases the size of the 
aggregates). Osteoarthritis is a common condition of cartilage failure in which the careful 
regulation to maintain normal cartilage function has been disrupted.  
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3.5 The aggrecan knockout mouse 
The first example of a mutated proteoglycan gene identified in mammals is the cmd aggrecan 
gene, which gives rise to cartilage matrix deficiency (cmd) in mice. The cmd mouse is thus a 
natural knockout mouse model of the aggrecan gene. The cmd aggrecan gene has a single 7-
bp deletion in exon 5, which encodes the B loop of the G1 domain. This deletion gives rise to a 
frame shift resulting in the creation of a termination codon in exon 6. The potentially truncated 
32-kDa polypeptide that is created by this nonsense mutation contains an incomplete 
proteoglycan tandem repeat structure that is incapable of HA-binding. However, biochemical 
and immunological studies demonstrate a complete absence of aggrecan in the cartilage 
matrix of cmd mice. Homozygotes cmd (-/-) are characterized by dwarfism, a short snout, and 
a cleft palate and die shortly after birth due to respiratory failure.  Unlike the cartilage of wild-
type mice in which extensive matrix can be seen, the cartilage of homozygous mice appears 
as tightly packed chondrocytes with little matrix. Heterozygotes cmd (+/-), on the other hand, 
are born normal (Watanabe and Yamada, 2002).  
 
Although normal at birth, cmd heterozygotes exhibit two abnormal phenotypes as some 
differences in the metabolism of aggrecan may occur and create abnormal phenotypic 
changes after birth (due to the presence of only one normal allele of the gene). These 
abnormal phenotypes include slight dwarfism as well as late onset spinal misalignment. These 
heterozygotes usually die at 12-15 months of age compared to the average age of 2-2.5 years 
for wild-type mice. They die because they are unable to eat and starve to death within a month 
following acquisition of gait disturbance and decreased movement, which the mouse aquires 
due to its spinal distortions. Histology reveals that the degenerative changes that occur in 
heterozygotes are present within the cervico-thoracic spine where the vertebral bodies are 
deformed with the disappearance of the apophysis, and the herniated intervertebral disc likely 
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causes the spastic gait. Despite this, the knee joint and other cartilaginous tissues are 
apparently normal (Watanabe and Yamada, 2002).  
 
The mRNA levels of aggrecan are reduced in cmd-mutant mice. RT-PCR studies reveal that 
these levels are reduced by 59% in homozygotes and 19% in heterozygotes compared to wild-
type mice. Because of the relatively rapid turnover of aggrecan within cartilage, decreased 
synthesis may cause significant reduction of its deposition in tissue, which eventually leads to 
abnormal phenotypes in the heterozygotes (Watanabe and Yamada, 2002). 
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4 Osteoarthritis  
4.1 Overview 
The frequency and continual development of osteoarthritis (OA) represents a widespread 
cause of physical morbidity and impaired quality of life throughout the industrialized world. 
Short of surgical joint replacement, treatment of OA is limited to taking care of patients 
symptomatically and supportively.   
 
Being the most common joint disorder, OA affects 10-25% of all people aged over 65 (data 
taken from http://www.arc.org.uk). It is a degenerative joint disease resulting from a 
combination of risk factors that contribute to the pathogenesis of the disease. These include 
both mechanical stresses - such as obesity, misalignment, joint trauma and surgery - as well 
as biomechanical abnormalities - such as genetic predisposition and other metabolic disorders.  
Age and gender are also significant risk factors. Eventually, these risk factors lead to injury in 
all of the different components of the joint but primarily involving cartilage, bone and synovium 
(Figure 9). The effects on these three joint compartments manifest as articular cartilage 
breakdown, osteophyte formation, subchondral sclerosis, and alterations of the synovium on 
both morphologic and biochemical levels (Krasnokutsky et al., 2007).  
 
Cartilage has received the most attention in the study of OA due to articular chondrocytes 
acting as potential instigators of disease. These cells are responsible for the anabolic-catabolic 
balance required for matrix maintenance and tissue function due to their ability to synthesise 
the structural components of the extra-cellular matrix (ECM) along with matrix-degrading 
proteases (Aigner et al., 2007). 
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Figure 9: Diagram illustrating the evolution of osteoarthritis over time. Left: joint is 
normal. Middle: initial stages of disease in which you start to see thinning cartilage as indicated 
by the arrow. Right: a joint in which the disease has progressed so far, the cartilage has been 
destroyed leaving behind remnants as indicated by the arrows. Adapted from 
www.cvtechnologies.com/ images/osteoarthritis.jpg 
 
4.2 The development of osteoarthritis 
During OA, osteoarthritic chondrocytes are exposed to abnormal extracellular stimuli. This is 
due to several factors: firstly, the ECM surrounding the cells is damaged by mechanical stress 
or enzymatic degradation through synovial proteases, making it more likely to exhibit altered 
biomechanical properties. These alterations include the production of matrix fragments such as 
fragments of fibronectin, collagen, hylauronic acid and other cartilage matrix proteins, all of 
which may be important contributors to disease progression. These fragments can stimulate 
chondrocytes to produce inflammatory mediators and proteolytic enzymes that are present in 
OA cartilage (Homandberg, 1999), (Knudson et al., 2000), (Tchetina et al., 2007) 
 
Secondly, there are differences in the concentrations of growth factors, cytokines, chemokines 
and other inflammatory mediators diffusing into the cartilage from the synovial joint space. 
These factors are potent regulators of the chondrocyte phenotype and their concentrations are 
also modified in diseased cartilage by their increased expression in chondrocytes themselves 
as mentioned above. The inflammatory mediators produced by chondrocytes include: 
cytokines and chemokines such as IL-1, IL-6, IL-7, IL-8, IL-17, IL-18, MCP-1, LIF, GRO and 
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oncostatin M; reactive oxygen species such as nitric oxide, superoxide, hydrogen peroxide and 
peroxynitrate; and lipid-derived inflammatory mediators such as prostaglandins and 
leukotrienes (Goldring and Goldring, 2007), (Middleton and Tyler, 1992), (van der Kraan et al., 
2002), (Middleton et al., 1996). These mediators can work in an autocrine and paracrine 
manner to alter gene expression in chondrocytes. More specifically, they activate and even 
upregulate the expression of several matrix-degrading proteases, for example the matrix 
metalloproteinases (MMPs), which have an important role in the breakdown of collagenous 
and noncollagenous matrix components (Aigner et al., 2007). Type II collagen is cleaved 
mainly by collagenase 3 (MMP-13) and is further degraded by gelatinases (MMP-2 and MMP-
9)  (Billinghurst et al., 1997). As previously mentioned, it is thought that aggrecan is degraded 
mainly by the enzyme ADAMTS-5 (Sandy, 2006).  
 
As well as stimulating the production of catabolic factors in chondrocytes, the inflammatory 
mediators produced by these cells also contribute to cartilage loss through the inhibition of 
matrix synthesis. As the disease develops, chondrocytes typically respond to the damage and 
loss of ECM in several ways. The first is by proliferating, which results in the formation of 
chondrocyte clusters or ‘clones’ and the second is by attempting to produce new matrix. This 
new matrix, however, includes matrix proteins more commonly found during development 
(such as type IIA procollagen as opposed to Type II collagen). Regardless of the novel matrix 
being produced, there is still an imbalance between synthesis and degradation, which results 
in a net loss of matrix. Osteoarthritic chondrocytes in the articular cartilage undergo a 
phenotypic switch to chondrocytes present in the hypertrophic zone of the growth plate (which 
produce type X collagen and collagenase MMP-13) and this may at least be partly responsible 
for the changes seen in OA (Loeser, 2008).  
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So, not only do chondrocytes have a direct role in this degradation process but they also fail to 
compensate for matrix damage induced externally. Normally, when a tissue is damaged or 
under stress, the surrounding cells sense a change in the matrix and react with an appropriate 
repair response. One of the significant repair responses is the removal of the damaged matrix 
proteins, which may explain the initial production of proteolytic enzymes by chondrocytes as 
OA progresses. As soon as the damaged proteins are cleaned up, the proteolytic process 
needs to be switched off so that the cells can synthesize new matrix components. In order to 
shut down this catabolic process and stimulate the production of new matrix, a host of growth 
factors (such as BMP-2, BMP-7, CDMPs, IGF-1 and TGF-!) that are produced by 
chondrocytes and stored in cartilage bound to matrix proteins are released from the matrix as it 
is degraded. In the OA joint, however, this is not the case and it seems that this anabolic phase 
of matrix remodelling is insufficient or defective (Loeser, 2008).  
 
As mentioned above, although alterations in cartilage with normal aging are independent of the 
changes that take place in OA, aging may be an important factor that contributes to the 
imbalance in cartilage remodelling. With increasing age, cells are less responsive to growth 
factor stimulation (Loeser and Shakoor, 2003). This is most probably the cause of the 
insufficient growth factor activity in aged cartilage. As a result of this poor activity, cartilage 
would continue to degrade under mechanical forces due to a continued cycle of unchecked 
matrix degradation.  
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4.3 Understanding Osteoarthritis pathogenesis and testing 
therapeutic ideas 
 
There is a crucial need for animal models of osteoarthritis that can be used as research tools 
to uncover potential molecular markers for the onset of the disease and understand the role of 
gender and environmental factors in regulating the occurrence of the disease. There are now 
several lines of transgenic mice that acquire premature osteoarthritis. These have mutations or 
deletions of genes encoding several matrix and associated proteins, including type II, IX and XI 
collagen, membrane type 1 matrix metalloproteinase (MT-1-MMP), the "1 integrin subunit as 
well as ADAMTS5 (Young, 2005). Taken together, mouse models that either resist 
osteoarthritis or prematurely acquire osteoarthritis can be useful research tools to understand 
the molecular basis of osteoarthritis and for designing new treatments for the disease. 
Unfortunately, within these mouse models, embryonic lethality is often encountered due to the 
essential role of various genes in early embryonic development. Moreover, if the animal does 
survive, the outcomes of the gene deletions are difficult to interpret because of the severe 
skeletal malformations that may occur during development. An inducible and tissue specific 
(cartilage) gene deletion/overexpression approach would therefore be a better method to 
determine the function of a gene, its involvement in the progression of OA coupled with any 
potential therapeutic value it may have. This would increase the versatility and power of the 
murine system.  
 
As mentioned earlier, aggrecan is a chondrocyte-specific protein and its expression is detected 
in growth plate and articular chondrocytes of long bones and other cartilage tissues in the body 
(Murphy et al., 1999). Unlike collagen type II, aggrecan is expressed continuously in cartilage 
(Chambers et al., 2002). To generate a chondrocyte-specific transgenic mouse model, the 
enzyme Cre recombinase can be fused to a mutated ligand-binding domain of the human 
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estrogen receptor (ER) and driven by the aggrecan promoter. This fusion protein will be 
expressed in chondrocytes and translocated into the nuclei in response to the estrogen 
antagonist tamoxifen or 4-hydroxy tamoxifen (Feil et al., 1996). Therefore, there is a need to 
increase our understanding of the transcription mechanisms that govern the expression of 
aggrecan.  
 
The advent of the Cre-loxP recombination system has enabled the conditional inactivation of 
genes in the adult mouse. Bacteriophage P1 encodes the 38kDa Cre recombinase protein that 
catalyzes site-specific DNA recombination between 34 bp repeats named loxP.  In Cre-
mediated recombination, the resultant DNA structures depend on the orientation of these loxP 
sites. Two directly orientated repeats of loxP lead to the exision of intervening sequences 
leaving behind a single site within the genome whereas inverted repeats lead to the inversion 
of the involved sequences (Lakso et al., 1992), (Orban et al., 1992).  
 
The Cre-loxP system in mice relies on two key components - the conditional allele and the Cre 
driver. To produce a transgenic mouse with the conditional allele, a targeted mouse mutation in 
which mouse embryonic stem cells are targeted by homologous recombination is generated. 
This conditional allele harbors loxP recognition sites flanking critical DNA sequences such as 
exons and/or regulatory elements of the gene of interest. The Cre driver, on the other hand, is 
a transgenic mouse in which the expression of the enzyme Cre recombinase is controlled by 
tissue-specific regulatory elements. In order for this system to be inducible through which the 
precise timing of gene activation can be controlled, a fusion polypeptide between Cre 
recombinase and a mutant ligand binding domain of the estrogen receptor (called CreERT2) 
was also generated (Indra et al., 1999). The G400V/M543A/L544A triple mutation of the 
human estrogen receptor prevents binding to the natural ligand beta estradiol and retains the 
fusion protein in the cytosol. However, upon association with the synthetic ligand 4-hydroxy 
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(OH)-tamoxifen - an antagonist of the estrogen receptor – the protein translocates into the 
nucleus, where it mediates the excision of the loxP-flanked DNA sequence. Tamoxifen can 
therefore be administered to mice at specific times either during embryonic development or in 
adult animals to allow for temporal control of gene expression (Leone et al., 2003).  
 
Eventually, the production of an inducible chondrocyte-specific transgenic mouse model will 
enable us to activate/inactivate different genes specifically in cartilage following or preceding 
the induction of OA through surgery. For example, the mouse model can be mated to floxed 
transgenic mice in which particular genes (such as FGF-2, cytokines or TIMP-3) or a 
transcriptional stop sequence (that inhibits transcription) can be excised following activation of 
Cre recombinase. This can be done at any point in the progeny with the injection of tamoxifen.   
 
Increasing our understanding of the regulation of aggrecan would also be of direct importance 
towards our understanding of several cartilage diseases, such as those that are characterized 
by malformations of skeletal elements (chondrodysplasias) as well as those that are 
characterized by progressive and irreversible loss of adult articular cartilage (OA) since several 
disease-causing mutations have been found within the gene of humans and mice. For 
instance, as described in the ‘Introduction section 3.5’, there is a nonsense mutation in Agc1 
that leads to mouse cartilage matrix deficiency (Watanabe et al., 1994), (Kimata et al., 1981). 
Heterozygotes develop mild dwarfism along with spinal degeneration (Watanabe et al., 1997b). 
Homozygotes, on the other hand, die at birth and display severe dwarfism (Rittenhouse et al., 
1978). In humans, mutations of the aggrecan gene have been associated with 
spondyloepiphyseal dysplasia, OA and intervertebral disc degeneration (Gleghorn et al., 2005), 
(Horton et al., 1998), (Roughley et al., 2006). Furthermore, different forms of arthritis feature 
early with severe loss of aggrecan protein due to increased degradation and/or decreased 
production (see section 3.4). 
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5 Aims of PhD project 
 
Since little is known about the human aggrecan promoter, I have set out to try to identify the 
transcriptional regulatory mechanisms that direct chondrocyte specific expression of the 
Human aggrecan gene, which will in turn give us greater insight into osteoarthritis 
pathogenesis and therapies. This will be achieved by: 
 
1- Identifying and characterising the key regions in the human gene involved in regulating 
chondrocyte specific expression.  
2- Isolating these regions from genomic human DNA library clones and cloning them into 
expression cassettes for generating transgenic mice. 
3- Generating an inducible cartilage specific expression system using an aggrecan promoter 
and testing the functionality and specificity of this system under normal conditions as well as 
injury. 
4- Analysing the response of an identified human aggrecan promoter to injury. 
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Materials and Methods 
 
1  Isolation of nucleic acids: 
1.1 Isolation of plasmid DNA 
1.1.1 Mini-prep of plasmid DNA 
A single colony of transformed DH5" E.coli was used to inoculate 2 ml of Luria broth (LB) with 
appropriate antibiotic selection at the appropriate concentration (100 #g/ml ampicillin and 20 
#g/ml chloramphenicol). This was then incubated overnight at 37°C with shaking. The following 
day, 1.4 ml of overnight culture was transferred into a sterile 1.5 ml microcentrifuge tube and 
centrifuged at 10,000 x g for 5 minutes. The supernatant was discarded and the pellet of cells 
resuspended in 100 µl of buffer P1 (re-suspension buffer, Qiagen) by vortexing. This was 
followed by the addition of 100 µl of buffer P2 (lysis buffer, Qiagen). The solution was inverted 
6-8 times and incubated for 5 minutes. Next, 100 µl of buffer P3 (neutralisation buffer, Qiagen) 
was added. The solution was again inverted 6-8 times and incubated on ice for 15 minutes. 
Following this, the chilled solution was centrifuged at 12,000 x g for 5 minutes. The 
supernatant was transferred into a clean microcentrifuge tube containing 750 µl of ice-cold 
100% ethanol. This was centrifuged again at 12,000 x g for 10 minutes at 4°C. The 
supernatant was removed and the pelleted DNA washed in 100 µl 70% ethanol (at room 
temperature). Once the ethanol was removed, the DNA pellet was allowed to air dry. Lastly, 
the DNA pellet was resuspended in 40 µl of TE buffer. The purified plasmid was checked by 
digestion with appropriate enzymes and electrophoresed in a 1% (weight: volume) agarose 
gel, supplemented with ethidium bromide (0.2 ng/µl). The DNA was stored at -20°C.  
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1.1.2 Maxi-prep of plasmid DNA 
50 µl of the starter culture described above was used to inoculate 200 ml of LB (with 
appropriate antibiotic) and incubated overnight at 37°C with shaking. The ‘Qiagen Plasmid 
Maxi-prep Kit Cat No. 12163’ was used according to the manufacturer’s instructions to prepare 
the plasmid DNA from this culture. 
1.2 Isolation of genomic DNA from embryonic and adult tails 
The embryonic tail or adult tail biopsies were placed in sterile tubes with 200 µl of tail buffer 
(see Methods section 9.4) and 20 µl of proteinase K (10mg/ml, Sigma). After incubation at 
55°C overnight, 200 µl of  3.0M NH4OAc pH 8.0 was added. The tube was then vortexed and 
placed on ice for 5-10 minutes. Following this, the mix was spun down at 13,000 x g for 5 
minutes. The supernatant was transferred to a new tube and 200 µl of chloroform was then 
added. After vortex mixing, the solution was spun down at 13,000 x g for a further 5 minutes. 
Approximately 350 µl of the upper aqueous phase was removed into fresh tubes, and 1ml of 
absolute ethanol was added to precipitate the DNA. The tubes were centrifuged at 13,000 x g 
for 10 minutes at 4°C, the ethanol decanted and the resultant pellet washed in 100 µl of 70% 
ethanol. This ethanol was then removed and the resultant pellet left to air dry for 1-2 hours. 50 
µl and 200 µl of buffer TE were then added to the embryonic and adult tails respectively. The 
DNA was allowed to fully dissolve overnight.  
1.3 Oligonucleotides 
 
The web-based program primer 3 (www.primer3com) was used to design all oligonucleotides. 
These were then obtained from Sigma Aldrich and the stock re-suspended in TE buffer to a 
concentration of 100 pmol/µl, and stored at -20°C. 
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2  Standard manipulations of DNA 
In order to ligate DNA fragments into vectors and unless stated otherwise, inserts were 
generated by PCR, both were digested with appropriate restriction enzymes (vector and 
insert), isolated by gel electrophoresis, purified and then ligated. Vectors were always 
dephosphorylated.  
2.1 Polymerase chain reaction 
Proofreading PfX polymerase (Invitrogen) was used for the amplification of DNA fragments to 
be cloned into constructs directly used for microinjections. Taq polymerase (GoTaq®Flexi DNA 
Polymerase Promega Cat No. M8291) was used for the amplification of DNA fragments to be 
cloned into constructs used for recombineering. For PfX polymerase, the reaction was carried 
out with the final concentrations as follows: 50 ng of plasmid DNA or 100 ng of BAC DNA 
(template), 0.3 µM primer (for each forward and reverse), 1X Pfx amplification buffer, 1 mM 
MgSO4, 0.3 mM each dNTP, 1.0-2.5 Units of Pfx polymerase depending on amplicon size of 
DNA product and finally, distilled water made up to 50 µl. For Taq polymerase, the reaction 
was carried out with the final concentrations as follows: 50 ng of plasmid DNA or 100 ng of 
BAC DNA (template DNA), 0.1-1.0 µM primer (for each forward and reverse), 1X reaction 
buffer, 1-4 mM MgCl2, 0.2 mM each dNTP, 1.25 U Taq polymerase and distilled water made 
up to 50 µl. The DNA was denatured at 95°C and an annealing temperature range of 55-60°C 
was used in the form of a ‘touchdown PCR’ to account for different % of GC content in primers. 
The final part of the cycle was an extension at 72°C. The number of cycles used was 20-30 
depending on the nature of the experiment.  
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2.2 Digestion of DNA by restriction enzymes 
All restriction enzymes were obtained from New England Biolabs (NEB). The reactions were 
performed under conditions described in the NEB catalogue. The final reaction volumes varied 
depending on the volume of DNA to be digested with incubation periods of 1-8 hours. 
2.3 Agarose gel electrophoresis 
Gels were made at 1% (w:v) using agarose (Sigma) and 1 x TAE buffer (see Methods section 
9.1). The agarose was added to the TAE buffer and dissolved by boiling in a microwave for 
approximately 2 minutes per 100 ml. Ethidium bromide was then added to the cooled molten 
gel at a concentration of 0.2 µg/µl to enable visualisation of DNA under UV exposure. A 
loading buffer was always added to the DNA sample to be run at a final concentration of 1X 
prior to loading. Electrophoresis (Flowgen Horizontal 10 X 10 cm unit for restriction enzyme 
site analysis) was carried out at a constant field of 5-10 V/cm. DNA was visualised by 
Transillumination with ultraviolet light at 312 nm (for cloning) and 254 nm (for analysis).  
2.4 Isolation and purification of DNA from agarose gels 
For DNA samples ranging in size from 100bp-10kb, the ‘Qiagen QIAquick Gel Extraction Kit 
Cat. No. 28704’ was used for isolation and purification of DNA from agarose gels. This was 
done as described in the manufacturer’s protocol, with the resultant DNA suspended in a final 
volume of 30-50 µl of provided ‘elution buffer’. For DNA samples >10kb, the ‘Qiagen QIAEX II 
Gel Extraction Kit Cat No. 20021’ was used instead. This was done as described in the 
manufacturer’s protocol, with the resultant DNA suspended in a final volume of 20-40 µl of 
provided ‘elution buffer’. Electrophoresis of a sample of the eluted DNA was carried out to 
determine the quality and concentration. A nano-drop spectrophotometer was then used to 
measure the final concentration of the DNA. 
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2.5 Recombinant DNA procedures  
2.5.1 Blunt ending of 5’ and 3’ overhangs 
 
T4 DNA polymerase (NEB 3000 Units/ml) was used to blunt end 5’ and 3’ overhangs. 
Reactions were performed under conditions described in the NEB catalogue.  
2.5.2 Dephosphorylation  
Dephosphorylation of 5’ terminal phosphate groups was performed using Antarctic 
Phosphatase (NEB 5000 Units/ml) in an appropriate volume supplemented with 1 x Antarctic 
phosphatase buffer at 37°C for 30 minutes. Reactions were performed under conditions 
described in the NEB catalogue.  
2.5.3 DNA ligation  
T4 DNA ligase (NEB) was used to ligate insert DNA fragments into vector DNA. The ligations 
were performed with 20-50 ng of vector DNA and insert:vector molar ratio was at 3:1. Both  
sticky and blunt- ended ligations reactions were at a final volume of 20 µl for 4 hours at 25°C, 
and for blunt- were performed at a final volume of 20 µl for 16 hours at 15°C.  
2.6 Transformation of DH5! E.coli 
DH5" cells were transformed with newly cloned vectors. The competent cells were taken out of 
-80°C storage and thawed on ice for 20 minutes. Next, 10 µl of the ligation solution was added 
to 120 µl of cells, mixed and incubated on ice for 30 minutes. The transformation reaction was 
heat-shocked at 37°C for 5 minutes and then incubated on ice for a further 5 minutes. 
Following this, 500 µl of LB was added to the cells and incubated in a 250 rpm bacterial shaker 
for 1 hour at 37°C. The cells were spun down, re-suspended in a smaller volume of LB and 
plated on LB-agar plates with appropriate antibiotic selection. These were incubated at 37°C 
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overnight. Depending on the number of colonies that grew on the plate, 1-20 colonies were 
picked, grown overnight in 2 ml of medium and miniprepped. Restriction enzyme analysis was 
performed to identify successful cloning.  
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3 Cloning vectors 
 
3.1 pBluescript 
DNA fragments were cloned into pBluescript®II KS (+) phagemid (Figure 10) (Stratagene) as 
an intermediate vector for carrying out recombineering (see Methods section 4). pBluescript 
was either used as the targetting vector or the gap-repaired vector. All desired DNA fragments 
were eventually transferred into the appropriate expression vector, p!gal-Basic. pBluescript 
was  grown with ampicillin selection. 
3.2 p!gal-Basic 
The p!gal-Basic vector (Clontech) (Figure 11) was used in all in vivo transgenic work in order 
to identify potential human aggrecan regulatory sequences. p!gal-Basic is a mammalian 
reporter vector that lacks promoter or enhancer elements and so can be used to analyse the 
potential regulatory activity of cis-regulatory elements on gene expression in mammalian cells 
by assaying for !-galactosidase.  The vector has a polyadenylation signal upstream of the 
multiple cloning site (MCS), which reduces the background expression of !-galactosidase. It 
has a pUC origin of replication and an ampicillin resistance gene both allowing for the 
propagation and selection of varying forms of the vector in E.coli. All DNA fragments to be 
tested for regulatory activity were cloned into p!gal-Basic. 
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 Figure 10: pBluescript II KS (+/-) vector. Taken from 
http://www.genomics.agilent.com/files/Manual/212205_A01.pdf 
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Figure 11: p!gal-Basic vector.  Taken from http://www.clontech.com/images/pt/PT2109-5.pdf 
 
3.3 RP11-343B18 
RP11-343B18 is a bacterial artificial chromosome (BAC) cloned from Homo sapiens 
chromosome 15 and is 197370bp in size. It contains the entire human aggrecan gene along 
with >100kb of non-coding sequences upstream of the 5’ end of the gene. Sequencing of the 
BAC revealed a deleted fragment of DNA 92bp in size located between -68bp  to +23bp  
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relative to the human aggrecan TSS. Rp11-343B18 was grown with chloramphenicol selection. 
This BAC was obtained from the Sanger Institute (Cambridge, UK).  
3.4 RP11-1123E8 
RP11-1123E8 is a bacterial artificial chromosome (BAC) cloned from Homo sapiens 
chromosome 15 and is 142971bp in size. It contains the entire human aggrecan gene along 
with >80kb of non-coding sequences upstream of the 5’ end of the gene. Sequencing of the 
BAC revealed that the 92bp sequence missing from RP11-343B18 was present in RP11-
1123E8. RP11-11238 was grown with chloramphenicol selection. This BAC was obtained from 
CHORI (Children’s Hospital Oakland Research Institute, CA).  
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4 Recombineering 
 
The recombineering strain EL350 E.coli was used throughout the first part of the work 
described here. This was later substituted with the updated strain SW106. SW106 cells are 
derived from EL350 cells but can also be used for galK positive/negative selection. Like EL350, 
they contain an ara-inducible Cre gene. All recombineering strains were obtained from the 
National Institute of Health (http://recombineering.ncifcrf.gov/) in the USA.  
4.1 Making electro-competent EL350 or SW106 E.coli (for 
introducing BAC DNA, prior to recombineering): 
On day 1, the recombineering cells were streaked on an antibiotic free LB/agar plate. This was 
then incubated at 32°C overnight. On day 2, a colony was used to inoculate 2 ml of LB without 
antibiotic (grown overnight at 32°C and at 220 rpm). On day 3, 2 ml of the overnight culture 
was used to inoculate 100 ml LB without antibiotic (grown at 32 °C until OD600=0.4-0.6). Next, 
the cells were pelleted at 3500 rpm for 15 minutes at 4°C. They were then washed 3 x in 30 ml 
10% glycerol. Finally, they were resuspended in a few mls of 10% gycerol.  Cells were used 
immediately or stored in 40 µl aliquots at -80°C.  
4.2 Transforming a target BAC (RP11-343B18/RP11-1123E8) into 
electro-competent cells 
An aliquot of cells was taken out of -80°C storage and thawed on ice. Approximately 100 ng of 
'RP11-343B18' or 'RP11-1123E8’ DNA was added to these cells and incubated on ice for 10 
minutes. The DNA/cells mixture was then transferred to chilled 0.1 cm cuvettes (BIORAD 165-
2089) and pulsed using an electroporator (Resistance: 200 $, Volts: 1.75 V, Capacitance 2.5 
µF). The time constant should be approximately 4-5 ms. One ml of antibiotic free LB was then 
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quickly added to the cuvette and the solution transferred to a clean 15 ml tube. This was then 
shaken at 32°C for 1 hour. An LB/agar plate with chloramphenicol was then spread with 300 µl 
of the electroporated cells and incubated at 32°C overnight.  A glycerol stock was always made 
from the transformed recombineering cells. 
4.3 Recombineering 
Once the appropriate BAC (RP11-343B18 or RP11-1123E8) had been introduced into the 
recombineering competent cells, they had to be made electro-competent again, in order to 
allow for transfornation of the recipient (retreival) plasmid. On day 1, cells were streaked from a 
stock of EL350 or SW106 cells containing the desired BAC on an LB/agar plate with 
chloramphenicol selection and incubated overnight at 32°C. On day 2, a colony was used to 
inoculate 2 ml of LB with appropriate antibiotic resistance (grown overnight at 32°C and at 220 
rpm). On day 3, 2 ml of the overnight culture was used to inoculate 100 ml LB containing 
chloramphenicol  (grown at 32 °C until OD600=0.4-0.6). The 100 ml culture was then aliquoted 
into 5 x 10 ml samples on ice. Next, the samples were subject to heat shock by shaking at 
42°C for 15 minutes. These were then cooled in ice-cold water and pooled together. Next, the 
cells were pelleted at 3500 rpm for 15 minutes at 4°C. They were then washed 3 x in 30 ml 
10% glycerol. Finally, they were resuspended in a few mls of 10% gycerol. 1-3 µl of 20-50 ng 
recipient plasmid DNA was immediately electroporated into 40 µl aliquots of the cells as 
described in Methods section 4.1. The electroporation of the targetting DNA into these 
prepared E-competent cells to be recombined with RP11343B18 or RP11-1123E8 was carried 
out using the protocol in Methods section 4.2 with one exception; BAC DNA is substituted with 
the targetting DNA.  
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5 Generation of Constructs 
Unless stated otherwise, all the locations of the sequences below are relative to the Human 
Aggrecan TSS based on a TSS at position 87,147,670 on chromosome 15 (Assembly: March. 
2006 (NCBI36/hg18). 
 
AB: A short sequence representing the core/basal promoter of the human aggrecan gene and 
located -452bp to +375bp. This sequence, however, contains a deletion corresponding to 92bp 
between -68 to +23bp. 
AB+92: A short sequence representing the core/basal promoter of the human aggrecan gene 
and located -452bp to +375bp. This sequence includes the missing 92 bp. 
EF: A short DNA sequence located -20,054bp to -19,227bp. 
cis 3: A short DNA sequence located -10,703bp to -10,343bp. 
IJ: A short DNA sequence located -13,519bp to -13,019bp. 
cis 7: A short sequence located within the 14th intron of the human aggrecan gene at 
+64,630bp to +65,005bp. 
pBS/cis 6 5’arm: A short sequence of DNA encompassing 416bp of AB which corresponds to 
the location -41bp to +375bp with an additional 31 base pairs at its 3’end corresponding to the 
sequence in the p!gal-Basic vector from the KpnI site to the XhoI site in the MCS. 
pBS/cis 6 3’arm: A short sequence of DNA encompassing the first 292bp of the LacZ gene 
within the the p!gal-Basic vector with an additional 150bp at the 5’end corresponding to the 
sequence found in the p!gal-Basic vector between the XhoI site in the MCS and the LacZ 
gene.  
cis 6: An approximately 3kb sequence located +5,000bp to +7,813bp. 
A1: A short sequence located -9,477bp to -9,118bp relative to the mouse Agc TSS. A1 is the 
mouse equivalent sequence to the human cis 3 fragment. 
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Table 4: List of constructs generated. The names of the constructs are shown in the middle 
column while the methods in which they were cloned are shown in the column on the right.  
The constructs are illustrated below with further details on their generation.  
 
 Name of Construct Method of Cloning 
1 %galAB restriction site cloning 
2 %galAB+92 restriction site cloning 
3 %galAB+EF restriction site cloning 
4 !galAB+92 +EF restriction site cloning 
5 !gal AB + cis 3 restriction site cloning 
6 !galAB+92 + cis 3 restriction site cloning 
7 !galAB + IJ + EF restriction site cloning 
8 !galAB + A1 + A4 restriction site cloning 
9 pBS/cis 7 recomb restriction site cloning 
10 pBSAB + EF restriction site cloning 
11 pBSAGG20 recombineering 
12 !AGG20 restriction site cloning 
13 !AGG10 restriction site cloning 
14 !AGG13 restriction digestion 
15 !galAB + 7 recombineering 
16 !AGG20 + int3 recombineering 
17 ColII4xA1Cre restriction site cloning using 
sequence from Veronique 
Lefebvre's group, Lerner 
Research Institute, Ohio  
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1-!galAB 
 
 
 
 
p!gal-Basic vector was digested with BglII and XhoI restriction enzymes. AB was amplified by 
PCR performed on the BAC RP11343-B18. The primers used were ‘forward A (XhoI)’ and 
‘reverse B (BglII)’. The bracketed restriction sites XhoI and BglII were designed at the 5’ends of 
these primers. The subsequent PCR product AB was verified on an agarose gel and digested 
overnight with XhoI and BglII and finally ligated to the digested p!gal-Basic vector. The 
transgene was excised from the plasmid backbone by digestion with KpnI and BamHI. 
 
2- !galAB+92 
 
p!gal-Basic vector was digested with BglII and XhoI restriction enzymes. AB+92 was amplified 
by PCR performed on the BAC RP11-1123E8. The primers used were ‘forward A (XhoI)’ and 
‘reverse B (BglII)’. The bracketed restriction sites XhoI and BglII were designed at the 5’ends of 
these primers. The subsequent PCR product AB+92 was verified on an agarose gel and 
digested overnight with XhoI and BglII and finally ligated to the digested p!gal-Basic vector.  
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3- !galAB+EF 
 
p!gal-Basic vector was digested with BglII and NheI restriction enzymes. AB was amplified by 
PCR performed on the BAC RP11343-B18. The primers used were ‘forward A (XhoI)’ and 
‘reverse B (BglII)’. The bracketed restriction sites XhoI and BglII were designed at the 5’ends of 
these primers. EF was amplified by PCR performed on the BAC RP11-343B18. The primers 
used were ‘forward E (NheISalI)’ and ‘reverse F (XhoI)’. The bracketed restriction sites 
5’NheI+SalI3’ and XhoI were designed at the 5’ends of these primers. The subsequent PCR 
product AB was verified on an agarose gel and digested overnight with XhoI and BglII. EF 
however was prepared in the same way but digested with NheI and XhoI instead. Finally, they 
were ligated via a three-way ligation to the digested p!gal-Basic vector. !galAB+EF was used 
to clone !galAB+IJ+EF. 
 
4- !galAB+92+EF 
 
p!gal-Basic vector was digested with BglII and NheI restriction enzymes. AB+92 was amplified 
by PCR performed on the BAC RP11-1123E8. The primers used were ‘forward A (XhoI)’ and 
‘reverse B (BglII)’. The bracketed restriction sites XhoI and BglII were designed at the 5’ends of 
these primers. EF was amplified by PCR performed on the BAC RP11-343B18. The primers 
used were ‘forward E (NheI)’ and ‘reverse F (XhoI)’. The bracketed restriction sites NheI and 
XhoI were designed at the 5’ends of these primers. The subsequent PCR product AB+92 was 
verified on an agarose gel and digested overnight with XhoI and BglII. EF however was 
prepared in the same way but digested with NheI and XhoI instead. Finally, they were ligated 
via a three-way ligation to the digested p!gal-Basic vector. !galAB+92+EF will be used for 
recombineering of  !AGG20+92. 
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5- !galAB+ cis  3 
 
p!gal-Basic vector was digested with BglII and NheI restriction enzymes. AB was amplified by 
PCR performed on the BAC RP11343-B18. The primers used were ‘forward A (XhoI)’ and 
‘reverse B (BglII)’. The bracketed restriction sites XhoI and BglII were designed at the 5’ends of 
these primers. cis 3 was amplified by PCR performed on the BAC RP11-343B18. The primers 
used were ‘forward cis 3 (NheI)’ and ‘reverse cis 3 (XhoI)’. The bracketed restriction sites NheI 
and XhoI were designed at the 5’ends of these primers. The subsequent PCR product AB was 
verified on an agarose gel and digested overnight with XhoI and BglII. cis 3 however was 
prepared in the same way but digested with NheI and XhoI instead. Finally, they were ligated 
via a three-way ligation to the digested p!gal-Basic vector. The transgene was excised from 
the plasmid backbone by digestion with KpnI and BamHI. 
 
6- !galAB+92+ cis  3 
 
p!gal-Basic vector was digested with BglII and NheI restriction enzymes. AB+92 was amplified 
by PCR performed on the BAC RP11-1123E8. The primers used were ‘forward A (XhoI)’ and 
‘reverse B (BglII)’. The bracketed restriction sites XhoI and BglII were designed at the 5’ends of 
these primers. cis 3 was amplified by PCR performed on the BAC RP11-343B18. The primers 
used were ‘forward cis 3 (NheI)’ and ‘reverse cis 3 (XhoI)’. The bracketed restriction sites NheI 
and XhoI were designed at the 5’ends of these primers. The subsequent PCR product AB+92 
was verified on an agarose gel and digested overnight with XhoI and BglII. Cis 3 however was 
prepared in the same way but digested with NheI and XhoI instead. Finally, they were ligated 
via a three-way ligation to the digested p!gal-Basic vector. The transgene was excised from 
the plasmid backbone by digestion with KpnI and BamHI. 
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7- !galAB+IJ+EF 
 
!galAB+EF was digested with XhoI and AscI restriction enzymes. AscI restriction site in 
!galAB+EF is located 264bp downstream of the XhoI site within AB. IJ was amplified by PCR 
performed on the BAC RP11-343B18. The primers used were ‘forward I (XhoI)’ and ‘reverse F 
(AscI)’. The bracketed restriction sites XhoI and AscI were designed at the 5’ends of these 
primers. The subsequent PCR product IJ was verified on an agarose gel and digested 
overnight with XhoI and AscI. Finally, it was ligated to the digested !galAB+EF vector. 
!galAB+IJ+EF was used for recombineering of !galAB+7. 
 
8- !galAB+ cis  3+ cis 7 
 
!galAB+cis 3 was digested with BglII and HindIII restriction enzymes. HindIII restriction site is 
found within the MCS of the p!gal-Basic vector. Cis 7 was amplified by PCR performed on the 
BAC RP11343-B18. The primers used were ‘forward cis 7 (BglII)’ and ‘reverse cis 7 (HindIII)’. 
The bracketed restriction sites BglII and HindIII were designed at the 5’ends of these primers. 
The subsequent PCR product cis 7 was verified on an agarose gel and digested overnight with 
BglII and HindIII. Finally, it was ligated to the digested !galAB+cis 3 vector. The transgene was 
excised from the plasmid backbone by digestion with KpnI and BamHI. 
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9- pBS/cis 6 recomb  
 
pBluescript®II KS (+) vector was digested with SacII and EcoRI restriction enzymes. The 
pBS/cis 6 5’arm was amplified by PCR performed on the vector !galAB. The primers used 
were ‘Forward 5’arm for pBS/cis 6 (SacII)’ and ‘Reverse 5’arm for pBS/cis 6 (NotI)’. The 
bracketed restriction sites SacII and NotI were designed at the 5’ends of these primers. The 
pBS/cis 6 3’arm was amplified by PCR performed on !galAB. The primers used were ‘Forward 
3’arm for pBS/cis 6 (BamHI)’ and ‘Reverse 3’arm for pBS/cis 6 (EcoRI)’. The bracketed 
restriction sites BamHI and EcoRI were designed at the 5’ends of these primers. cis 6 was 
amplified by PCR performed on the BAC RP11-343B18. The primers used were ‘Forward cis 6 
(NotI)’ and ‘Reverse cis 6 (BamHI)’. The bracketed restriction sites NotI and BamHI were 
designed at the 5’ends of these primers. The subsequent 5’arm PCR product was verified on 
an agarose gel and digested overnight with SacII and NotI. The 3’arm and cis 6 were verified in 
the same way but digested with BamHI+EcoRI and NotI+BamHI respectively. Finally, all three 
fragments were ligated via a four-way ligation to the digested pBluescript®II KS (+) vector. 
pBS/cis 6 recomb  was used as the targeting vector for recombineering of !AGG20+ cis 6.  
 
10- pBSAB + EF 
 
pBluescript®II KS (+) vector was digested with SpeI and NotI restriction enzymes. AB was 
amplified by PCR performed on the BAC RP11343-B18. The primers used were ‘forward A 
(XbaI)’ and ‘reverse B (NotI)’. The bracketed restriction sites XbaI and NotI were designed at 
the 5’ends of these primers. EF was amplified by PCR performed on the BAC RP11-343B18. 
The primers used were ‘forward E (SpeI)’ and ‘reverse F (XbaI)’. The bracketed restriction sites 
SpeI and XbaI were designed at the 5’ends of these primers. The subsequent PCR product AB 
was verified on an agarose gel and digested overnight with XbaI and NotI. EF however was 
prepared in the same way but digested with SpeI and XbaI instead. Finally, they were ligated 
via a three-way ligation to the digested pBluescript®II KS (+) vector. pBSAB+EF was used for 
recombineering of pBSAGG20.  
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11- pBSAGG20 
 
pBSAGG20, which contains approximately 20kb of human aggrecan non-coding sequence (-
20,054bp to +375bp relative to the TSS), was generated by recombineering using pBSAB+EF 
as the gap-repaired vector. For more details, see Results Chapter 1 section 1.2.4.1.  
 
12- !AGG20 (version 1) 
 
    !AGG20 (version 2) 
 
To generate !AGG20, the p!gal-Basic vector was digested with KpnI and blunt ended. Next, 
pBSAGG20 was digested with the restriction enzymes SalI and NotI to retrieve the non-coding 
20kb human aggrecan sequence (-20,054bp to +375bp relative to the human Agc TSS), which 
was then blunt-ended. The two DNA fragments were then ligated to each other and a construct 
containing the 20kb sequence in the correct orientation was identified. The fusion of the blunt 
ended SalI site on the 20kb sequence to the blunt ended KpnI site on the p!gal-Basic vector 
regenerated a SalI site. The transgene was excised from the plasmid backbone by digestion 
with SalI. !AGG20 version 1 and 2 are the exact same construct with different representations 
to further clarify the construction of some of the subsequent constructs below.  
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13- !AGG10  
 
To generate !AGG10, the vector !AGG20 was digested with BstBI (-13,838bp relative to the 
human Agc TSS) and KpnI (-4,182bp relative to the human Agc TSS) to release an 
approximately 10kb fragment within the 20kb sequence in !AGG20 (See !AGG20 version one 
to note relative locations of restriction sites used). The vector was then blunt-ended and ligated 
to recircularize. It was excised from the plasmid backbone by digestion with SalI. 
 
14- !AGG13 
 
Unlike all the other vectors described, !AGG13 isn’t a self-propagating vector and is merely a 
digested product of the vector !AGG20. To generate !AGG13, the vector !AGG20 was 
digested with AhdI (-13,030bp relative to the human Agc TSS) and SalI deleting the ampicillin 
resistance gene along with approximately 7kb of the 20kb sequence in !AGG20 (see !AGG20 
version 2). The AhdI and SalI sites in the figure represent digested sites and the fragment is 
linear.  !AGG13 was injected into pronuclei in this format. 
 
15- !galAB+7 
 
!galAB+7, which contains approximately 7kb of the human aggrecan non-coding sequence (-
20,054bp to -13,030bp relative to the TSS) fused to AB, was generated by recombineering 
using !galAB+IJ+EF as the gap-repaired vector. It was excised from the plasmid backbone by 
digestion with SalI. For more details, see Results Chapter 1 section 1.2.5.2 .  
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16- !AGG20+ cis  6 
 
!AGG20+cis 6, which contains approximately 20kb of human aggrecan non-coding sequence 
(-20,054bp to +375bp relative to the TSS) fused to cis 6 (located downstream of the 20kb 
sequence), was generated by recombineering using pBS/cis 6 recomb as the targeting vector 
and linearized !AGG20 as the gap-repaired vector. It was excised from the plasmid backbone 
by digestion with SalI. For more details, see Results Chapter 1 section 1.2.6.1.  
 
17- ColII4xA1Cre 
 
The original vector containing ColII4xA1 sequence was obtained from Veronique Lefebvre’s 
group (Han and Lefebvre, 2008). The A1 sequence was amplified by PCR performed on 129 
mouse genomic DNA. The Forward and Reverse primers used were designed with BamHI and 
BglII restriction sites respectively at the 5’ ends. The A1 PCR product was verified on an 
agarose gel and digested with BamHI and BglII. It was then ligated into pCR4-TOPO 
(invitrogen) and a clone consisting of 4 tandem copies of the A1 sequence was selected. 
Cloning the four copies of A1 into a LacZ reporter containing the &309 to +308 Col2a1 
sequence (Zhou et al., 1995) generated the colII4xA1 transgene. ColII4xA1Cre was generated 
by cloning colII4xA1 upstream of the CreERT2 fusion gene, an IRES sequence and the flirefly 
luciferase gene.  
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List of primers used are shown below:  
Table 5: Table representing the names of the primers used, their sequences and the 
generated products of each primer pair. Restriction cloning sites are underlined. 
 
Name of Primer Sequence of Primer PCR product 
description 
Forward A 
(XbaI) 
 
5’ ATT CTA GAC CAG CCT CAG CTG 
CAG AAC C 3’ 
 Reverse B  
(NotI) 
5’ ATA AGA ATG CGG CCG CCC TTG 
AAG AGT TGG ACT CC 3’ 
Basal promoter 
called AB to be 
cloned into pBS 
Forward E  
(SpeI) 
5’ TGA CTA GTG CTG AGC TGG GTT 
AAC ACC 3’ 
Reverse F 
(XbaI) 
5’ AGT CTA GAG TTA AGC CCG CAA 
ACT TGT 3’ 
5’ arm of ~20kb 
aggrecan 
sequence  to be 
cloned into pBS 
Forward A  
(XhoI) 
5’ ATA ACT CGA GCC AGC CTC AGC 
TGC AGA ACC 3’ 
Reverse B  
(BglII) 
5’ATA AGA TCT CCT TGA AGA GTT 
GGA CTC C 3’ 
 
Basal promoter 
called AB to be 
cloned into 
pbgal basic 
Forward E  
(NheI) 
 5’ TAA GCT AGC GTC GAC GCT GAG 
CTG GGT TAA CAC C 3’  
 Reverse F  
(XhoI) 
5’ATA ACT CGA GGT TAA GCC CGC 
AAA CTT GT 3’ 
 
5’ arm of ~20kb 
aggrecan 
sequence to be 
cloned into 
pbgal basic 
Forward I  
(XhoI) 
5’ ATA ACT TAA GCA ACT GAG GCT 
GTT CAC AA 3’ 
Reverse J  
(AscI) 
5’ ATA ACT CGA GCT TGG ACC CAA 
AGT CAG AA 3’ 
 
3’arm of deleted 
7kb sequence 
to be cloned 
into p!gal 
Forward cis 3 
(NheI) 
5' ATA GCT AGC TCC AGA ATG GAA 
GGG CCA AG 3' 
Reverse cis 3 
(XhoI) 
5' AAT ACT CGA GCT TTT CCA GAG 
TCA AAA GTC A 3' 
cis 3 sequence 
to be cloned 
into p!gal basic 
Forward cis 7 
(BglII) 
5' ATA AGA TCT GCA GCA GCA GCA 
ACA GTT C 3' 
Reverse cis 7 
(HindIII) 
5' ATA AAG CTT GGC CCC TGA AAT 
GGC TCT  3' 
cis 7 sequence 
to be cloned 
into p!gal basic 
Forward 5’arm 
for pBS/cis 6 
(SacII) 
5’ ATA CCG CGG CCC GTC CCT ATG 
TAT GTG T 3’ 
 
Reverse 5'arm 
for pBS/cis 6 
(NotI) 
5’ ATA AGA ATG CGG CCG CTC GAG 
CTA GCA CGC GTA AG 3’ 
 
5’arm sequence 
fused to cis 6 to 
be recombined 
into  p!gal 
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Forward 3'arm 
for pBS/cis 6 
(BamHI) 
5’ AAG GAT CCA TCT AAG TAA GCT 
TGG GGG ATC G 3’ 
 
Reverse 3'arm 
for pBS/cis 6 
(EcoRI) 
5’ AAG AAT TCA TAG GTT ACG TTG 
GTG TAG ATG G 3’ 
3’arm sequence 
fused to cis 6 to 
be recombined 
into  p!gal 
Forward cis 6 
(NotI) 
5’ ATA AGA ATG CGG CCG CGG GAA 
GAC GGA CTG TAA CCA 3’ 
Reverse cis 6 
(BamHI) 
5’ AAG GAT CCA AGG TCC ATC AGC 
ATT TT 3’ 
cis 6 sequence 
to be 
recombined into 
!AGG20.   
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6 Generation of transgenic mouse embryos and lines 
Transgenic mice were generated in collaboration with Professor Dominic Wells and Ke Liu 
from the Kennedy Institute of Rheumatology (KIR). For all procedures, C57BL10 x CBA/J F1 
mice were used. All techniques performed on animals were licensed under the Animals 
(Scientific Procedures) Act 1986, personal license number (PIL) 70/20608 and project license 
number (PPL) 70/6483.  
6.1 Transgenic media 
M2 and M16 media was purchased from Speciality Media (New Jersey, USA) and made up 
according to manufacturers’ instructions. M16 was covered in mineral oil and incubated at 
37°C in 5% CO2, 95% air to simulate in vivo conditions during use. M2 was kept at room 
temperature. 
6.2 Preparation of DNA for microinjection 
Fragments of linear DNA for microinjection were isolated from their plasmid vectors with the 
appropriate restriction enzymes, blunt ended and gel-purified in Ethidium bromide (EtBr) free 
gels without UV exposure. This was done by running two identically digested samples 
alongside each other on an EtBr free gel, cutting the gel vertically between the two samples, 
staining one of the halves in an EtBr solution and exposing this half to UV to mark by gel 
excision the location of the desired band. Finally, the desired band was cut from the other non-
stained half using the stained gel for guidance. The DNA was then purified from the gel using 
spin columns (see Methods section 2.4).  The concentration of the DNA was established, 
diluted to 2 ng/µl with embryo water (Sigma), and stored at -20°C. 
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6.3 Preparation of egg donors by superovulation    
Superovulation was performed on F1 females between 4-6 weeks of age. On day one, 5 IU 
follicle stimulating hormone (Intervet UK Lt; folligon) was administered to each mouse via 
intraperitoneal injection. On day 3, approximately 46 hours later, 5 IU lutanising hormone 
(Intervet UK Lt; chorulon) was administered to each mouse via intraperitoneal injection. 
Following this injection, the mice were mated with F1 males overnight. 
 
On the morning of day 4, copulation plugs were checked to identify mated females. From 
these, oviducts were removed and dissected in M2 media giving an average of 10-15 eggs per 
oviduct. These were removed by forceps and transferred into clean media via mouth 
pippetting. Cumulus cells were removed by treatment with a few drops of hyaluronidase (300 
µg/ml) in M2. The eggs were gently shaken until the cumulus cells had visibly detached from 
the egg surfaces (>4 minutes). They were thoroughly rinsed, and transferred to M16 media to 
be incubated for 1-2 hours.  
6.4 Injection of fertilised eggs.  
Injection of fertilised eggs was done approximately 72 hours after superovulation. This is 
described in Hogan et al (1994). Undamaged eggs were transferred to clean M16 and 
incubated until their transfer into pseudopregnant females. 
6.5 Transfer to pseudopregnant recipients 
Mating with vasectomised F1 males overnight on day 3 generated pseudopregnant mice. 
Females with copulation plugs were selected and used 1 day post-coitum. The mice were 
anaethetised with 50 µl hypnorm (Janssen; fentanyl citrate, final concentration 0.79 mg/ml; 
fluanisone, final concentration 2.5 mg/ml) and 50 µl hypnoval (Roche; midazolam, final 
concentration 1.25 mg/ml) via intraperitonel injection. Microinjected eggs, at 1 cell stage, were 
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transferred through the infundibulum to the oviducts. 20-30 eggs were transferred per 
pseudopregnant female.  
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7 Transgenic mouse analysis 
 
7.1 Analysis of transgenic mouse embryos 
7.1.1 Collection of transient transgenic embryos. 
Unless otherwise stated, mice were collected at the E14.5 stage of gestation (14.5 dpc). The 
embryonic tails were removed into separate sterile tubes and the yolk sac discarded. This was 
done in ice cold PBS. DNA was extracted from the embryonic tails using the protocol 1.2.  
7.1.2 Genotyping by PCR. 
For detection of transgenics harbouring DNA from the human aggrecan lacZ constructs, the 
polymerase chain reaction was used with Taq polymerase (Methods section 2.1).  
The primers used were: 
Reverse primer: 5’ TCA CGT TCT TGT TGG TCA AAG 3’ 
Forward primer: 5’ CGG CAG GTA CCG AGC TCT T 3’  
7.1.3 X-gal staining of embryos  
To assay for the expression of the !-galactosidase gene, the embryos were stained with X-gal 
(5-bromo-4-chloro-3-indolyl-!-d-galactopyranoside). To do this, the embryos were put in 5 ml 
fixative solution (see Methods section 9.4) for 15 minutes, and then rinsed in 5 ml of rinse 
solution (see Methods section 9.4) for 3X30 minutes at room temperature. The rinse was finally 
replaced with 5 ml of staining X-gal solution (see Methods section 9.4) and the embryos 
rotated overnight in the dark at room temperature.  
7.1.4 Histological analysis 
Embryos that expressed the lacZ gene were embedded in paraffin wax and sectioned for 
histological analysis. The embryos were removed from the staining solution, washed in rinse 
PhD Thesis                                                                                                                           Andrea Layyous     
  
 113 
solution and put in 5 ml fixative for two hours. This was then replaced sequentially with 5 ml of 
30% ethanol, 50% ethanol, and 70% ethanol, each for 30 minutes. Once in 70% ethanol, the 
embryos could be stored at -20°C. Before embedding in wax, they were further dehydrated 
sequentially in 80% ethanol for 30 minutes, 90% ethanol for 30 minutes, and 100% ethanol 3 
times for 30 minutes. The embryos were then put in 5 ml of 50% ethanol/ 50% xylene for 15 
minutes, then 100% xylene until the embryos sunk.  Finally, they were removed and placed in 
molten paraffin wax at 65 degrees Celcius for 4-8 hours. They were then transferred to a 
plastic mould containing paraffin wax and left to set. Unless otherwise stated, all steps were 
performed at room temperature. The wax blocks were then cut by David Essex (Charing Cross 
Hospital) at 6 #m, counterstained with eosin, Haematoxilin or both and examined under a 
microscope.  
7.2 Analysis of adult transgenic mouse lines 
Throughout my PhD, I helped generate and was responsible for two mouse lines which 
contained the following transgenes:  !AGG20 and ColII4xA1Cre (see constructs 12 + 17, 
Methods section 5).  
7.2.1 Analysis of !AGG20 line 
7.2.1.1 Genotyping using Real-time PCR 
‘JumpStartTM Taq ReadyMixTM for Quantitative PCR’ (Sigma D7440) was used for genotyping 
the !AGG20 line. Before setting up the PCR reaction, a mix of the two sets of primers and 
fluorescent probes to be used was prepared (each at 10 µM) and stored at -20°C. Each 
reaction was carried out at a final volume of 10 µl as follows: 5 µl of 2x PCR mix, 1.6 µl of 25 
mM MgCl2 (final concentration of 5.5 mM), 100-200 ng of template DNA extracted from adult 
tails, 0.12 µl of Primer/probe mix (final concentration of 20 nM for each) and 2.28 µl of water. 
The PCR reaction was carried out as follows: Initial 94°C step for 10 minutes. Then, 40 repeat 
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cycles of 94°C for 30 seconds followed by 60°C for 60 seconds.  The primers used were for 
LacZ as well as 18S (for normalization). The LacZ probe was designed with the fluorescein 6-
FAM (green) at its 5’ end while the 18S probe was designed with HEX (pink) at its 5’ end. Both 
LacZ and 18S fluorescent probes were designed with the universal fluorescence quencher 
BHQ1 at their 3’ ends. 
 
Sequences of Primers and probes: 
LacZ Probe: 5'6FAM TCAGCCGGAAAACCTACCGGATTGA 3'BHQ1 
LacZ forward primer:  
GTGCACGGCAGATACACTTG 
LacZ Reverse: 
AACGGTAATCGCCATTTGACCAC 
18S Probe: 
5'HEX CTTCCGGGAAACCAAAGTCT 3'BHQ1 
18S Forward: 
GACCATAAACGATGCCGACTG 
18S Reverse: 
CCCTTCCGTCAATTCCTTTAAG 
 
7.2.1.2 X-gal staining of !AGG20 adult mice 
To assay for the expression of the !-galactosidase gene in adult mice from the !AGG20 line, 
mice of different ages were culled and dissected to isolate different tissues to be stained with 
X-gal. To do this, the dissected tissue such as knees, hips, digits or spine were put in 50 ml 
fixative solution for 2 hours, and then rinsed in 50 ml of rinse solution for 3X30 minutes at room 
temperature. The rinse was replaced with 50 ml of staining X-gal solution and the tissue 
rotated overnight in the dark at room temperature. See methods section 9.4 for preparation of 
fixative, rinse and X-gal solutions. The same was done for the knees of !AGG20 mice that had 
undergone DMM or axial loading (see methods section 8), 
7.2.1.3 Histological analysis of X-gal stained tissue 
Dissected tissue that expressed the LacZ gene was removed from the staining solution, 
washed in rinse solution and fixed in 10% formalin. They were then decalcified in dilute formic 
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acid, and embedded in paraffin wax to be sectioned for histological analysis. The 
decalcification, embedding and cutting was done by David Essex (Charing Cross Hospital). 
The wax blocks were cut at 6 #m, counterstained with eosin, Haematoxilin or both and 
examined under a microscope.  
7.2.1.4 Immunohistochemical analysis 
7.2.1.4.1 BR1 antibody staining  
BR1, generated by Professor Tim Hardingham and donated by Alan Murdoch (University of 
Manchester), is a polyclonal rabbit anti-pig antibody raised against the G1 domain of aggrecan. 
It was used to determine endogenous levels of aggrecan in the transgenic line '%AGG20'. 
Dako EnVision+ System-HRP (DAB) for use with rabbit primary antibodies was used to 
visualise the binding of BR1.  
 
 Slides with wildtype embryonic paraffin sections at different ages or with paraffin sections of 
wildtype/!AGG20 transgenic tail tips were dehydrated overnight in a 37°C oven, deparafinised 
in xylene baths for 2x5 minutes, and rehydrated in 2x absolute ethanol baths followed by 1x 
90% and 1x 70% ethanol baths (changing baths every 5 minutes and tapping off any excess 
liquid after each step). The slides were then placed in distilled water for a minimum of 30 
seconds and washed 3x in PBS for 5 minutes each. Bovine testicular hyalouronidase (1000 
U/ml made up in PBS) was added to the slides for 1 hour at 37°C for antigen retrieval. They 
were then rinsed 3x in PBS for 5 minutes each and incubated for 10 minutes with a peroxidase 
block to quench any endogenous peroxidase activity the sample may have. After rinsing the 
slides again 3x in PBS, they were incubated in 1% non-fat milk made up in PBS for 1 hour at 
room temperature. The milk was tapped off and the slides incubated with BR1 antibody 
(1:1000 made up in Dako Antibody Diluent) at 4°C overnight. The next day, the slides were 
rinsed 3x in PBS for 5 minutes each and incubated for 30 minutes with the secondary antibody 
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(peroxidase labelled polymer conjugated to goat anti-rabbit immunoglobulins). The secondary 
antibody was washed off 3x in PBS for 5 minutes each and the peroxidase substrate added 
(DAB+ chromogen made up in DAB+ substrate buffer) for 30 seconds- 5 minutes. Slides were 
then rinsed in running tap water for 10 minutes and counterstained with Harris haematoxylin for 
3 minutes at room temperature. They were then rinsed again in running tap water for 10 
minutes and placed in 70% ethanol for 2 minutes, 95% ethanol for 2 minutes, 2x100% ethanol 
for 2 minutes each and finally 2x Xylene for 5 minutes each. They were mounted by 
coverslipping with histomount solution (National Diagnostics, HS103). 
7.2.1.4.2 !-galactosidase antibody staining  
The !-galactosidase antibody staining was performed by Dr Phuong Vo at the Kennedy 
Institute of Rheumatology. The antibody used was a polyclonal rabbit anti-!-galactosidase 
antibody (Abcam # Ab616). It was used as a more sensitive method of detection of !-
galactosidase protein (indicating LacZ reporter gene expression). Dako EnVision+ System-
HRP (DAB) for use with rabbit primary antibodies was used to visualise the binding of the anti-
!-galactosidase antibody.  
 
 Slides with coronal paraffin sections of axial loaded knees/contralateral knees from !AGG20 
transgnic mice were dehydrated overnight in a 37°C oven, deparafinised in xylene baths for 
2x5 minutes, and rehydrated in 2x absolute ethanol baths followed by 1x 90% and 1x 70% 
ethanol baths (changing baths every 5 minutes and tapping off any excess liquid after each 
step). The slides were then placed in 2 consecutive baths of distilled water each for 5 minutes. 
For antigen retrieval, the slides were boiled within Sodium citrate buffer (pH 6.0) in a pressure 
cooker for 10 minutes.  They were then allowed to cool on a bench for 30 minutes. Following 
this, they were washed 2x in PBS for 5 minutes each and incubated for 10 minutes with a 
peroxidase block to quench any endogenous peroxidase activity the sample may have. After 
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rinsing the slides again 2x in PBS for 5 minutes each, they were incubated in 1% non-fat milk 
made up in PBS for 1 hour at room temperature. The milk was tapped off and the slides 
incubated with the anti-!-galactosidase antibody (1:1000 made up in 1% non-fat milk) for 1 
hour at room temperature. The slides were then rinsed 2x PBS for 5 minutes each with 
agitation (0.01% Tween-20 optional) and incubated for 30 minutes with the secondary antibody 
(peroxidase labelled polymer conjugated to goat anti-rabbit immunoglobulins). The secondary 
antibody was washed off 2x in PBS for 5 minutes each with agitation and the peroxidase 
substrate added (DAB+ chromogen made up in DAB+ substrate buffer) for 30 seconds- 5 
minutes. Slides were then rinsed in running tap water for 10 minutes, placed in 70% ethanol for 
2 minutes, 95% ethanol for 2 minutes, 2x100% ethanol for 2 minutes each and finally 2x 
Xylene for 5 minutes each. They were mounted by coverslipping with histomount solution 
(National Diagnostics, HS103). 
7.2.2 Analysis of ColII4xA1Cre line 
7.2.2.1 Genotyping using Real-time PCR 
‘JumpStartTM Taq ReadyMixTM for Quantitative PCR’ (Sigma D7440) was used for genotyping 
the ColII4xA1Cre line. Before setting up the PCR reaction, a mix of the two sets of primers and 
fluorescent probes to be used was prepared (each at 10 µM) and stored at -20°C. Each 
reaction was carried out at a final volume of 10 µl as follows: 5 µl of 2xPCR mix, 1.6 µl of 25 
mM MgCl2 (final concentration of 5.5 mM), 100-200 ng of template DNA extracted from adult 
tails, 0.12 µl of Primer/probe mix (final concentration of 20 nM for each) and 2.28 µl of water. 
The PCR reaction was carried out as follows: Initial 94°C step for 10 minutes. Then, 40 repeat 
cycles of 94°C for 30 seconds followed by 60°C for 60 seconds.  The primers used were Cre 
as well as 18S primers (for normalization). The Cre probe was designed with the fluorescein 6-
FAM (green) at its 5’ end while the 18S probe was designed with HEX (pink) at its 5’ end. Both 
Cre and 18S fluorescent probes were designed with the universal fluorescence quencher 
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BHQ1 at their 3’ ends. 
Sequences of Primers and probes: 
Cre Probe: 5'6FAM AAACATGCTTCATCGTCGGTCCGG3'BHQ1 
Cre forward primer:  
GCGGTCTGGCAGTAAAAACTATC 
Cre Reverse primer: 
GTGAAACAGCATTGCTGTCACTT 
18S Probe: 
5'HEX CTTCCGGGAAACCAAAGTCT 3'BHQ1 
18S Forward primer: 
GACCATAAACGATGCCGACTG 
18S Reverse primer: 
CCCTTCCGTCAATTCCTTTAAG 
 
7.2.2.2 Luciferase detection 
Han Lim Ngee from the Kennedy Institure of Rheumatology assisted with all the in vivo 
bioluminescent imaging carried out. To assay for the expression of the Luciferase gene in adult 
mice from the ColII4xA1Cre line, In vivo bioluminescent imaging was performed in a Kodak 
imaging system that includes an integrated isoflurane apparatus and induction chamber for 
temporary anaesthesia of the mice. First, the mice are placed in the induction chamber and 
anesthetized with isoflurane/oxygen. After a few minutes, the anesthetized mice were removed 
from the induction chamber and placed on a stage with continuous isoflurane delivery. 
Because fur naturally autofluoresces and can also block the emmision of light, the legs and 
knees of the mice were shaved with an electric shaver. The mice were then injected with the 
substrate D-luciferin (Sigma) into the intraperitoneal cavity at a dose of 150 mg/kg body weight 
(30 mg/ml D-luciferin) approximately 5 min before imaging. To carry out the bioluminescence 
imaging, the mice were placed dorsal side up in the imaging chamber with isoflurane. Mice 
were exposed for 10 minutes after which dorsal images were collected. Mice were then 
removed from the imaging chambers and allowed to wake up in their cages. 
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7.2.2.3 Assaying for Cre recombinase activity  
To characterize the spatial and temporal pattern of Cre expression and activity in the 
ColII4xA1Cre line, the double-fluorescent Cre Reporter mouse (described in more detail in 
Results Chapter 2 section 2.1) was used. A heterozygous male ColII4xA1Cre mouse was 
crossed with 2 homozygous female double-fluorescent reporter mice. The pregnant mothers 
were injected intraperitoneally with 4x5 mg of tamoxifen (sigma) dissolved in corn oil on the 
last 4 days of gestation.  Pups from one of the pregnant mothers were sacrificed at 1 week of 
age while those from the 2nd pregnant mother were sacrificed at 2 weeks of age.  The hips and 
knees of the 1 and 2-week-old mice pups were snap-frozen by embedding them into the 
bottom of a cork mould pre-filled with OCT (Tissue-Tek) and placing them using forceps on an 
isopentane-filled beaker that has been put in liquid nitrogen.  The cryo-preserved tissues were 
then sectioned (6 µm sections) using a CV1900 cryostat (Leica Microsystems) equipped with a 
tungsten blade. The sectioned tissue was fixed for 10 minutes with 4% paraformaldehyde, 
washed 3x with PBS, then mounted by coverslipping with 80% glycerol and viewed using 
Ultraview confocal microscopy (60 oil immersion lens).  
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8 Osteoarthritis models 
 
8.1 Surgical induction of OA through the destabilisation of the 
medial meniscus (DMM) model 
Mice were anaesthetized by intraperitoneal injection of Hypnorm® (VetaPharma Ltd., Leeds, 
UK) and Hypnovel® (Roche). After shaving of the ventral portion of the right knee, a midline 
incision was made over the ventral aspect and the medial compartment of the knee. The 
medial meniscus was identified, and using an ophthalmic scalpel, its anterior horn was 
released by sharp dissection of the attachments to the tibial plateau. Mobility of the anterior 
half of the medial meniscus was confirmed by displacement with forceps. The parapatellar 
window was closed with an absorbable suture (Ethicon, USA), and the skin closed with fine 
non-absorbable sutures (Ethicon, USA).  A technician at the Kennedy Institute of 
Rheumatology performed the DMM surgeries.  
8.1.1 DMM of line 12 ("AGG20 transgenics) 
DMM was performed on the right knees of twelve ‘line 12’ heterozygote mice of both sexes at 8 
weeks of age. The left contralateral knees were used as controls. 6 mice were sacrificed at 4 
weeks and a further 6 at 8 weeks post-operatively and the operated + control unoperated 
knees dissected, fixed, stained with X-gal as described in results section 7.2.1.2. Dissected 
knees specimens were removed from the staining solution, washed in rinse solution and fixed 
in 10% formalin. They were then decalcified for 3 weeks in EDTA, and embedded in paraffin 
wax to be sectioned for histological analysis. The decalcification, embedding and cutting was 
done by David Essex (Charing Cross Hospital). The wax blocks were cut into coronal sections 
(8µm thick) and stained with Safranin O and/or haematoxilin and Eosin. Sections were 
evaluated across 10 levels at 80 µm intervals. Each knee yielded approximately 10 slides for 
scoring qualitatively based on The OARSI Osteoarthritis Cartilage Histopathology scoring 
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system which itself is based on both the severity (grade) and extent (stage) of OA in the 
articular cartilage (Pritzker et al., 2006). The qualitative score given indicates the most 
advanced OA grade/stage observed in the section, e.g., grade 2, stage 3. 
8.1.2 DMM of line 39 (ColII4xA1Cre transgenics) 
DMM was performed on the right knees of 5 heterozygote transgenic mice from line 39 as well 
as 1 wildtype littermate (control) at 8 weeks of age. Both sexes were used. The left 
contralateral knees were also used as controls. Mice were analysed before surgery (0 weeks) 
and 1,2,3,4 and 8 weeks post-operatively by in vivo bioluminescence imaging as described in 
Results section 7.2.2.2.  
8.2 Axial Loading of murine tibias 
 
The loading experiments were performed in Dr Andrew A. Pitsillides’ lab at the Royal 
Veterinary College (De Souza et al., 2005).  
 
The loading apparatus used was constructed from a single pair of custom-built padded cups; 
the top cup demonstrates a concavity that is equivalent to an imprint of the flexed knee, acting 
to restrict forward slippage of the knee from the cup. The bottom cup, however, holds the ankle 
and is flexed at approximately 45° (Figure 12A and B). The cups are positioned within a servo-
hydraulic materials testing machine (Model HC10, Dartec, Ltd., Stourbridge, UK) and are 
aligned vertically. The upper cup into which the knee is positioned was connected to the 
actuator, the lower cup found on the ‘load cell’, and the actuator operated in ‘load control’ to 
administer dynamic compression to the tibia (Figure. 12B). 
 
The right tibia of each loaded mouse (left acting as contralateral control) was held in the 
padded cups, and dynamic (2 Hz, with 10 s rest periods between cycles) axial loads were 
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applied (peak load 2–13 N, strain rate at the gauge site 0.0015–0.002 µ'/s, 28–44 N/s, 40 
cycles/day) through the knee joint three times a week for 2 weeks (a total of 6 times).   
8.2.1 Axial loading of line 12 ("AGG20 transgenics) 
Axial loading (Figure 12) was performed on the right knees of12 mice of both sexes at 8 weeks 
of age. 2 weeks after a total of 6 axial loads, the mice were sacrificed and the knees dissected, 
fixed, stained with X-gal as described in results section 7.2.1.2. Dissected knees specimens 
were removed from the staining solution, washed in rinse solution and fixed in 10% formalin. 
They were then decalcified for 3 weeks in EDTA, and embedded in paraffin wax to be 
sectioned for histological analysis. The decalcification, embedding and cutting was done by 
David Essex (Charing Cross Hospital). The wax blocks were cut into coronal sections (8µm 
thick) and stained with Eosin or a !-galactosidase antibody. Sections were evaluated across 
10 levels at 80 µm intervals. Each knee yielded approximately 10 slides for scoring qualitatively 
based on The OARSI Osteoarthritis Cartilage Histopathology scoring system which itself is 
based on both the severity (grade) and extent (stage) of OA in the articular cartilage (Pritzker 
et al., 2006). The qualitative score given indicates the most advanced OA grade/stage 
observed in the section, e.g., grade 2, stage 3. 
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Figure 12: Mechanism of axial loading. A) Diagrammatic representation of the flexed 
mouse right hind limb in position in the loading apparatus, showing the relative position of the 
bones, their relationship with the upper and lower loading cups, the direction of loading and 
approximate location of the strain gauges (a, lateral and b, medial) on the tibial mid-shaft. B) 
Diagrammatic representation of cross-section of the tibial mid-shaft showing the location of the 
attached strain gauges on medial and lateral surfaces of the tibia. From (De Souza et al., 
2005).  
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9 Stock solutions 
 
All chemicals were obtained from Sigma unless otherwise stated. 
9.1 Standard solutions 
 
TE buffer                                         10mM Tris/HCL (pH 7.4), 1mM EDTA (pH 8) 
 
PBS 
 
Per litre: 10g NaCl, 0.25g KCl, 1.44g Na2HPO4, 0.25g KH2PO4 
50x TAE buffer  
 
Per litre: 242g Tris, 100ml 0.5M EDTA (pH 8.0), 57.1ml Glacial 
Acetic Acid, in water (final pH 7.6-7.8) 
 
9.2 Bacterial culture and transformations 
 
 
LB-broth with ampicillin                Per litre: 10g Tryptone (pancreatic digest of casein), 5g yeast 
extract, 5g NaCl, 100µg/ml ampicillin  
LB-agar with ampicillin 
 
Per litre:  10g Tryptone (pancreatic digest of casein), 5g yeast 
extract, 5g NaCl, 15g Agar, 100µg/ml  ampicillin  
 
9.3 DNA preparation 
 
Resuspension buffer P1 15mM Tris (pH 8.0), 10mM EDTA (pH 8.0), 100#g/ml RNase A 
Lysis buffer P2  
 
0.2M NaOH, 1% (w:v) SDS 
Neutralisation buffer P3 3M KOAc (pH 5.5) 
DNA loading buffer (6x) 
 
2.5% Ficoll 400, 11mM EDTA, 3.3mM Tris-HCL, 0.017% SDS, 
0.015% Bromophenol Blue (pH 8.0) 
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9.4 Analysis of transgenic embryos 
 
Tail buffer                                 0.1 M EDTA, 0.1 M NaCl, 0.05 M tris/HCl (pH 8.0).  
FiX     2% formaldehyde, 0.2% glutaraldehyde, 0.1 M NaH2PO4, 0.1 M 
Na2HPO4, 5 mM EGTA (pH 8.0), 2 mM MgCl2 , in water 
 
Rinse                                     2mM MgCl2, 0.1% (w/v) Sodium deoxycholate, 0.2% (v/v) Igepal 
CA-630 in PBS 
Stain Per 100ml:  4ml of X-gal (dissolved at 25mg/ml in 
dimethylformamide),     mg K4Fe(CN)6, mg K3Fe(CN)6 in rinse 
solution.            
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Results 
 
I have divided the ‘Results’ section into three chapters. Each chapter contains a brief overview 
of the experimental work (background), a report of the data itself (results) and finally a 
discussion of the data evaluating the findings in context of the published literature (discussion).  
Chapter 1: Locating cis-acting sequences that regulate 
the cartilage-specific expression of the human aggrecan 
gene: 
1.1 Background 
The main aims of this result chapter are both to identify the human DNA sequence(s) 
necessary to confer full endogenous aggrecan expression, and to characterize the minimal 
sequence necessary for this level of expression. This was investigated using transgenic mice. 
Several combinations of linear DNA fragments were fused to the human aggrecan minimal 
promoter and the LacZ reporter gene (methods section 5). For some of these constructs, I 
adopted a method based on gap repair homologous recombination in E.coli called 
“Recombineering”.  
Recombineering uses recombination proteins provided from ( phage. The artificially 
engineered recombineering bacterial strain (EL350) contains a defective ( prophage inserted 
into the bacterial genome. The phage genes of interest, exo, bet, and gam, which are involved 
in bacterial recombination, are transcribed from the (PL promoter. This promoter is repressed 
by the temperature-sensitive repressor cI857 at 32°C and derepressed at 42°C. When bacteria 
containing this prophage are kept at 32°C no recombination proteins are produced. However, 
after a brief (15 minutes) heat-
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produced. exo is a 5'-3' exonuclease that creates single-stranded overhangs on introduced 
linear DNA. bet protects these overhangs and assists in the subsequent recombination 
process. gam prevents degradation of linear DNA by inhibiting E.coli RecBCD protein. Linear 
DNA (PCR product, oligo, etc.) with sufficient homology in the 5' and 3' ends to a target DNA 
molecule already present in the bacteria (plasmid, BAC, or the bacterial genome itself) can be 
introduced into recombination competent EL350 bacteria using electroporation. The introduced 
DNA will now be modified by exo and bet and undergo homologous recombination with the 
target molecule. The method has also been shown to work by co-electroporation of a 
supercoiled plasmid and a linear piece of DNA into heat-shocked, electrocompetent bacteria 
(Liu et al., 2003). 
The linearised constructs were injected into fertilized mouse oocytes to generate mice in which 
reporter gene expression indicated the presence of cis-regulatory element(s) within the DNA 
upstream of the reporter. The pattern of reporter gene expression in these transgenic mice, as 
demonstrated by X-gal staining, was used to elucidate the function of the construct injected. 
Since a minimal promoter of human AGC1 has been identified (Valhmu et al., 1998a), 
transgenic mice were also generated with a construct consisting of the minimal promoter alone 
fused to the LacZ gene. The level and pattern of reporter gene expression seen in these 
transgenic mice provided a baseline, to which the pattern and extent of expression driven by 
other combinations of fragments fused to the minimal promoter was compared.  
 
The LacZ gene is a bacterial reporter gene that encodes the enzyme !-galactosidase (!-gal). 
!-galactosidase catalyses the cleavage of galactose rings from a number of different 
substrates including X-gal. X-gal changes from a colourless compound to a deep blue one 
following this cleavage. In the transgenic mice that were generated here, this dark blue staining 
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was indicative of the regulatory activity and expression pattern exerted by the DNA sequences 
driving this reporter gene.  
 
As the main purpose of this study was to screen for functional cis-regulatory elements, and 
since the insertion site of the transgene and the number of copies inserted could affect the 
expression pattern, founder embryos were used as they are more practical than establishing 
transgenic lines. After injection, the oocytes were transplanted into a surrogate mother, and the 
developing embryos removed before birth. In this way, a number of embryos - each containing 
different copies of the transgene integrated at different sites in the genome – were examined 
and the variation of expression due to these factors could be taken into account. Doing this for 
established transgenic lines would have been a much more lengthy and costly approach and 
beyond the scope of the work presented here. However, the advantage of this would be the 
ability to look at the same transgene integration and copy number at different stages of 
development. This was done for one of the constructed transgenes.  
 
Founder embryos were removed at E14.5, unless otherwise stated. The embryos weren’t 
normally removed after E16.5 due to the keratinisation of the skin, which occurs around then. 
This results in the inability of the X-gal solution to penetrate, thus making consistent staining of 
the embryos impossible. 
 
Within embryos of the same litter, and between E14.5 embryos from different litters and 
different experiments, it is important to note that they may have slight developmental 
differences as they normally develop at different rates (most notable in the extent of bone 
growth and ossification). These developmental differences as well as the variations in 
transgene copy number and integration sites can account for some of the differences seen 
between embryos expressing the same construct. It is important to note, however, that 
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embryonic staining is due to expression of the LacZ transgene rather than an artefact due to 
bacterial LacZ expression and/or metallic contact with the embryo if the staining is bilateral and 
symmetrical within the embryo  
 
The differentiating chondrocytes responsible for the synthesis of aggrecan during development 
are described in the main Introduction section 2.2. Since aggrecan is mainly synthesised in 
developing cartilage, the expression of the transgene was particularly investigated in the 
developing axial (skull, ossicles of the inner ear, the hyoid bone of the throat, the rib cage and 
the vertebral column) and appendicular (upper and lower limbs) skeleton. Ossification in the 
mouse embryos commences at around E13, when both mesenchymal and pre-cartilagenous 
condensations are visible. At this time, chondrification of the vertebral column begins, 
proceeding in rostral to caudal direction. As discussed, the condensation and chondrification of 
skeletal elements culminate in the differentiation of chondrocytes and in this way form a 
cartilage model of the future axial skeleton. However, by E14-15.5, ossification also becomes 
visible in the clavicle, ribs, femur and humerus, ulna and radius, maxilla, mandible, frontal and 
parietal bones of the head, and scapula, hip bones, tibia and fibula of the body (Kaufmann, 
1995). It is important to note that the half-life of the !-galactosidase protein is 24-48 hours and 
that any staining seen within a particular tissue could be due to the expression of this reporter 
gene within 24-48 hours prior to assaying for regulatory activity of the transgene.  
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1.2 Results 
1.2.1 The use of the BR1 antibody to monitor endogenous expression of the 
aggrecan gene in mouse embryos 
Before attempting to pursue the cis-regulatory regions of the human aggrecan gene that 
govern its endogenous expression in developing embryos, I needed to establish a reliable 
pattern of endogenous aggrecan gene expression in embryos at different stages of 
development. I optimised the use of the BR1 antibody, which was raised against the G1 
domain of aggrecan  (see Methods 7.2.1.4.1), on paraffin embedded sections of mouse 
embryos at E11.5, E13.5, E15.5 and E17.5. At E11.5, antibody staining is localised to the 
somites, which will eventually become rib and vertebra cartilage (Figure 13A). At E13.5, E15.5 
and E17.5, the BR1 staining is localised to the developing axial and appendicular embryonic 
skeleton. At E13.5, there is antibody staining in several developing cartilaginous structures 
such as the ear, the nasal cartilage, the Meckel’s cartilage, the humerus, the vertebrae, the 
ribs, the digits of the forelimbs and the femur (Figure 13B). There was also staining in the digits 
of the hindlimb and the ankle in other serial sections (not shown). At E15.5, the staining of the 
antibody was found in all the positively stained anatomical regions at E13.5 with the addition of 
the chondrocranium (including the frontal bone) as well as the developing scapular cartilage 
(Figure 13C). At E17.5, in addition to the developing axial and appendicular skeleton (Figure 
13D+F+G), the tracheal cartilage showed positive staining (Figure 13E).  
1.2.2 In silico analysis of aggrecan gene identity between rats and humans 
In order to begin my search for the key areas in the human aggrecan gene that are responsible 
for chondrocyte specific expression, I used a web-based program, vista 
(http://pipeline.lbl.gov/cgi-bin/gateway2), to look at sequences that have high identity between 
species indicating evolutionary conserved and therefore important regions within the gene. My 
PhD Thesis                                                                                                                           Andrea Layyous     
  
 131 
search included ~20kb of non-coding sequences upstream of the aggrecan gene in order to 
take into account any shifting of enhancer elements that may have occurred during evolution.   
 
Figure 14 demonstrates the homologous sequences found between humans and rats 
throughout the non-coding sequences ranging between -20kb relative to the transcriptional 
start site (TSS) up to and including the 3’UTR of the gene. Taking into account this homology 
search, the information that had already been published on the rat upstream enhancer (Doege 
et al., 2002) as well as the knowledge that sox9 plays an important role in the development of 
cartilage and is therefore important for the regulation of aggrecan ((Bi et al., 2001), (Kist et al., 
2002), (Sekiya et al., 2000), (Han and Lefebvre, 2008)), I hypothesised that the regions circled 
1-7 (named cis 1-7) in Figure 14 could potentially be cis-regulatory sequences. cis 1-4 lie 
upstream of the start site and are in the approximate positions ‘-20 to -19.7kb’, ‘-14.5 to -
14.4kb’, ‘-10.9 to -10.2kb’, and ‘-3.8 to -3.7kb’ respectively. Cis 5 lies around/includes the 1st 
exon/5’UTR/previously determined basal promoter of the human aggrecan gene (-390 to 
+375bp). Unlike cis 1-5, which correspond to red coloured peaks (Figure 14) indicating highly 
conserved regions, cis 6 is not coloured but was selected due to the presence of 3 putative 
sox9 binding sites within it. It is located at the 5’ end of the large 1st intron of the gene (between 
+5 and +8kb relative to the TSS). The sox9 putative binding sites were identified using the 
program genomatix (http://www.genomatix.de/) and are located at +5.3kb, +6.8kb and +7.4kb 
relative to the TSS. Finally, cis 7 is positioned within the 14th intron of the human aggrecan 
gene between +64.6kb and +65.0kb relative to the TSS. My interest in cis 7 lies in the fact that 
it’s the only sequence within the investigated region in which the homology even to fugu 
remains relatively high. Figure 15 demonstrates the identity between humans, rats, chickens 
and fugu in this region.  
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Figure 13: Paraffin sections of mouse embryos at different stages of development 
stained with the BR1 antibody. A) E11.5 embryo B) E13.5 embryo C) E15.5 embryo D) 
E17.5 embryo. A (ankle),  CC (chondrocranium), E (ear cartilage), F (femur), FD (forelimb 
digits), H (humerus), HD (hindlimb digits), M (Meckel’s cartilage), N (nasal cartilage), RA 
(radius), R (rib cartilage), SC (scapular cartilage), SO (somites), TI (tibia), TR (trachea), V 
(vertebral cartilage).
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1.2.3 The human aggrecan minimal promoter (-452bp to +375bp) 
As discussed in the background of this result chapter, the pattern of LacZ gene expression in 
mouse transgenics driven only by the human aggrecan minimal promoter defines the baseline 
expression that all future staining patterns can be compared to.  All other constructs used to 
create transgenic embryos for the purpose of characterizing the human aggrecan regulatory 
sequences contain the minimal promoter and LacZ gene along with different combinations of 
DNA sequences containing the circled fragments in Figure 14.  Therefore, it is necessary to 
see the expression driven by the minimal promoter alone. 
 
The human aggrecan minimal promoter used was based on the data published by Valhmu et al 
(see Introduction section 3.3.3) along with the information from my in silico analysis in which 
cis 5 corresponds to this minimal promoter.  Although the published data indicates the 5’UTR  
(0bp to +375bp relative to the TSS) of the gene as the primary regulatory sequence able to act 
as the minimal promoter required to drive basal expression of the aggrecan gene, the vista 
analysis shown in Figure 14 showed high sequence identity between humans and rats from  -
390 to +375bp.  Thus, as the human aggrecan minimal promoter, I used the sequence 
corresponding to -452 to +375bp which was named AB. This ensured the inclusion of the 
5’UTR as well as the upstream conserved sequence. AB was cloned in the p!gal-basic vector 
and the final vector named !galAB (see Methods section 5 construct 1). Transgenic mice were 
generated harbouring this construct.  
 
Although the 5’UTR was sufficient to drive reporter gene expression in vitro (Valhmu et al., 
1998a), this wasn’t the case for the in vivo transgenic embryos that we generated harbouring 
this sequence. There was no blue staining in any of the positive transgenics. It was thus 
assumed that any staining seen from now on due to the injection of other constructs was due 
to sequences that lie outside this minimal promoter interacting with it to drive transcription of 
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the gene. Table 6 details the number of transgenic and expressing embryos produced with this 
construct.  
Table 6: Summary of mice transgenic and expressing !galAB (minimal promoter/ -452bp 
to +375bp).  ‘Positive embryos’ indicates the total number of embryos in which the transgene 
has become integrated throughout each session. ‘Expressing embryos’ indicates the total 
number of embryos in which the integrated reporter gene is being expressed. The ‘Percentage 
of embryos expressing the transgene’ was derived by dividing the number of expressing 
embryos by the number of positive embryos and multiplying this figure by 100.  
 
Construct Positive embryos 
by PCR 
Expressing 
embryos 
Percentage of 
embryos 
expressing the 
transgene (%) 
!galAB  10 0 0 
 
 
1.2.4 The role of the DNA sequences upstream of the human aggrecan 
minimal promoter 
1.2.4.1 cis 1-4  
 
In order to examine the functionality of the potential cis-regulatory fragments cis 1-4 (Figure 
14), I cloned a DNA sequence around 20 kilobases in size that contained cis 1-4 along with the 
minimal promoter AB within cis 5 into the reporter vector p!gal-basic. To do this, I used 
‘Recombineering’. This method was used rather than standard DNA restriction cloning 
because of the size of the DNA fragment to be cloned. Large DNA fragments have few unique 
restriction sites and are difficult to manipulate.  
 
According to the recombineering method, I cloned a 5’ fragment of DNA corresponding to the 
5’end of the ~20kb fragment of DNA (named EF) along with a 3’ fragment corresponding to the 
minimal promoter of the aggrecan gene (AB) into the pBluescript KS+ vector to produce 
pBSAB + EF (Methods section 5 construct 10). This vector was then linearized and 
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electroporated into recombination competent EL350 cells containing the RP11-343B18 BAC 
(Figure 16). The resultant vector containing the ~20kb fragment of non-coding aggrecan DNA 
was called pBSAGG20 (Methods section 5 construct 11). 
 
Once the construction of this new plasmid was confirmed via several restriction digestions, the 
~20kb fragment was sub-cloned into the !gal-basic vector upstream of the LacZ gene by blunt-
ended ligation. This construct was called !AGG20 (Methods section 5 construct 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16:  Diagram representing the recombineering strategy used to clone the large 
~20kb sequence (-20,054kb to +375bp) from the human aggrecan gene into the pBS KS+ 
vector.  pBSAB + EF, containing the the 5’ arm (EF) and 3’arm (AB – corresponding to the 
minimal promoter) was linearised with XbaI.The 5’ and 3’ arms are coloured in red and blue 
respectively. The target vector, from which the aggrecan DNA is derived is the BAC RP11-
343B18, shown here as a rectangle. The resultant vector containing the ~20kb sequence was 
called pBSAGG20.  
 
 
PhD Thesis                                                                                                                           Andrea Layyous     
  
 138 
!AGG20 was injected into fertilised oocytes that were in turn transferred into pseudopregnant 
mothers (Methods section 6). These mothers were sacrificed at E14.5 and the embryos 
assayed for the expression of the LacZ gene. The embryos were evaluated for LacZ 
expression (blue staining) by whole mount X-gal staining overnight  (Methods section 7.1.3). 
Three out of 7 positive embryos showed identical and symmetrical patterns of reporter gene 
expression in cartilage (Table 7). Blue staining was observed in the developing cartilage of the 
long bones of the fore and hind limbs, the ribs, the scapulae, the digits and some craniofacial 
cartilages (Meckel’s cartilage). There was also some staining in the tongue. However, no 
staining was seen in the vertebrae (Table 8). Figure 17 shows two of the transgenic embryos 
that expressed the reporter gene exclusively in cartilage. Histological sections of the X-gal blue 
stained embryos showed that the LacZ expression did in fact occur exclusively in the 
developing cartilage e.g the developing cartilage of the ribs (Figure 18A), the hindlimb digits 
(Figure 18B), the ulna and radius (Figure 18C) and the femur, tibia and fibula (Figure 18D). 
The staining was relatively strong in all of these regions and was present in most of the 
proliferating (smaller cells) and hypertrophic chondrocytes (enlarged cells). 
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Figure 17:  2 representative E14.5 wholemount embryos expressing !-galactosidase 
(blue staining) driven by the !AGG20 promoter (-20,054bp - +375bp).  A, B, and E  
are images from 1 transgenic embryo while C,D and F  are images from the another. Both 
mice show identical and symmetrical staining. A,B,C and D are lateral images while E and F 
are dorsal images. F (femur), FD (forelimb digits), FI (fibula), H (humerus), HD (hindlimb 
digits), M (Meckel’s cartilage), R (rib cartilage), RA (radius), SC (scapular cartilage). T 
(tongue), U (ulna). 
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Figure 18: Histological sections of a blue stained transgenic embryo expressing !-
galactosidase driven by the !AGG20 promoter (-20,054bp to +375bp). Blue staining 
localised in chondrocytes of the developing  A) ribs (R). B) the digits of the hindlimb (HD). C) 
the ulna (U)/radius (RA) of the forelimb. D. the fumur (F), tibia (TI) and fibula (FI). These 
sections are counterstained with eosin. 
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Table 7: Summary of transgenic and expressing mice driven by the !AGG20 promoter (-
20,054bp to +375bp). ‘Positive embryos’ indicates the total number of embryos in which the 
transgene has become integrated throughout each session. ‘Expressing embryos’ indicates the 
total number of embryos in which the integrated reporter gene is being expressed. The 
‘Percentage of embryos expressing the transgene’ was derived by dividing the number of 
expressing embryos by the number of positive embryos and multiplying this figure by 100.  
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!AGG20  7 3 42 
 
 
Table 8: Average levels of expression for !AGG20 transgenic mice after overnight 
staining at room temperature. – no staining, + staining just detectable, ++ low level staining, 
+++high level staining, ++++very high level staining. 
 
Tissue Intensity of staining Tissue Intensity of staining 
Chondrocranium - Digits of the hindlimbs ++ 
Cartilage of the eye 
socket - Scapular cartilage +++ 
Nasal cartilage - Cartilage of the humerus +++ 
Meckels cartilage + Cartilage of the ulna +++ 
Cartilage of the ribs 
(costal) +++ Cartilage of the radius +++ 
Cartilage of the femur ++ Intervertebral discs - 
Cartilage of the tibia +++ Vertebral cartilage - 
Cartilage of the fibula +++ Cartilage of the ear - 
Digits of the forelimbs +++ Tongue +++ 
 
 
!AGG20 was injected on another occasion (Table 9) and the embryos sacrificed and stained at 
E16.5 so as to verify whether the missing vertebral body expression gets switched on at a later 
stage in development. The pattern of !-galactosidase expression (blue staining) in the E16.5 
!AGG20 transgenic embryo mimicked the pattern of expression in the E14.5 !AGG20 
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transgenic embryo in that all anatomical regions that were positive at E14.5 remained positive 
at E16.5 (Figure 19A+B+E+F) with the exception of the tongue. However, the intensity of the 
staining was much higher and was widened spatially to include more facial cartilages such as 
the nasal cartilage, the cartilage of the ear and the cartilage of the eye socket (Figure 19C) as 
well as the vertebral bodies and intervertebral disc (Figure 19D). It is important to note that at 
this stage of development, we would expect staining in the chondrocranium (Figure 13C). 
However, there was no staining detected in the chondrocranium. The intensity and localisation  
of X-gal staining is shown in Table 10. 
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Figure 19:  Representative E16.5 wholemount embryo expressing !-galactosidase (blue 
staining) driven by the !AGG20 promoter (-20,054bp to +375bp).  A and B) ventral 
images of whole embryo C) craniofacial cartilages D) vertebral bodies and intervertebral discs 
E) ribs F) forelimb digits. E (ear cartilage), EY (cartilage of the eye socket), F (femur), FD 
(forelimb digits), FI (fibula), HD (hindlimb digits), IV (intervertebral discs), M (Meckel’s 
cartilage), R (rib cartilage), RA (radius), U (ulna). VB (vertebral bodies). 
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Table 9: Summary of transgenic and expressing mice driven by the !AGG20 promoter (-
20,054bp to +375bp).  ‘Positive embryos’ indicates the total number of embryos in which the 
transgene has become integrated throughout each session. ‘Expressing embryos’ indicates the 
total number of embryos in which the integrated reporter gene is being expressed. The 
‘Percentage of embryos expressing the transgene’ was derived by dividing the number of 
expressing embryos by the number of positive embryos and multiplying this figure by 100.  
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!AGG20  3 1 33 
 
Table 10: Average levels of expression for !AGG20 transgenic mice at E16.5 after 
overnight staining at room temperature. – no staining, + staining just detectable, ++ low  
level staining,++high level staining, ++++very high level staining. 
 
Tissue Intensity of staining Tissue Intensity of staining 
Chondrocranium - Digits of the hindlimbs ++++ 
Cartilage of the eye 
socket +++ Scapular cartilage +++ 
Nasal cartilage +++ Cartilage of the humerus +++ 
Meckels cartilage ++ Cartilage of the ulna +++ 
Cartilage of the ribs 
(costal) +++ Cartilage of the radius +++ 
Cartilage of the femur +++ Intervertebral discs +++ 
Cartilage of the tibia +++ Vertebral cartilage  +++ 
Cartilage of the fibula +++ Cartilage of the ear +++ 
Digits of the forelimbs ++++ Tongue - 
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Now that the presence of cis-regulatory element(s) within the "20kb sequence had been 
established, the next step was to narrow this down in order to identify the minimal region 
required for the cartilage specific expression driven by this fragment. In parallel with this, I 
wanted to investigate the other potential regulatory regions identified in figure 14 (cis 6 + cis 7) 
since the LacZ expression driven by !AGG20 didn’t exactly match endogenous aggrecan 
expression and showed lagging in the vertebral X-gal staining as well as missing staining in the 
chondrocranium. 
 
1.2.5 Identifying the minimal region of regulatory sequence required for 
chondrocyte specific expression of aggrecan 
1.2.5.1 cis 3 + 4  
 
To try and identify the location of the putative regulatory element(s) within the "20kb fragment 
in !AGG20 and decipher the function, if any, of cis 1-4, I made a series of constructs which 
contained different combinations of the ‘cis’ elements that I had identified in the vista analysis 
(Figure 14). In order to identify which of these sequences was necessary, I used the program 
blast (Basic Local Alignment Search Tool), which is a widely available alogorithm used to 
compare the nucleotides of two DNA sequences (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). 
The two sequences under comparison here were the ~20kb regulatory sequence found in 
!AGG20 along with the ~5kb rat non-coding sequence shown to act as a chondrocyte specific 
enhancer element when fused to the rat aggrecan ‘basal promoter’ (Doege et al., 2002).  
 
The results showed an approximately 400bp highly homologous region (83% identity – 
378/451 base pairs) located between -10.7kb to -10.4kb relative to the TSS of the human 
aggrecan gene (Figure 20). This sequence lies within cis 3. I removed ~7kb of DNA from the 5’ 
end of !AGG20 via the restriction endonucleases AhdI and SalI leaving behind ~13kb of 
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human aggrecan non-coding DNA (corresponding to -13,030bp to +375bp relative to the TSS) 
upstream of the LacZ transgene. The resultant linear fragment of DNA was named !AGG13 
and encompassed cis 3-5 without cis 1 and 2 (Methods section 5 construct 14).  
 
Figure 20: "400bp sequence with 83% identity between Human DNA (-10.7kb to 10.4kb 
relative to the human aggrecan TSS) and Rat DNA (-9.2kb to -8.7kb relative to the rat 
aggrecan TSS). The sequence was shown to be the most highly conserved sequence 
identified by performing a blast Alignment between the ~20kb regulatory sequence found in 
!AGG20 (between -20,054bp and +375bp relative to the human aggrecan TSS) with the ~5kb 
rat non-coding sequence (between -12kb and -7kb relative to the rat aggrecan TSS) shown to 
act as a chondrocyte specific enhancer element when fused to the rat aggrecan ‘basal 
promoter’. 
Rat 
 
Human 
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This shorter fragment was then injected into the pronuclei of fertilized murine eggs to generate 
!AGG13 transgenic embryos. The embryos were evaluated for LacZ expression by whole 
mount X-gal staining overnight as before. None of the positive embryos showed any kind of 
staining. This newly integrated DNA fragment therefore seemed to have lost vital sequences 
that enabled it to regulate the expression of the LacZ gene in cartilage. Table 11 shows the 
number of positive embryos containing the injected transgene and the number of transgenic 
embryos expressing the reporter gene. 
Table 11: Summary of transgenic and expressing mice driven by the !AGG13 promoter 
(-13,030bp to +375bp). ‘Positive embryos’ indicates the total number of embryos in which the 
transgene has become integrated throughout each session. ‘Expressing embryos’ indicates 
the total number of embryos in which the integrated reporter gene is being expressed. The 
‘Percentage of embryos expressing the transgene’ was derived by dividing the number of 
expressing embryos by the number of positive embryos and multiplying this figure by 100.  
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!AGG13 11 0 0 
 
 
1.2.5.2 cis 1 + 2  
Next, I decided to clone this seemingly important deleted ~7kb fragment (corresponding to -
20,054bp to -13,030bp relative to the TSS) directly upstream of the human aggrecan basal 
promoter AB and into the !gal-basic vector. This would exclude cis 3 and 4 while including cis 
1, 2 and 5 in the construct. As before, the cloning was carried out by recombineering (Figure 
21). According to the recombineering method and to generate the retreival plasmid, I cloned a 
5’ fragment of DNA corresponding to the 5’end of the deleted "7kb fragment (same as the 5’ 
arm used to clone the ~20kb fragment in !AGG20 and named EF) along with a 3’ fragment 
corresponding to the 3’ end of the deleted "7kb fragment (named IJ) upstream of the minimal 
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promoter of the aggrecan gene (AB) and into the p!gal basic vector. This vector was named 
!galAB+IJ+EF (see Methods section 5 construct 7). This vector was then linearized by 
digesting between the 5’ and 3’ arms and co-electroporated with a linear target DNA sequence 
(the deleted ~7kb fragment) into recombination competent EL350 cells. The resultant vector 
was named !galAB + 7 (see Methods section 5 construct 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Diagram representing the recombineering strategy used to clone the deleted 
7kb fragment into the p!gal-Basic vector upstream of the basal promoter and LacZ  
gene.  The 5’ arm (EF) and 3’ arm (IJ) are coloured in dark blue and purple respectively while 
the ‘basal promoter’ (AB) is coloured in red. The LacZ gene is shown in light blue.  Here, the 
targeting 7kb fragment is digested out of !AGG20 to be recombined into the p!gal-Basic 
vector upstream of the basal promoter of aggrecan.  
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The vector ‘!galAB + 7’ was then digested to release its backbone and subsequently injected 
into the pronuclei of fertilised murine eggs. Out of several injections and numerous 
transgenics, two E14.5 embryos showed similar and symmetrical cartilage specific expression 
in fewer developing cartilaginous regions compared to the E14.5 !AGG20 transgenic embryo 
(Table 12 + 13). Figure 22 Demonstrates one of these embryos. Staining was present in the 
cartilage of the long bones of the forelimbs - ulna and radius (Figure 22D), the nasal cartilage 
(Figure 22C) and minimal expression in the cartilage of the developing hindlimbs - femur and 
tibia (Figure 22B). Figure 23 shows histological sections of the hindlimb including the tibia and 
digits (Figure 23A), the elbow including the humerus, ulna and radius (Figure 23B) as well as 
the ribs (Figure 23C-E) of the representative !galAB + 7 embryo shown in Figure 22. In all 
histological sections, the staining is evident in both proliferating and hypertrophic chondrocytes 
but is lower, more random and scattered/mosaic compared to the staining present within the 
histological sections of the E14.5 !AGG20 embryo in Figure 18.  
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Figure 22: Representative E14.5 wholemount embryo expressing !-galactosidase (blue 
staining) driven by the !galAB+7 promoter (-20,054bp to -13,030bp fused to minimal 
promoter/-452bp to +375bp). A and B) embryo shows completely symmetrical staining. A,B 
and D are lateral images while C is a ventral image. E (ear cartilage), F (femur), FD (forelimb 
digits), N (nasal cartilage), RA (radius), TI (tibia), U (ulna). 
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Figure 23: Histological sections of a representative !galAB+7 blue stained embryo. A) 
10x magnification of the tibia (TI), fibula (FI) and digits of the hindlimb (HD) (left) with 
corresponding 20x magnification of boxed regions (right). Upper boxed region shows 
expression of the transgene in the hypertrophic chondrocytes of one of the digits while lower 
boxed region shows expression of the transgene in the proliferating and hypertrophic 
chondrocytes of the tibia. B) Humerus, ulna and radius all expressing !-galactosidase in a 
scattered fashion in the proliferating and hypertrophic chondrocytes. C-E) Ribs expressing !-
galactosidase in a scattered fashion within hypertrophic chondrocytes. Arrows point to 
examples of blue stained cells. These sections were eosin counterstained. 
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Table 12: Summary of transgenic and expressing mice driven by the !galAB+7 promoter 
(-20,054bp to -13,030bp fused to minimal promoter/ -452bp to +375bp).  ‘Positive embryos’ 
indicates the total number of embryos in which the transgene has become integrated 
throughout each session. ‘Expressing embryos’ indicates the total number of embryos in which 
the integrated reporter gene is being expressed. The ‘Percentage of embryos expressing the 
transgene’ was derived by dividing the number of expressing embryos by the number of 
positive embryos and multiplying this figure by 100. 
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!galAB+7 21 2 10 
 
Table 13: Average levels of expression for !galAB+7 transgenic mice after overnight 
staining at room temperature. – no staining, + staining just detectable, ++ low level staining, 
+++high level staining, ++++very high level staining.  
 
Tissue Intensity of staining Tissue Intensity of staining 
Chondrocranium - Digits of the hindlimbs - 
Cartilage of the eye 
socket - Scapular cartilage - 
Nasal cartilage ++ Cartilage of the humerus - 
Meckels cartilage - Cartilage of the ulna +++ 
Cartilage of the ribs 
(costal) - Cartilage of the radius +++ 
Cartilage of the femur + Intervertebral discs - 
Cartilage of the tibia + Vertebral cartilage  - 
Cartilage of the fibula - Cartilage of the ear + 
Digits of the forelimbs ++ Tongue - 
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1.2.5.3 cis 1+2+4  
In the next construct, I removed a fragment of DNA approximately 10kb in size within the 
approximately 20kb sequence in ‘!AGG20’ between " 14kb and 4kb upstream of the 
transcriptional start site by restriction enzymes KpnI and BstBI (Methods section 5 construct 
13). This construct was named ‘!AGG10’ and excluded cis 3 while including cis 1,2,4 and 5. 
This yielded 18 transgenic embryos at E14.5 containing the transgene with no expression 
(Table 14). It seemed that the cartilage specific expression seen in the !AGG20 transgenics 
was lost.  
Table 14: Summary of transgenic and expressing mice driven by the !AGG10 promoter 
(-20,054bp to -13,838bp fused to -4,182bp to +375bp). ‘Positive embryos’ indicates the total 
number of embryos in which the transgene has become integrated throughout each session. 
‘Expressing embryos’ indicates the total number of embryos in which the integrated reporter 
gene is being expressed. The ‘Percentage of embryos expressing the transgene’ was derived 
by dividing the number of expressing embryos by the number of positive embryos and 
multiplying this figure by 100.  
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!AGG10 18 0 0 
 
 
1.2.5.4 Missing 92bp sequence  
 
When  !AGG20 was initially cloned, the sequencing of the minimal promoter AB within cis 5 on 
the 3’ end of the "20kb fragment showed a deletion of 92 base pairs between -68 to +23bp 
relative to the TSS.  Upon further investigation, it was clear that the BAC RP11 343B18 used to 
create !AGG20 harboured this deletion. Nevertheless, !AGG20 transgenics displayed 
cartilaginous expression and the "20kb sequence was manipulated to produce all subsequent 
clones in which some also activated LacZ expression in transgenic embryos. It was possible, 
however, that the 92 base pairs played a necessary role for the full endogenous expression of 
the gene and therefore had to be investigated. Validating a role for the missing 92 base pairs 
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would require cloning a new "20kb fragment inclusive of this missing sequence within the 
vector backbone !gal basic in the same way. I acquired a new BAC (RP11-1123E8) and 
checked for the presence of the lacking sequence. Following this, a targeting vector containing 
the new 5’ and 3’ arms was cloned and called !galAB+92+EF (see Methods section 5 construct 
4). Ongoing work at the KIR will be done to perform the necessary recombineering 
experiments to produce a construct containing the "20kb fragment in !AGG20 with the 
inclusion of the missing 92 base pairs (!AGG20+92) and consequently generate !AGG20+92 
transgenic embryos.  
 
I also performed other experiments to investigate the role of the missing 92 base pairs. Around 
2 years into my PhD, the paper by Yu Han and Véronique Lefebvre (2008) ‘L-Sox5 and Sox6 
Drive Expression of the Aggrecan Gene in Cartilage by Securing Binding of Sox9 to a Far-
Upstream Enhancer’ was published and it confirmed the presence of an approximately 400 
base pair enhancer within cis 3 that I had already identified (Figure 20). I designed and 
constructed two clones; one containing the minimal promoter AB fused to the highly 
homologous 400 base pair fragment within cis 3 and the other containing the same sequences 
with the inclusion of the missing 92 base pairs (amplified from the new BAC RP11-1123E8).  
The constructs were named ‘!galAB+cis 3’ (see Methods section 5 construct 5) and 
‘!galAB+92+cis 3’ (see Methods section 5 construct 6) respectively.  
 
Upon linearization of the construct ‘!galAB+cis 3’, it was microinjected into the pronuclei of 
fertilized eggs and embryos were sacrificed at E14.5 days and stained with X-gal.  Out of 8 
transgenics, 1 embryo showed minimal cartilage specific expression in far fewer anatomical 
regions compared to the E14.5 !AGG20 embryos (Table 15 + 16). Figure 24 shows this 
embryo in which the !-galactosidase expression/blue staining is limited to the nasal cartilage 
(Figure 24B) and the cartilage of the distal digits of the forelimb (Figure 24A).  
PhD Thesis                                                                                                                          Andrea Layyous     
  
 155 
 
 
Figure 24: Representative E14.5 wholemount embryo expressing !-galactosidase (blue 
staining) driven by the !galAB + cis 3 promoter (-10,703bp - -10,343bp fused to minimal 
promoter/-452bp - +375bp). A) Lateral image of embryo B) Facial region. FD (forelimb digits), 
N (nasal cartilage). 
Table 15: Summary of transgenic and expressing mice driven by the !galAB + cis 3 
promoter (-10,703bp to -10,343bp fused to minimal promoter/-452bp to +375bp).  ‘Positive 
embryos’ indicates the total number of embryos in which the transgene has become integrated 
throughout each session. ‘Expressing embryos’ indicates the total number of embryos in which 
the integrated reporter gene is being expressed. The ‘Percentage of embryos expressing the 
transgene’ was derived by dividing the number of expressing embryos by the number of 
positive embryos and multiplying this figure by 100.  
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!galAB+cis 3 8 1 13 
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Table 16: Average levels of expression for !galAB+cis 3 transgenic mice after overnight 
staining at room temperature. – no staining, + staining just detectable, ++ low level staining, 
+++high level staining, ++++very high level staining.  
 
Tissue Intensity of staining Tissue Intensity of staining 
Chondrocranium - Digits of the Hindlimbs - 
Cartilage of the eye 
socket - Scapular cartilage - 
Nasal cartilage ++ Cartilage of the humerus - 
Meckels cartilage - Cartilage of the ulna - 
Cartilage of the ribs 
(costal) - Cartilage of the radius - 
Cartilage of the femur - Intervertebral discs - 
Cartilage of the tibia - Vertebral cartilage  - 
Cartilage of the fibula - Cartilage of the ear - 
Digits of the 
Forelimbs ++ Tongue - 
 
 
The construct ‘!AGGAB+92+ cis 3’ was also linearized, microinjected into the pronuclei of 
fertilized eggs, and embryos sacrificed at E14.5 days and stained with X-gal. Four out of 11 
positive transgenic embryos showed different levels/patterns of cartilaginous expression (Table 
17 + 18). In 2 of the 4 expressing embryos, the staining was localized to the developing 
cartilage of the long bones of the fore and hind limbs, the ribs, the scapulae, and the digits 
(Figure 25E+F and Figure 25G+H). This somewhat resembled the staining pattern of the 
!AGG20 transgenic embryos but with a much lower intensity and with the exclusion of the 
staining found in the tongue and meckel’s cartilage of the !AGG20 transgenic embryos. In the 
other 2 embryos, the staining pattern was also cartilage-specific but different. One embryo 
showed very strong X-gal staining in the ulna and radius with weaker staining in the first and 
fifth digit of the forelimbs (Figure 25A-D) and the other showed weak staining in the ribs, 
scapula, cartilage of the eye socket and the digits of the forelimb (Figure 25I+J). Figure 26 
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shows a representative histological saggital section of the forelimb and torso of the positive 
expressing !AGGAB+92+ cis 3 transgenic embryo in Figure 25A-D. It is clear from this section 
that the blue staining is located in the developing cartilage of the humerus and ulna and is very 
weak + scattered randomly across the proliferating chondrocytes and larger hypertrophic 
chondrocytes. However, in this embryo, although there is staining located within the 
chondrocytes of the developing long bones of the forelimb, it is also more strongly found in 
fibroblasts surrounding these developing bones.  Aggrecan is not known to be expressed 
within fibroblasts at this stage of development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PhD Thesis                                                                                                                          Andrea Layyous     
  
 158 
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Figure 25:  4 representative E14.5 wholemount embryos expressing !-galactosidase 
(blue staining) driven by the !galAB+92+cis 3 promoter (-10,703bp to -10,343bp fused to 
minimal promoter including missing 92 base pairs/-452bp to +375bp). A, B, C and D are 
images from the 1st transgenic embryo. E + F are images from 2nd, G + H are images from the 
3rd while I + J are images from the 4th transgenic embryo. All individual embryos show 
symmetrical staining. All images are lateral except for C, which is a ventral image. E (ear), EY 
(cartilage of the eye socket), F (femur), FD (forelimb digits), FI (fibula), H (humerus), HD 
(hindlimb digits), R (rib cartilage), RA (radius), SC (scapular cartilage), TI (tibia), U (ulna). 
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Figure 26: Histological section of a !galAB+92+cis 3 blue stained embryos. A,B and C are 
different magnifications of the same section. A) 4x magnification of saggital section of 
transgenic embryo showing the hindlimb and the upper torso. B) 10x magnification of humerus. 
C) 20x magnification of humerus showing scattered blue X-gal staining in small proliferating 
chondrocytes and large hypertrophic chondrocytes as well as non-chondrocytic fibroblastic 
cells. Section was eosin counterstained.  H (humerus), R (rib cartilage), RA (radius), U (ulna). 
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Table 17: Summary of transgenic and expressing mice driven by the !AGGAB+92+ cis 3 
promoter (-10,703bp to -10,343bp fused to minimal promoter including missing 92 
base pairs /-452bp to +375bp). .  ‘Positive embryos’ indicates the total number of embryos 
in which the transgene has become integrated throughout each session. ‘Expressing embryos’ 
indicates the total number of embryos in which the integrated reporter gene is being 
expressed. The ‘Percentage of embryos expressing the transgene’ was derived by dividing the 
number of expressing embryos by the number of positive embryos and multiplying this figure 
by 100.  
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
‘!AGGAB+92+cis 3’  11 4 36 
 
Table 18: Average levels of expression for !AGGAB+92+ cis 3 transgenic mice after 
overnight staining at room temperature. – no staining, + staining just detectable, ++ low 
level staining, +++high level staining, ++++very high level staining.  
a staining only found in 1 out of 4 expressing embryos 
b staining of the ribs found in 3 out of 4 expressing embryos, one of which only shows staining 
in the distal part of the developing ribs 
c staining found in 2 out of 4 expressing embryos 
d staining found in all 4 expressing embryos, but localised to the first and fifth digit in one of the 
empressing embryos 
e staining found in 3 out of 4 expressing embryos 
f staining found in 3 out of 4 expressing embryos, one of which shows high level staining 
compared to low level staining in the other 2 
 
 
Tissue Intensity of staining Tissue Intensity of staining 
Chondrocranium - Digits of the hindlimbs - e 
Cartilage of the eye 
socket + a Scapular cartilage + e 
Nasal cartilage - Cartilage of the humerus + c 
Meckels cartilage - Cartilage of the ulna ++ f 
Cartilage of the ribs 
(costal) + b Cartilage of the radius ++ f 
Cartilage of the femur + c Intervertebral discs - 
Cartilage of the tibia ++ c Vertebral cartilage  - 
Cartilage of the fibula ++ c Cartilage of the ear + a 
Digits of the forelimbs ++ d Tongue - 
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1.2.6 Finding additional cis-acting element(s) 
1.2.6.1 cis 6  
 
To test the potential regulatory activity of cis 6, approximately 3kb of non-coding DNA within 
the first intron of the human aggrecan gene (+5 to +8kb) was cloned directly downstream of 
the 20kb fragment in !AGG20 and upstream of the LacZ reporter gene. According to the 
recombineering method, I cloned the 5’ arm corresponding to the 3’ end of AB from !AGG20 
along with a 3’ arm corresponding to the 5’ end of the LacZ gene from !AGG20 on either end 
of cis 6 into the pBluescript KS+ vector (Figure 27.1 and 27.2). The resultant vector was called 
pBS/cis 6 recomb (Methods section 5 construct 9). The 5’arm/cis 6/3’arm fragment was then 
digested out of pBS/cis 6 recomb and used as a target linear sequence. !AGG20 was digested 
with XhoI and used as the retrieval targeting plasmid (Figure 27.3). The resultant gap-repaired 
vector was named ‘!AGG20 + cis 6’ (Methods section 5 construct 16). !AGG20 + cis 6 was 
then digested to release its backbone and subsequently injected into the pronuclei of fertilised 
murine eggs. The microinjection of !AGG20 + cis 6 yielded 3 transgenic embryos with identical 
and symmetrical patterns of reporter gene expression (Table 19 + 20). Figure 28 shows 3 of 
these embryos. The expression of the transgene was reduced in comparison to !AGG20 
transgenic embryos and limited to the distal digits of the forelimbs as well as the long bones of 
the fore and hindlimbs where only minimal expression was noted. All other cartilage specific 
expression found in the !AGG20 embryos was lost.  
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Figure 27: Diagram representing the recombineering strategy used to clone the 3kb 
intronic sequences (+5kb to +8kb) in an indirect way from the BAC RP11-343B18 into 
!AGG20 downstream of the ~20 kb insert and upstream of the LacZ  gene.  The indirect 
method uses pBS KS+ as an intermediate target vector. The 5’ and 3’ arms are coloured in red 
and blue respectively while the 3kb intronic sequence is coloured in pink. The pBS KS+ 
multiple cloning site is green. Note: cis 6 was amplified by proof-reading pfx polymerase and 
used to generate the vector  !AGG20 + cis 6. 
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Figure 28:  3 representative E14.5  wholemount embryos expressing !-galactosidase 
(blue staining) driven by the  !AGG20 + cis 6 promoter (-20,054bp to +375bp fused to 
+5,000bp to +7,813bp). A, B, C and D are images from 1 transgenic embryo while E and F are 
each from separate embryos. A) Saggital image of upper torso region including head. B) 
Saggital image of lower torso region including hindlimbs. C, E and F) forelimbs D) Hindlimb. 
FD (forelimb digits), FI (fibula), HD (hindlimb digits), RA (radius), TI (tibia), U (ulna). 
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Table 19: Summary of transgenic and expressing mice driven by the !AGG20 + cis 6 
promoter (-20,054bp to +375bp fused to +5,000bp to +7,813bp).  ‘Positive embryos’ 
indicates the total number of embryos in which the transgene has become integrated 
throughout each session. ‘Expressing embryos’ indicates the total number of embryos in which 
the integrated reporter gene is being expressed. The ‘Percentage of embryos expressing the 
transgene’ was derived by dividing the number of expressing embryos by the number of 
positive embryos and multiplying this figure by 100. 
 
Construct Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!AGG20 + cis 6 18 3 17 
 
Table 20: Average levels of expression for !AGG20 + cis 6 transgenic mice after 
overnight staining at room temperature. – no staining, + staining just detectable, ++ low 
level staining, +++high level staining, ++++very high level staining.  
 
 
Tissue Intensity of staining Tissue Intensity of staining 
Chondrocranium - Digits of the hindlimbs + 
Cartilage of the eye 
socket - Scapular cartilage - 
Nasal cartilage - Cartilage of the humerus - 
Meckels cartilage - Cartilage of the ulna ++ 
Cartilage of the ribs 
(costal) - Cartilage of the radius ++ 
Cartilage of the femur - Intervertebral discs - 
Cartilage of the tibia ++ Vertebral cartilage  - 
Cartilage of the fibula - Cartilage of the ear - 
Digits of the forelimbs ++ Tongue - 
 
 
1.2.6.2 cis 7  
 
 The highly conserved sequence cis 7 between humans and fugu within the 14th intron of the 
human aggrecan gene is around 150 base pairs (see Figure 15). I designed primers flanking a 
400 base pair region, which encompassed the homologous sequence and cloned it 
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downstream of cis 3 and AB (including missing 92 base pairs). The resultant vector was called 
‘!AGGAB+92+ cis 3 + cis 7’ (Methods section 5 construct 8). Unfortunately, although this 
construct was microinjected several times, no positive transgenic embryos have been yielded.  
1.2.7 !AGG20 line 
In order to monitor the expression driven by the "20kb fragment in !AGG20 –with the missing 
92 base pairs in the minimal/basal promoter- throughout adulthood, I created a line.  To find 
transgenic expressors, I took tail tips of 5-week-old weaned pups and stained them with the 
substrate X-gal. I identified one transgenic pup in which the nucleus pulposus of the 
intervertebral discs, the superficial proliferating chondrocytes as well as a few deeper 
hypertrophic chondrocytes of the growth plate of the vertebral bodies stained blue. There was 
no blue staining in the annulus fibrosus or the cartilage end plate. Figure 29 shows images 
(Figure 29A) and sections (Figure 29C + E) from this 5-week-old transgenic mouse’s tail tip. A 
wildtype tail was also stained with X-gal to identify background endogenous !-galactosidase 
expression in bone (Figure 29B). The positive expressor that was identified was bred to 
produce a homozygous line named line 12 (after the founder). Tail tips of 5-week-old wildtypes 
were also stained with the BR1 antibody to compare endogenous aggrecan expression with 
that of the reporter gene in line 12. Endogenous aggrecan expression was similarly found to be 
present within the nucleus pulposes of the intervertebral discs as well as the proliferating and 
hypertrophic chondrocytes of the surrounding growth plate cartilage (Figure 29D + F). 
However, unlike the pattern of expression seen in the X-gal stained transgenic tail tips of line 
12, there was some antibody staining present in the annulus fibrosus and the cartilage end 
plate of the wildtype tail tips and the staining present in the hypertrophic chondrocytes was 
more intense.  
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Figure 29 (next page): Tail tips of 5-week-old weaned pups stained with the substrate X-
gal. A, C, D, E and F are tails tips from line 12 !AGG20 transgenics while B, G, H and I are tail 
tips from wild type mice. A + B) whole mount X-gal stained tail tips of a line 12 !AGG20 
transgenic (A) and a wildtype littermate (B). C) 4x magnification of eosin counterstained 
section of line 12 !AGG20 transgenic tail tip. D) 4x magnification of a BR1 antibody stained 
wildtype tail tip. E) 10x magnification of eosin counterstained sections of line 12 !AGG20 
transgenic tail tips. F) 10x magnification of a BR1 antibody stained wildtype tail tip. AF (annulus 
fibrosus), CE (cartilaginous end-plate), GP (growth plate), IV (intervertebral disc) NP (nucleus 
pulposus), VB (vertebral body). Black arrows are pointed to blue stained !-galactosidase 
positive cells/regions. Red arrows are pointed to brown BR1 antibody stained cells/regions.  
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Next, I planned an experiment in which I could monitor the activity of the regulatory "20kb 
sequence in line 12 in a 4-month-old adult mouse while verifying its activity at the embryonic 
stage (already tested).  A 4 month-old homozygous male was crossed with 2 F1 females. The 
females had plugs on two consecutive days and were sacrificed approximately 2 weeks later 
alongside the homozygous male.  Along with the E13.5 and E14.5 embryos retrieved from the 
pregnant mothers, the heart, lungs, kidneys, brain, liver, spleen, spine, foot pad, thorax, hips, 
knees and tail of the homozygous male were also dissected and stained overnight with X-gal. 
 
As expected, the embryos at various stages of development (Figure 30.1 A-D) were all positive 
for cartilage-specific expression and with the exception of 1 embryo, were comparable to the 
1st ‘!AGG20’ transgenic embryos acquired through microinjections. This particular embryo 
(Figure 30.1A, embryo on the left +Figure 30.1C) had blue staining in the nasal cartilage which 
was probably due to it being slightly more developed than the E14.5 !AGG20 transgenic 
embryos generated by microinjections (Figure 17). Regarding the adult male, the heart, lungs, 
kidneys, brain, liver, spleen, spine and thorax were all negative (data not shown). Figure 30.2 
A-D shows wholemount images of the knee (Figure 30.2A), footpad (Figure 30.2B), tail (Figure 
30.2C) and hip (Figure 30.2D) from this adult male. There was no blue staining in the footpad. 
However, the hips, knee and tail all showed some positive staining. Histological sections of 
these tissues were prepared in order to verify whether the macroscopic blue staining seen in 
the different tissues was due to LacZ transgene expression or simply due to endogenous !-
galactosidase expression that occurs in bone marrow tissue.  
                                          
                  
                    
 
 
PhD Thesis                                                                                                                          Andrea Layyous     
  
 170 
 
 
 
 
 
                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.1 + 30.2 (next page): 30.1) Wholemount X-gal blue staining of heterozygous 
E12.5-E14.5 embryos from line 12 (with !AGG20 transgene).  A and B) lateral  images of 
E14.5 line 12 embryos C) Ventral image of E14.5 line 12 embryo  D) lateral images of E12.5 
(left) and E13.5 (right) line 12 embryos. 30.2) Wholemount X-gal blue staining of 
homozygous 4 month old adult mouse from line 12 (with !AGG20 transgene). A) Knee of 
4 month old adult from line 12 B) Footpad of line 12 4 month old mouse C) Cross section of tail 
from line 12 4 month old mouse D) Hip of 4 month old adult from line 12.  N (nasal cartilage), F 
(femur), FD (forelimb digits), FI (fibula), HD (hindlimb digits), M (Meckel’s cartilage), PA 
(Patella), P (Pelvis), R (rib cartilage), RA (radius), SC (scapular cartilage), T (tongue), TA (tail), 
TI (tibia), U (ulna). 
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Figure 31 shows saggital histological sections of the tail and hip shown in Figure 30.2C + 
30.2D respectively. These sections were also counterstained with the BR1 antibody in order to 
distinguish between the endogenous expression of the gene as well as the expression driven 
by the 20kb transgenic sequence in line 12. The tail section in Figure 31A showed similar blue 
staining to what was previously seen in Figure 29. As was the case before, the blue X-gal 
staining and the brown BR1 antibody staining colocalised in the nucleus pulposus and the 
proliferating + hypertrophic cells of the vertebral growth plate. However, there was only BR1 
antibody staining in the annulus fibrosus and the cartilage end plate. There was a big 
difference between the BR1 antibody staining and the blue staining in the hip sections.  In 
Figure 31B, only 3 of the deeper chondrocytes showed blue staining whereas all the 
chondrocytes were positive for BR1 antibody staining. 
 
The coronal sections of the mouse knee in Figure 30.2A are shown in Figure 32. There was no 
blue staining evident in the lateral or medial articular cartilage and there was very minimal blue 
staining in the deep hypertrophic chondrocytes of the medial and tibial growth plates (Figure 
32D+E).  
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Figure 31: Paraffin sections of the line 12 (!AGG20 transgene) mouse tails (A) and hip 
(B) stained with the X-gal substrate and counterstained with the BR1 antibody. A) 10x 
magnification of a transgenic tail tip section (left) with corresponding 20x magnification of 
boxed regions (right). B) 10x magnification of a transgenic hip section (left) with corresponding 
20x magnification of boxed region (right). AC (articular cartilage), AF (annulus fibrosus), CE 
(cartilaginous end-plate), GP (growth plate), HC (hypertrophic chondrocytes) NP (nucleus 
pulposus), TC (terminal chondrocytes). Black arrows are pointed to blue stained !-
galactosidase positive cells/regions.  
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Figure 32: Coronal sections of a representative 4 month old line 12 
(!AGG20) mouse knee in which the hypertrophic blue-stained 
chondrocytes have been circled. A) 4x magnification of whole knee B) 20x 
magnification of lateral articular cartilage C) 20x magnification of medial articular cartilage D) 
20x magnification of lateral tibial growth plate E) 20x magnification of medial tibial growth plate. 
Section was counterstained with eosin. 
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1.2.8 Summary of Results  
 
Table 21: Summary of mice transgenic and expressing all generated constructs for 
microinjection.  ‘Positive embryos’ indicates the total number of embryos in which the 
transgene has become integrated throughout each session. ‘Expressing embryos’ indicates 
the total number of embryos in which the integrated reporter gene is being expressed. The 
‘Percentage of embryos expressing the transgene’ was derived by dividing the number of 
expressing embryos by the number of positive embryos and multiplying this figure by 100.  
 
 
Construct 
Number of 
embryos positive 
by PCR 
Number of 
embryos 
expressing the 
transgene 
Percentage of 
embryos 
expressing the 
transgene (%) 
!galAB 10 0 0 
!AGG20 (E14.5) 7 3 42 
!AGG20 (E16.5) 3 1 33 
!AGG13 11 0 0 
!galAB+7 21 2 10 
!AGG10 18 0 0 
!galAB+cis 3 8 1 13 
!galAB+92+cis 3 11 4 36 
!AGG20 + cis 6 18 3 17 
 
 
Table 22 (next page): Average levels of expression for all transgenic mice after 
overnight staining at room temperature. – no staining, + staining just detectable, ++ low 
level staining, +++high level staining, ++++very high level staining.  
a staining only found in 1 out of 4 expressing embryos 
b staining of the ribs found in 3 out of 4 expressing embryos, one of which only shows staining 
in the distal part of the developing ribs 
c staining found in 2 out of 4 expressing embryos 
d staining found in all 4 expressing embryos, but localised to the first and fifth digit in one of the 
empressing embryos 
e staining found in 3 out of 4 expressing embryos 
f staining found in 3 out of 4 expressing embryos, one of which shows high level staining 
compared to low level staining in the other 2 
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Tissue 
!galAB !AGG20 
(E14.5) 
!AGG20 
(E16.5) 
!AGG
13 
!galAB
+7 
!AGG10 !galAB+cis
3 
!galAB+92+cis
3 
!AGG20+cis
6 
Chondro- 
cranium 
- - - - - - - - - 
Cartilage 
of the eye 
socket 
- - +++ - - - - + a - 
Nasal 
cartilage 
- - +++ - ++ - ++ - - 
Meckels 
cartilage 
- + ++ - - - - - - 
Cartilage 
of the ribs 
(costal) 
- +++ +++ - - - - + b - 
Cartilage 
of the 
femur 
- ++ +++ - + - - + c - 
Cartilage 
of the 
tibia 
- +++ +++ - + - - ++ c ++ 
Cartilage 
of the 
fibula 
- +++ +++ - - - - ++ c - 
Digits of 
the 
forelimbs 
- +++ ++++ - ++ - ++ ++ d ++ 
Digits of 
the 
hindlimbs 
- ++ ++++ - - - - - e + 
Scapular 
cartilage 
- +++ +++ - - - - + e - 
Cartilage 
of the 
humerus 
- +++ +++ - - - - + c - 
Cartilage 
of the 
ulna 
- +++ +++ - +++ - - ++ f ++ 
Cartilage 
of the 
radius 
- +++ +++ - +++ - - ++ f ++ 
Intervert-
ebral 
discs 
- - +++ - - - - - - 
Vertebral 
cartilage 
- - +++ - - - - - - 
Cartilage 
of the ear 
- - +++ - + - - + a - 
Tongue - +++ - - - - - - - 
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1.3 Discussion 
 
 
1.3.1 Using transgenic mouse embryos as a model to study the regulation 
of the aggrecan gene 
There are several reasons for my choice to use transgenic mouse embryos rather than 
transient-transfection assays to study the regulation of aggrecan gene expression. Firstly, 
there are a lot of published data demonstrating the accurate correlation between the 
endogenous expression of genes and their expression in transgenic mouse embryos in which 
transgenes have been introduced alongside a reporter gene such as LacZ.  An example of this 
comes from a study carried out by Whiting J et al. using a Hox-2.6-lacZ reporter gene in 
transgenic mice; they showed that the overall expression pattern of the endogenous Hox-2.6 
gene could be reconstructed. The transgene was expressed with the correct spatial distribution 
and temporal pattern. Furthermore, direct comparison by in situ hybridization revealed that the 
levels of transgene expression were also similar to those of the endogenous gene (Whiting et 
al., 1991).  
 
Secondly, the use of transient-transfection assays is very limited due to the restrictive nature of 
primary chondrocytic cell lines. Immediately after isolation from their natural protective 
environment, chondrocytes show hardly any proliferative activity. If they do however start to 
proliferate, this usually indicates the loss of a differentiated phenotype. This involves a change 
in cell shape as well as significant differences in gene expression pattern. Even the 
immortalised chondrocyte cell lines C-28/I2, T/C-28a2 and T/C-28a4, which have become a 
common tool in cartilage research, are still quite problematic since they show less expression 
of genes of matrix synthesis and turnover (Finger et al., 2003). Analysing the expression of 
aggrecan in vitro will therefore be quite challenging with culture conditions differing greatly from 
the in vivo conditions that make transgenic mouse experiments so useful. 
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Thirdly, transgenic mouse experiments shouldn’t take longer than transient- transfection 
assays. It takes 14.5 days to grow transgenic embryos to the level at which they can be 
analysed for aggrecan gene expression. This is roughly the same amount of time it takes to 
attain a transiently transfected cell line. And finally, with transgenic experiments, you can 
visualise the expression of a gene throughout the organism as a whole in a temporal and 
spatial manner. For example, it is possible to determine the different cartilaginous tissues in 
which aggrecan is expressed and the time-points at which they begin to show this expression. 
 
1.3.2 In silico  analysis of the aggrecan gene 
The web-based program Vista was used to look at identities between different non-coding 
sequences of the aggrecan gene across two different species, rats and humans. This seems to 
be a good way to identify evolutionarily conserved and therefore important regions within the 
genome. In support of this, in a study carried out by Pennacchio et al, extreme evolutionary 
sequence conservation was used as a filter to identify putative gene regulatory elements. This 
led to the characterisation of the in vivo enhancer activity of a large group of non-coding 
elements in the human genome that are conserved in human vs pufferfish fugu (Takifugu 
rubripes), or ultraconserved in human vs mouse vs rat. Of the 167 extremely conserved 
sequences tested in transgenic mouse enhancer assays, 45% functioned reproducibly as 
tissue-specific enhancers of gene expression at embryonic day 11.5 (Pennacchio et al., 2006). 
This serves as an argument for the investigation of human DNA regulatory sequences in a 
mouse system. 
 
When comparing human and rat aggrecan non-coding sequences, there are several relatively 
highly conserved sequences to be found upstream of and around the transcriptional start site. 
For my purposes, these regions were named cis 1-5. cis 1-4 lie upstream of the start site and 
are in the approximate positions ‘-20- -19.7kb ’, ‘-14.5 - -14.4kb’, ‘-10.9 - -10.2kb’, and ‘-3.8 - -
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3.7kb’ respectively.  cis 5 (-390 - +375bp) lies around/includes the 1st exon/5’UTR/previously 
determined basal promoter of the human aggrecan gene. Unlike cis 1-5, which are relatively 
highly conserved as indicated by the coloured peaks in Figure 14, cis 6 has a lower level of 
conservation between humans and rats and was selected due to the presence of 3 putative 
sox9 binding sites within it. It is located at the 5’ end of the large 1st intron of the gene 
(between +5 and +8kb relative to the TSS). The sox9 putative binding sites were identified 
using the program genomatix (http://www.genomatix.de/) and are located at +5.3kb, +6.8kb and 
+7.4kb relative to the TSS. Finally, cis 7 is positioned within the 14th intron of the human 
aggrecan gene between +64.6kb and +65.0kb relative to the TSS. My interest in cis 7 was due 
to the fact that it was the only sequence within the investigated region in which the 
conservation down to fugu remained relatively high (Figure 15).  
 
1.3.3 The human aggrecan minimal promoter within cis  5 (-452bp - +375bp) 
As discussed, the human aggrecan minimal promoter used was based on the data published 
by Valhmu et al along with the information from my In silico analysis in which cis 5 includes this 
minimal promoter.  Although the published data points to the 5’UTR  (0bp - +375bp relative to 
the TSS) of the gene as the primary regulatory sequence able to act as the minimal promoter 
required to drive basal expression of the aggrecan gene, the vista analysis shown in Figure 14 
showed high sequence identity between humans and rats from  -390 - +375bp.  Thus, as the 
human aggrecan minimal promoter, I used the sequence corresponding to -452 - +375bp, 
which was named AB. This ensured the inclusion of the 5’UTR as well as the upstream 
conserved sequence. Although the 5’UTR was sufficient to drive reporter gene expression by 
about 8 fold in chondrocytes and 40 fold in NIH 3T3 cells (in vitro) (Valhmu et al., 1998a), this 
was not the case for the transgenic embryos harbouring this sequence (in vivo). There was no 
blue staining in any of the positive transgenics (Table 6). This result corresponded somewhat 
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with the data from Han and Lefebvre (2008) where the ‘mouse aggrecan minimal promoter’ 
corresponding to the sequence -596bp - +90bp relative to the mouse TSS was completely 
inactive when tested alone in RCS cells (Han and Lefebvre, 2008). This sequence was most 
probably selected as a ‘basal promoter’ due to it containing two glucocorticoid receptor- 
binding sequences (TGTTCT/C) and one GGGCGG sequence (SP-1 site) as well as several 
homologous direct repeat sequences. In addition to this, a region that shows identity to a 
sequence of the promoter of the rat type-II collagen gene, which itself is highly conserved in 
both the rat and mouse type-II collagen genes and is known to be important for type-II collagen 
gene promoter activity (Watanabe et al., 1995). It would be interesting to test whether the 
activity of this promoter is switched on in vitro with the inclusion of the mouse 1st exon/5’UTR 
which is 509bp in size (+1 - +509bp relative to the mouse TSS). Nevertheless, the combination 
of this data supports the conclusion that the selected human aggrecan minimal promoter AB is 
unable to drive reporter gene expression in vivo.  At this point, it was therefore assumed that 
any reporter gene activity was due to sequences that lie outside this minimal promoter 
interacting with it to drive transcription of the gene.  
 
1.3.4 Investigating the potential regulatory activities of cis 1-4 
1.3.4.1 cis 1-4 (located at -20 to -19.7kb, -14.5 to -14.4kb, -10.9 to -10.2kb, and -
3.8 to -3.7kb respectively). 
At the time I started this work, the only in vivo experiment that had been performed in order to 
locate cis-regulatory ‘enhancer’ sequences was by Doege and colleagues whose work focused 
on the rat aggrecan gene (Doege et al., 2002). They showed that an Agc1 4.7kb (P3) 
upstream region was able to activate an Agc1 3.4kb (P0) promoter in transgenic embryos, but 
weakly and only in hypertrophic chondrocytes in a subset of cartilage elements. Taking this 
into account as well as the in silico homology search in Figure 14, I cloned a DNA fragment 
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around 20 kilobases in size (ranging from -20,054bp to +375bp relative to the TSS) into the 
!gal-basic vector upstream of the LacZ reporter gene. This included cis 1-4 as well as the 
minimal promoter AB within cis 5. By cloning and analyzing such a large fragment, I also took 
into account any shifting of cis-regulatory elements that may have occurred during evolution. It 
is important to note that any statements made below assume that the cis-regulatory sequences 
that drive the expression of the human aggrecan gene endogenously fall only within the highly 
homologous sequences illustrated by the vista analysis, cis 1-5 (Figure 14).   
 
The vector containing cis 1-5 was named !AGG20 and microinjected into the pronuclei of 
fertilised murine oocytes. The results of the transgenic mouse experiments revealed the 
existence of cis-acting elements other than the basal promoter upstream of the TSS of the 
aggrecan gene that are responsible for the chondrocyte specific expression of the gene. 
Approximately 40% (3 embryos) of the positive transgenic mice expressed the transgene 
identically, symmetrically and specifically in the developing cartilage/differentiated 
chondrocytes of the long bones of the hind and fore limbs, the ribs, the scapulae, some facial 
cartilaginous structures (meckel’s cartilage) and the digits (Figures 17). The histological 
sections in Figure 18 showed that the !-galactosidase expression was present in both the 
proliferating and hypertrophic chondrocytes of the developing cartilaginous structures. The 
presence of the !-galactosidase protein in the hypertrophic chondrocytes is most probably due 
to the stability of the protein and the progression of the cells. Henry et al (2009) also came 
across this when they compared aggrecan mRNA expression (detected by RNA in situ 
hybridization) that was present in the proliferating chondrocytes of the ulna growth plate but 
was not observed in the hypertrophic chondrocytes with the expression of aggrecan in a 
reporter mouse in which aggrecan expression coincides with LacZ expression. In this latter 
mouse, positive X-gal staining was observed in both the proliferating and hypertrophic 
chondrocytes of the ulna (Henry et al., 2009). The observation of the same expression pattern 
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in three of the positive !AGG20 transgenic embryos makes the possibility of insertional 
position artefacts extremely unlikely. 
 
It is obvious that the pattern of transgene expression is different when comparing the 
transgenic mice expressing !AGG20 with those expressing the P3/P0 transgene (Doege et al., 
2002). The !AGG20 transgenics displayed a more intense and spacially increased pattern of 
transgene expression when compared with the P3/P0 transgenics. Unlike the P3/P0 
transgenics, they expressed LacZ in the developing cartilage of the digits and in addition to 
hypertrophic chondrocyte expression, !-galactosidase expression was present in proliferating 
chondrocytes. From this, I propose the following of which at least one statement is possible:  
 
1- This ~20kb fragment must have additional necessary cis-regulatory elements that the 
rat -12kb - -7kb/basal promoter fused DNA does not. 
2- Enhancer element(s) found within P3 might require a minimal distance from the P0 
element in order for it/them to function normally. Since the ~20kb fragment in !AGG20 
was not modified from what is present within the human genome, the location and 
relative distances between the ‘regulatory sequence(s)’ in the construct will therefore 
reflect what is true endogenously. 
3- There may be other elements such as silencers within P3 or P0, which weaken the 
regulatory activity of the entire sequence. These silencers could be neutralised by the 
presence of other sequences within the ~20kb fragment.  
1.3.4.2 cis 3+4 (-10.9 to -10.2kb and -3.8 to -3.7kb respectively). 
In order to minimise the size of the DNA fragment that can drive the expression of aggrecan 
specifically in cartilage. !AGG20 was shortened by ~7kb from its 5’end (generating !AGG13) 
and used to produce transgenic mice. In doing this, the DNA sequence containing cis 1 + 2 
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was removed leaving behind cis 3 + 4 along with the minimal promoter AB, within cis 5. This 
cut off point was primarily selected in order to include the "400 bp sequence with high identity 
across humans and rats that is present within cis 3 and the fragment P3 (Doege et al., 2002) 
located between -10.7kb and -10.4kb relative to the human aggrecan TSS. 
  
Despite the generation of 11 positive !AGG13 transgenic embryos, none showed any form of 
X-gal staining (Table 11). On its own, the ~13kb stretch of DNA did not seem to drive 
transcription of the reporter gene. Therefore, with regards to cis 3+4, it was possible that one 
or both of these regions were either non-essential (are not real cis-regulatory sequences), 
necessary regulatory sequences but insufficient (require other fragment(s) to interact with) or 
negative regulatory sequences that downregulate the activity of the reporter gene.   
1.3.4.3 cis 1+2 (-20 to -19.7kb and -14.5 to -14.4kb respectively). 
To test whether the regions corresponding to cis 3 and/or cis 4 were either insufficient or 
unnecessary, the deleted 7kb fragment containing cis 1 + 2 was fused immediately upstream 
of the minimal promoter AB (generating the construct !galAB+7) and used to produce 
transgenic mice.  A similar embryonic expression pattern to that generated by the !AGG20 
transgene would indicate that cis 3 and/or cis 4 are unnecessary while a different expression 
pattern would indicate their insufficiency. 
 
The results of generating E14.5 !galAB+7 transgenic embryos revealed the existence of cis-
acting elements other than the basal promoter within the fused 7kb stretch of DNA containing 
cis 1 and 2. Approximately 10% (2 embryos) of the positive transgenic mice showed similar 
and symmetrical cartilage specific expression in the cartilage of the long bones of the forelimbs 
(ulna and radius), the nasal cartilage and minimal expression in the cartilage of the developing 
hindlimbs (femur and tibia) (see Figure 22 and Table 12+13).   Although the expressing 
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!galAB+7 transgenic embryos showed cartilage-specific expression of the transgene, the LacZ 
expression in the !AGG20 transgenics was more intense with a wider range of positive 
developing cartilaginous structures (digits, ribs, scapulae, etc). It was also clear when 
comparing the histological sections of the !galAB+7 transgenic embryos (Figure 23) with the 
!AGG20 transgenic embryos (Figure 18) that although there was also blue LacZ staining in the 
proliferating and hypertrophic chondrocytes of the !galAB+7 embryos, this staining was more 
scattered/mosaic across the cells with far fewer cells stained blue. It was possible, therefore, 
that although the 7kb stretch of DNA containing cis 1 and 2 had a regulatory sequence(s) that 
could drive cartilage specific expression of the transgene, other regulatory sequences within 
!AGG20 which could correspond to cis 3 and/or 4 were also necessary but probably 
insufficient. This is further supported by the fact that only 10% of the positive !galAB+7 
transgenic embryos expressed the transgene compared with 40% for the !AGG20 transgenic 
embryos. From this, I propose the following of which at least one statement is possible:  
 
1- This ~7kb fragment must have necessary cis-regulatory element(s) to drive endogenous 
aggrecan expression. 
2- Like the cis-regulatory elements in !AGG13 (cis 3+4), these elements are necessary 
but insufficient to drive endogenous cartilage specific aggrecan expression. 
1.3.4.4 cis 1+2 and 4 (-20 to -19.7kb, -14.5 to -14.4kb and -3.8 to -3.7kb 
respectively). 
The fact that the blast alignment of the P3 and P0 rat fragments (Doege et al., 2002) with the 
!AGG20 sequence revealed a highly conserved approximately 400 bp sequence within cis 3 
led me to believe that it was cis 3 that was the relevant and necessary regulatory sequence 
within !AGG13 that potentially interacted with the regulatory sequence(s) in !galAB+7. To test 
this, I generated a construct (called !AGG10) lacking the cis 3 sequence but containing the cis 
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1,2 and sequences along with the minimal promoter AB by removing a fragment of DNA 
approximately 10kb in size within the 20kb sequence in !AGG20 between " -14kb and -4kb 
relative to the TSS. Out of 18 positive E14.5 transgenic embryos, none showed any reporter 
gene expression as indicated by the lack of blue staining (Table 14). It is important to note that 
unlike !galAB+7, which was able to drive minimal cartilage specific expression in 10% of the 
positive transgenic embryos, !AGG10 (containing all the fragments present in !galAB+7 in 
addition to cis 4) showed expression in 0% of the positive transgenic embryos. From this I 
concluded that: 
 
1- The deleted 10kb sequence contains a potential cis-regulatory element (cis 3) that is 
necessary but insufficient to drive endogenous expression of aggrecan. 
2- It is possible that cis 4 has a negative regulatory effect on the expression of the reporter 
gene. 
1.3.4.5 cis 3 (-10.9 to -10.2kb)  
Given the negative results from the !AGG10 transgenics and the fact that the blast alignment 
between the P3/P0 rat fragments (Doege et al., 2002) and the !AGG20 sequence revealed a 
highly conserved "400bp sequence within cis 3 (between -10.7kb and -10.4kb), it was highly 
likely that cis 3 could be indespensible for the endogenous expression of aggrecan. At this 
point in my Phd, Veronique Lefebvre’s group published data on the mouse aggrecan promoter 
that showed that a short regulatory sequence, which they named A1 and that corresponded to 
the "400bp sequence that I identified within cis 3, could function as an enhancer that can drive 
cartilage specific expression of a reporter gene (Han and Lefebvre, 2008). However, although 
they showed that when multimerised (x4), this sequence was able to direct expression of the 
Col2a1 minimal promoter (-309 bp - +308 bp relative to the TSS) in both embryonic and adult 
cartilage in transgenic mice in a manner that matches aggrecan expression, they showed no 
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evidence that this was true for the Agc1 minimal promoter fused to 1 copy of the A1 sequence. 
The only data shown on the gene regulation driven by the A1 sequence fused to the Agc1 
minimal promoter was in RCS cells in which they showed that the Agc1 promoter was weakly 
but significantly activated by 1 copy of the!A1 sequence and more powerfully activated by 4 
copies of!A1.  
 
In order to test the regulatory role of the highly conserved "400bp sequence within cis 3, I 
constructed a clone containing the minimal promoter AB fused to the highly homologous 400 
base pair fragment within cis 3. The construct was named ‘!galAB+cis 3’.  Out of 8 
transgenics, 1 embryo (12.5%) showed minimal cartilage specific expression limited to the 
nasal cartilage and the cartilage of the distal digits of the forelimb (Table 15 + 16 and Figure 
24). From this, I concluded that cis 3 definitely is a cis-regulatory sequence that is necessary 
but insufficient as only 12.5% of the positive ‘!galAB+cis 3’ transgenic embryos expressed the 
transgene compared with 40% for the !AGG20 transgenic embryos. This expression was also 
a lot weaker and limited to 2 developing cartilagenous elements.  
 
1.3.4.6 Hypothesised roles of cis 1-5 
 
From the above data, I hypothesized the following: 
1- cis 5, in which the minimal promoter of the human aggrecan gene lies, is unable to drive 
reporter gene expression in vivo and requires other regulatory sequences to interact 
with in order to drive the endogenous expression pattern of the aggrecan gene.   
2- cis 4 is a negative regulatory sequence (silencer) as is shown by the fact that unlike 
!galAB+7 (containing cis 1,2 and 5), which was able to drive minmal cartilage specific 
expression, !AGG10 (containing all the fragments present in !galAB+7 in addition to cis 
4) showed no expression in any of the positive transgenic embryos. Also, !AGG13, 
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which contained cis 3,4 and 5 showed no expression of the transgene unlike 
!galAB+cis 3 (containing cis 3 and 5 and excluding cis 4), which showed minimal 
cartilage-specific expression in 12.5% of the positive transgenic embryos. This is further 
supported by the paper by Pirok et al in which the deletion of two copies of the 
sequence CACCTCC (CIIS2) approximately 870 and 720 base pairs upstream of the 
chicken aggrecan start site reduced the cell type specificity of reporter gene expression 
but increased the overall promoter activity (Pirok et al., 1997). 
3- cis 3 is an enhancer sequence that is necessary but insufficient to drive endogenous 
aggrecan expression as is shown by Han and Lefebvre’s (2008) work, the ability of the 
!galAB+cis 3 transgenic embryo to drive cartilage specific expression and the fact that 
none of the !AGG10 transgenics (which excluded cis 3) drove the expression of the 
reporter gene.   
4- cis 1 and/or cis 2 are also necessary but insufficient to drive the reporter gene 
expression seen in the !AGG20 transgenic embryos as is shown by their ability to 
activate the minimal promoter in the !galAB+7 transgenics and the inability of !AGG13 
(which excludes cis 1 and 2) to drive reporter gene expression. They could possibly 
interact with cis 3 to drive full endogenous aggrecan expression and counteract the 
negative regulatory effect that cis 4 has on expression of the reporter gene. 
To test this further, it would be useful to create a construct composing of cis 1,2,3 and 5 
and excluding cis 4.  
 
1.3.5 Finding additional cis-regulatory elements in the aggrecan gene 
Although these results clearly confirmed a major role for the ~20kb fragment containing cis 1-5 
in the tissue-specific regulation of aggrecan, there were some indications that it may not be 
sufficient for all aspects of aggrecan regulation. It was quite surprising that the reporter gene 
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expression in the vertebral bodies of the !AGG20 transgenic embryos was switched on as late 
as E16.5. Also, even at E16.5, there was no X-gal staining in the chondrocranium. The 
expectations of the temporal and spatial pattern of aggrecan gene expression were initially 
based on a comparison with the expression pattern driven by the type II collagen p3000i3020 
promoter/enhancer in E14.5 transgenic mouse embryos (Zhou et al., 1995). However, the 
generation of the Agc1tm(IRES-CreERT2/+) transgenics in De Crombrugghe’s laboratory (Henry et 
al., 2009), in which the Cre recombinase gene was knocked into the 3’ untranslated region of 
the endogenous mouse aggrecan gene as well as the BR1 antibody stained mouse sections in 
Figure 13 enabled the use of other more comparable ~~ results. This was necessary since 
there is a big difference in the intensity and a smaller difference in the spatial orientation of 
LacZ gene expression between the tamoxifen induced Agc1tm(IRES-CreERT2/+);Rosa26 Cre 
reporter double transgenics and the ‘p3000i3020’ transgenic embryos at E14.5.  There are 
different possible explanations for this. Firstly, it has been suggested that there would be 
differences in developmental expression between type II collagen and aggrecan (Sandell, 
1994), (Han and Lefebvre, 2008). Also, even where these genes are coexpressed, there are 
differences of at least 5-fold in the steady-state levels of their mRNAs (Oxford et al., 1994). 
Therefore, we only used the Agc1tm(IRES-CreERT2/+);Rosa26 Cre reporter double transgenic 
embryos + the BR1 antibody stained mouse sections as reliable comparitive tools. The 
tamoxifen induced Agc1tm(IRES-CreERT2/+);Rosa26 Cre reporter double transgenic embryos, in 
which the vertebral body expression of the Cre recombinase gene started as early as E13.5,  
showed more intense X-gal staining that was localized to a wider range of cartilaginous regions 
(such as the chondrocranium) in E15.5 embryos when compared to the E14.5 and E16.5 
!AGG20 transgenic embryos. The BR1 antibody stained mouse sections also showed 
aggrecan staining in the vertebral bodies as early as E13.5 as well as staining in the 
chondrocranium at E15.5. It can therefore be concluded that the activity of !AGG20 may just 
represent a specialised subprogram for aggrecan’s expression so there was a need to identify 
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additional areas of the gene, which can supplement its function. 
 
1.3.5.1 Missing 92 base pair sequence 
 
When  !AGG20 was initially cloned, the sequencing of the minimal promoter AB within cis 5 on 
the 3’ end of the "20kb fragment showed a deletion of 92 base pairs (-68 to + 23bp) which was 
also found in the BAC RP11 343B18 used to retrieve human aggrecan promoter DNA. Fresh 
stocks of the BAC were ordered but unfortunately all contained this deletion. In the meantime, 
transgenic embryos were generated using the !AGG20 construct and they displayed 
cartilaginous expression that was similar but not identical to endogenous aggrecan expression. 
!AGG20 was further manipulated to produce other constructs some of which also drove 
cartilage specific expression of LacZ. On the one hand, the missing 92 base pairs could be 
inconsequential. This is somewhat supported by the work done by Valhmu et al to elucidate 
the role of the minimal aggrecan promoter by using luciferase reporter constructs driven by the 
human aggrecan promoter (taken as -701bp - +52bp relative to the human aggrecan TSS, 
87,147,670 on chromosome 15, Assembly: March. 2006 NCBI36/hg18). The sequential 
deletions of a large portion of this so-called human aggrecan proximal promoter from -701bp - -
52bp had very little effect on promoter activity when the 5’UTR (+1 - +375bp) was present. 
However, when the 5’UTR was removed, leaving a 5’ flanking sequence of -701bp - +25bp or -
52bp - +25bp, luciferase activity was reduced 85-100%. It is possible that the whole sequence 
from -701bp up to +25bp, which includes the missing 92 bp, is unnecessary since, on its own, 
it was not able to drive substantial luciferase activity.  On the other hand, the sequence 
between -52bp and +25bp could be necessary but insufficient. This is more likely as the 
5’UTR, which can act as the minimal promoter required to drive basal expression of the 
aggrecan gene, does include the sequence between +1 and +25bp. Therefore, within the 
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missing 92bp (-68 to +23bp), 23bp are part of the 5’UTR and have been excluded from 
!AGG20 and all subsequent clones generated.  
 
Within the human aggrecan promoter, there are several putative SP-1/AP-2 binding sites 
(CCCGCC), including a cluster of SP-1/AP-2 binding sites around the TSS (Figure 33).  SP-1 
plays a key role in regulating transcription initiation of TATA-less and CAAT-less promoters by 
possibly recruiting the TFIID protein to the transcription initiation complex. Three overlapping 
SP-1/AP-2 binding sites span the TSS of the human aggrecan promoter. One of these 
overlapping sites is present within the missing 92 base pairs, whereas the second and third are 
located at positions -142bp and -246bp. In the rat gene, there is only one copy of the SP-1/ 
AP-2 site in a position equivalent to that of the overlapping SP-1/AP-2 sites in the human 
promoter (Doege et al., 1994).  
 
It is possible that the minimal promoter in all the constructs that I have produced was able to 
compensate for the lack of one of the overlapping SP-1/AP-2 sites due to the presence of two 
others. It is clear from the rat promoter that the presence of one overlapping site is sufficient for 
gene expression. Having said that, in both the rat and human genes, transcription is initiated 
23-24bp downstream of a conserved TATG direct repeat (located at -31bp in the human gene), 
which could be important for the correct transcriptional initiation of the gene as this sequence 
may be the equivalent of a TATA box in TATA-less promoters such as the aggrecan promoter 
(Figure 33). However, the bovine aggrecan gene can undergo transcriptional initiation at four 
different sites upstream of this TATG repeat suggesting that the promoter can find alternative 
routes to initiate transcription (Watanabe et al., 1995).  
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Figure 33: Sequence of the human aggrecan minimal promoter. The missing 92bp 
sequence in the RP11-343B18 BAC is shown in the purple box. Several putative binding sites 
for ubiquitous transcription factors such as SP-1, AP-2, and AP-4 are located in both the 
promoter and exon 1. Recognition sequences for growth factor- and cytokine-inducible factors 
are also present. The promoter lacks a TATA box, but a TATGTATG sequence that is present 
at -31bp (highlighted in black) might function as a TATA element. Adapted from (Valhmu et al., 
1998a).  
 
Having made all these points, it was still possible that the lack of this sequence due to the 
missing 92bp/Sp-1/AP-2 sites in the constructs that I have generated may compromise the full 
expression of the gene in all cartilaginous elements of developing embryos. This notion is 
further supported by the work carried out by my supervisor George Bou-Gharios and his group 
on the Col1a2 promoter.  They set out to examine the transcriptional contribution of SP-1 sites 
in the proximal promoter within the context of the interaction with the far upstream enhancer by 
mutating the three SP-1 binding sites of the cytokine responsive element within the proximal 
promoter.  Transgenic embryos harbouring these mutations were found to express the LacZ 
reporter gene significantly less than the embryos harbouring the wild-type version of the 
proximal promoter/enhancer. Histological examination of the transgenic embryos harbouring 
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these mutations revealed that this was due to a mosaic pattern in the expression of the LacZ 
reporter gene. Also, some areas that were supposed to express the transgene showed no 
reporter gene expression. These results suggested that the SP-1 mutations impair transgene 
expression in addition to reducing the overall strength of the enhancer/promoter interaction for 
the Col1a2 gene (Tanaka et al., 2004). The lack of one of the SP-1/AP-2 overlapping sites in 
the transgenics may therefore compromise the interaction between the aggrecan minimal 
promoter and the cis 3 enhancer or a possible regulatory sequence present within cis 1 or cis 
2. 
 
  
Validating a role for the missing 92 base pairs required the cloning of a new "20kb fragment 
inclusive of this missing sequence within the vector backbone !gal basic in the same way. 
Although a new BAC containing the missing 92bp was finally acquired, I was not able to 
complete the recombineering experiments that are necessary to construct the clone due to a 
lack of time. I did, however, manage to construct a clone containing the minimal promoter AB 
including the missing 92bp sequence fused to the highly homologous 400 base pair fragment 
within cis 3 (called !galAB+92+cis 3). Compared to the results from the !galAB+cis 3 
transgenic, in which 1 embryo out of 8 positive transgenic (12.5%) showed minimal cartilage 
specific expression limited to the nasal cartilage and the cartilage of the distal digits of the 
forelimb (Table 16 and Figure 24), four of the 11 positive !galAB+92+cis 3 transgenics (36%) 
showed a more intense cartilage-specific pattern of LacZ expression (Figure 25) that in two of 
the embryos, mimicked the expression pattern of the !AGG20 transgenics (Figure 17). 
However, although it mimicked this expression pattern, it was still less intense and not present 
within the tongue and the facial meckel’s cartilage. Also, the regulatory activity driven by the 
!galAB+92+cis 3  promoter was inconsistent and slightly different in all expressing transgenic 
embryos unlike the expressing !AGG20 transgenics which all had the same expression 
profiles. Furthermore, the histological sections of a !AGG20 transgenic embryo (Figure 18), in 
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which most of the proliferating and hypertrophic chondrocytes were stained blue are very 
different to a histological section of a !galAB+92+cis 3 transgenic embryo (Figure 26), in which 
the blue staining was much weaker and very scattered/mosaic in the proliferating and 
hypertrophic chondrocytes. There was also staining in non-chondrocytic fibroblastic cells, 
which is not what we would expect at this stage of development.   
 
It is possible that along with the 7kb (-20kb to -13kb relative to the TSS and containing cis 1 
and 2) sequence’s hypothesized role in interacting with cis 3 to neutralize the negative 
regulatory effects that cis 4 potentially has on aggrecan gene expression, it may likely contain 
binding sites that can partially compensate for the missing 92 base pairs. I hypothesized this 
because transgenic embryos that harboured the 7kb sequence along with the 92 base pair 
deletion still showed cartilage-specific expression of the LacZ reporter gene (!AGG20 
transgenics, !galAB+7 transgenics but not !AGG10 transgenics possibly due to the absence 
of the cis 3 enhancer combined with the presence of cis 4). However, when both the 7kb and 
the 92base pairs were missing, the transgenic mice either did not have any expression 
(!AGG13 transgenics) or the expression was extremely low but still present in the forelimb 
digits and nasal area possibly due to the absence of the potential negative regulator cis 4 
(!galAB + cis 3 transgenic). In the !galAB+92 + cis 3 transgenics, there was also no ‘7kb 
sequence’ but in comparison to the !galAB + cis 3 transgenic, the expression was much higher 
most probably due to the presence of the 92 base pairs. However, It was still less than the 
!AGG20 transgenics but this was potentially due to the fact that there was no insulation of the 
short !galAB+92 + cis 3 regulatory sequence from the genome as is indicated by the lack of 
chondrocytic specificity in one of the embryos. Unlike the results of Han and Lefebvre (2008), 
the human cis 3 regulatory enhancer element is necessary but still insufficient in an 
endogenous setting in which it has not been multimerised and lies upstream of potential 
negative regulatory sequences. It would be extremely interesting to see what the inclusion of 
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cis 1 and 2 to the !galAB+92+cis 3 construct (excluding cis 4) would do for the expression 
pattern in transgenic embryos.  Since the "20kb regulatory sequence in !AGG20 has the 
regulatory potential to drive reporter gene expression in the vertebral bodies and intervertebral 
discs (as is seen in the E16.5 transgenic embryos), it is possible that the inclusion of the 92 
base pairs would be all that is required to boost the activity of the sequence further and enable 
earlier expression of the reporter gene in these elements.  
 
1.3.5.2 Regulatory role of cis 6 (+5,000bp - +7,813bp) 
As described in the Introduction section, transcription factors bind to cis-acting sequences 
to control gene expression. Those factors, such as sox9, which bind to consensus module 
sequences can bind to any promoter that contains these sequences. The binding of multiple 
factors may be essential for transcription initiation. Enhancers have sites for multiple trans-
acting factors to bind. Thus genes with enhancers may require several complexes to be 
constructed for gene expression to be initiated. In order to find potential additional cis-
regulatory elements that interact with the regulatory elements in the ~20kb fragment in 
!AGG20, I used the transcription factor sox9 for guidance since there was a lot of evidence for 
its involvement in the regulation of chondrocyte specific genes including collagen type II 
(Lefebvre et al., 1997).  
 
In order to find additional cis-regulatory element(s) that can supplement the activity of the 
!AGG20 fragment and intensify/widen the areas of reporter gene expression, I decided to 
examine DNA fragments in the first intron of the gene. Although a sox9 interaction site that is 
essential for enhancer activity has already been identified within the mouse A1 sequence 
(corresponding to cis 3 in humans), it is possible that another site is also necessary for the full 
endogenous expression of the gene. This sox9 interaction site was identified first by a ChIP 
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assay in which direct binding of the sox trio (sox9, L-sox6 and L-sox6) to this A1 sequence was 
recognized. Secondly, an EMSA approach was used to delineate the binding sites of the 
proteins in A1 (Han and Lefebvre, 2008). Whereas L-sox5/sox6 bind 3 elements in the A1 
sequence, sox9 binds a single element that is essential for enhancer activity. This element is a 
pair of sox-like sites separated by 4 nucleotides and oriented back to back. This configuration 
was proved to be critical. It seems that the consensus sox9 site in chondrocytes is a pair of 
sox-like sites positioned tail-to-tail and separated by 3 to 5 nucleotides. Interestingly, sox9 sites 
vary greatly amongst enhancers but not across species for any gene. These differences in 
sox9 sites amongst different enhancers may affect the efficiency of sox9 binding to DNA or its 
interaction with other proteins which is possibly what contributes to differences in expression 
levels and patterns between cartilage-specific genes. Another identified sox9 binding site in an 
additional enhancer sequence could therefore have a very different consensus binding site. 
The presence of an additional sox9 binding site within the aggrecan gene is supported by the 
fact that a) intron 1 of the mouse aggrecan gene has been shown to be responsive to sox9 
(Sekiya et al., 2000). This group suggested that the possible interplay between sox9 and intron 
1 could be what gives rise to chondrocyte specific regulation of mouse aggrecan b) By 
hybridising ChIP DNA to a microarray covering 80 genes, 2  hybridization peaks were detected 
for aggrecan (Oh et al.) and c) sox9 regulates the expression of collagen type II via a 
consensus site residing in the first intron of the gene (Lefebvre et al., 1997). This could be 
quite significant since it is possible that the regulatory mechanism by which matrix-specific 
genes are regulated has been conserved through evolution. 
 
 Using the internet-based program genomatix, a tool for investigating possible transcription 
binding sites within a desired sequence, I found 3 potential putative sox 9 binding sites within 
the first intron of the gene located at +5.3kb, +6.8kb and +7.4kb relative to the TSS. An 
approximately 3kb sequence (+5 - +8kb) called cis 6 and containing all these potential binding 
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sites was cloned downstream of the "20kb regulatory sequence in !AGG20 in order to test its 
potential regulatory activity. Three out of 17 positive transgenic embryos showed identical and 
symmetrical patterns of reporter gene expression (Figure 28). The expression of the 
transgene, however, was reduced and limited to the distal digits of the forelimbs as well as the 
long bones of the fore and hindlimbs where only minimal expression was noted (Table 20). It 
seems that cis 6 behaves as a silencer as opposed to an enhancer that can repress the 
expression of the transgene. Whether this is truly a silencer element that downregulates the 
expression of the aggrecan gene endogenously under certain conditions or whether the 
downregulation seen is just an artefact of fusing cis 6 directly downstream of the "20kb 
regulatory sequence in !AGG20 is unknown.  
 
1.3.5.3 cis 7 (+64,630bp to +65,005bp). 
Cis 7,  a 150bp highly conserved sequence located in intron 14 of the human aggrecan gene in 
which the homology down to fugu is relatively high, was cloned downstream of cis 3 and AB 
(including missing 92 base pairs). The resultant vector was called !AGGAB+92+ cis 3 + cis 7 
but unfortunately, no positive transgenic embryos were yielded. This sequence can possibly 
serve as a cis-regulatory sequence or even a microRNA target site. Although microRNAs 
usually target the 3’UTRs of target mRNA sequences, they can have complementary target 
sites within the coding sequence. microRNA 140 (miR-140), the only microRNA that has been 
shown to have a cartilage-specific expression pattern, is expressed in a differentiation-
dependent pattern in mesenchymal stem cells and articular chondrocytes. Also, its levels 
change in OA cartilage and in response to IL-1! stimulation. The increased expression of miR-
140 leads to the increased expression SOX9 and AGGRECAN (Miyaki et al., 2009). Although, 
studies on microRNAs have shown that they regulate gene expression by repressing 
translation or directing sequence-specific degradation of complementary mRNA, new evidence 
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has shown that some miRNA may also function to directly induce gene expression (Place et 
al., 2008). If not miR-140, cis 7 could be a target site for another microRNA. Another possibility 
is the sequence within cis 7 that it could be involved in RNA splicing. 
 
1.3.6 Adult !AGG20 transgenic line 12 
 
In order to monitor the expression driven by the "20kb fragment in !AGG20 –with the missing 
92 base pairs in the minimal/basal promoter- throughout adulthood, I created a line.  The tail 
tips of 5-week-old positive transgenic pups were used to identify positive expressors by 
staining them with X-gal. The blue staining pattern of the tail tips was then compared to BR1 
antibody stained histological sections of 5-week-old wild type tail tips. The blue staining was 
mostly present in the nucleus pulposus as well as the resting and proliferating chondrocytes of 
the growth plate of the vertebral bodies. There was some weak staining in the deeper 
hypertrophic cells as well.  The brown staining in the BR1 antibody stained wild type tail tip 
sections was also located in the nucleus pulposus as well as the resting and proliferating 
chondrocytes but was more predominant in the deeper hypertrophic cells. Another discrepancy 
in the staining patterns was due to the additional weak BR1 antibody staining in the annulus 
fibrosus and the cartilage end plate of the wild-type tail tips which was not found in the X-gal 
stained !AGG20 tail tips. These differences could have been due to a couple of things: Firstly, 
the X-gal staining method is a far less sensitive method of protein detection compared to 
antibody staining as it requires a certain threshold of protein to be present in order for it to be 
enzymatically active and catalyse the substrate. Secondly, there is a difference in turnover of 
aggrecan compared to !-galactosidase protein. The half-life of aggrecan is much longer than 
the half-life of the !-galactosidase protein (thought to be approximately 24-48 hours – see 
Results Chapter 3, Discussion section 3.3.1).  This may be why the BR1 antibody staining in 
the hypertrophic chondrocytes of the wildtype tail tip vertebral growth plate is much stronger 
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than the X-gal staining within the hypertrophic chondrocytes of the !AGG20 tail tip vertebral 
growth plate.  
 
Nevertheless, it is possible that this line does not express the reporter gene in the same way to 
what was previously seen in !AGG20 transgenic embryos due to the inevitable variation in the 
location of the inserted transgene within the chromatin. It was important to verify that in this 
particular line, the transgene wasn’t inserted into a silenced region of the chromatin. To check 
this, a 4 month-old homozygous male was crossed with 2 F1 females. The females had plugs 
on two consecutive days and were sacrificed approximately 2 weeks later alongside the 
homozygous male.  Along with the E13.5 and E14.5 embryos retrieved from the pregnant 
mothers, the heart, lungs, kidneys, brain, liver, spleen, spine, foot pad, thorax, hips, knees and 
tail of the homozygous male were also dissected and stained overnight with X-gal. 
 
The embryos at various stages of development were all positive for cartilage-specific 
expression and were comparable to the 1st ‘!AGG20’ transgenic embryos acquired through 
microinjections (Figure 30 A-D). Regarding the adult male, the heart, lungs, kidneys, brain, 
liver, spleen, spine and thorax were all n egative (data not shown). Although the results from 
the lungs, kidneys, and spleen were expected, the lack of X-gal staining in the heart, liver, 
brain, spine and thorax posed some questions (see Introduction section 3.3.2 for expression 
pattern of aggrecan). Aggrecan is known to be expressed in the brain postnatally as well as 
the hyaline cartilage of the vertebral end and growth plates, the fibrocartilage of the 
intervertebral discs and the hyaline costal cartilage in the thorax. Also, it was strange that there 
was no X-gal staining in the cartilaginous segments of the footpad and minimal staining in the 
hip and the knee. The few cells that were stained blue in the hip were deeper cells and the 
only cells stained blue in the knee were the hypertrophic cells of the tibial growth plate. None 
of the cells of the articular cartilage were positive. The inconsistency between the X-gal 
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staining and the BR1 antibody staining in the hip was too big to rule it down to a difference in 
turnover of the proteins.   As before, the tail was the only examined anatomical structure to 
show a high level of blue staining.  
 
There could be a number of reasons why the X-gal staining pattern in the different tissues and 
organs of the adult !AGG20 transgenics did not match the same staining profile seen 
embryonically. Firstly, although we verified that the transgene had not landed in a region of the 
chromatin that was silenced embryonically, it was not possible to know whether this region of 
chromatin was still active in adults due to the epigenetic modifications that can occur 
throughout different stages of development. It is possible that due to a difference in 
methylation pattern of histones that can occur post-development, the region of chromatin in 
which the !AGG20 transgene landed was silenced (Pedram et al., 2006), (Williams et al., 
2008). The only way to verify whether this is the case or not is to produce multiple other 
!AGG20 transgenic lines and compare the adult expression of the reporter gene in different 
tissues across the different lines.  
 
Another possibility is the involvement of the missing 92 bp in adult-specific expression of 
aggrecan. It is possible that the promoter is able to compensate for the lack of 92 bp sequence 
embryonically but not in adults due to a difference in transcriptional mechanisms that operate 
in embryonic vs adult cartilage.  Han and Lefebvre (2008) stated that the fact that the A1 
enhancer sequence drives gene expression with a pattern that is different from that of 
endogenous Col2a1 and Col2a1 reporters in that it is not expressed in skeletogenic 
mesenchymal cells, the perichondrium, and presumptive joint cells and is thus strictly specific 
for differentiated chondrocytes, the growth plate and articular cartilage through adulthood, can 
be useful to elucidate the specific transcriptional mechanisms operating in adult articular 
cartilage which remain unknown. They suggested that A1 constitutes a new tool to investigate 
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mechanisms that control gene expression differentially according to cartilage type, age, and 
physiological or pathological conditions (Han and Lefebvre, 2008). If the future generated 
!AGG20+92  transgenic lines are able to drive expression of the reporter gene with a similar 
pattern to endogenous aggrecan gene expression in adult cartilage, the "20kb ± the missing 
92 bp would serve as a new tool to elucidate the different transcriptional mechanisms that 
govern the expression of matrix genes such as aggrecan in differentiated embryonic 
chondrocytes vs differentiated adult chondrocytes. It is also possible that it is yet another cis-
regulatory sequence not found within the "20kb including the missing 92 bp that is important 
for the adult-specific regulation of aggrecan. 
 
The fact that the LacZ gene expression in the cartilaginous elements of the tail remains 
relatively high in the !AGG20 transgenic adults from line 12 could possible mean that the 
transcriptional mechanisms that govern the expression of aggrecan in the tails of mice could 
be different to those that govern the expression of the gene in other tissues.  
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Chapter 2: Conditional/inducible cartilage-specific model 
 
2.1 Background 
As mentioned earlier, aggrecan is a chondrocyte-specific protein and its expression is detected 
in growth plate and articular chondrocytes of long bones and other cartilage tissues in the body 
(Murphy et al., 1999). Unlike collagen type II, aggrecan is expressed continuously in cartilage 
(Chambers et al., 2002). To generate a chondrocyte-specific transgenic mouse model, the 
enzyme Cre recombinase can be fused to a mutated ligand-binding domain of the human 
estrogen receptor (ER) and driven by the aggrecan promoter. This fusion protein will be 
expressed in chondrocytes and translocated into the nuclei in response to the estrogen 
antagonist tamoxifen or 4-hydroxy tamoxifen (Feil et al., 1996). 
 
Characterizing the spatial and temporal pattern of Cre expression in a transgenic mouse line is 
generally achieved using a Cre reporter transgenic mouse that contains a marker gene (e.g 
LacZ, GFP, CFP or YFP) within its genome that is only expressed following Cre-mediated 
recombination. For these purposes, we used the global double-fluorescent Cre reporter mouse 
line. Within this Cre reporter line, a marker is expressed not only in cells that have undergone 
Cre-mediated recombination but also in those that have not.  The markers are membrane-
targeted tdTomato (‘mT’) and membrane-targeted EGFP (‘mG’). Prior to Cre excision, ‘mT’ is 
synthesised in cells while following excision, there is a switch to the production of ‘mG’ thereby 
allowing live visualisation and differentiation between recombined and non-recombined cells. 
The ‘mT/mG’ construct combines the use of a strong ubiquitous promoter pCA (Niwa et al., 
1991), with the ROSA26 targeting locus (Soriano, 1999). Figure 34 illustrates the mechanism 
by which cells switch from expressing mT before Cre-mediated exision to mG after Cre-
mediate exision. 
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Figure 34: Schematic diagram of the mT/mG construct before and after Cre-mediated 
recombination. mT/mG consists of a chicken !-actin core promoter with a CMV enhancer 
(pCA) that drives a loxP-flanked coding sequence of membrane-targeted tandem dimer 
Tomato (mT), which results in tdTomato expression with membrane localization. After Cre-
mediated intrachromosomal recombination, the mT sequence is excised allowing the pCA 
promoter to drive the expression of membrane-targeted enhanced green fluorescent protein 
(mG). Arrows denote the direction of transcription. Triangles represent loxP target sites for 
Cre-mediated recombination. PA denotes polyadenylation sequences. Adapted and modified 
from (Muzumdar et al., 2007). 
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2.2 Results  
 
In order to generate a conditional/inducible cartilage-specific transgenic mouse in which 
particular genes can be knocked out/over-expressed preceeding/following injury (that can lead 
to osteoarthritis), it was important to use a promoter that would drive cartilage-specific 
expression throughout adulthood, as osteoarthritis is a late-onset disease. For this reason, I 
opted against the use of the "20kb fragment in the !AGG20 transgenic line 12 which proved 
insufficient in driving adequate reporter gene expression in adult knee articular cartilage. 
 
 A more appropriate promoter would be the regulatory sequence created by Han and Lefebvre 
(Han and Lefebvre, 2008). The construct contained 4 copies of the mouse ‘aggrecan 
enhancer’ which they named A1 (corresponding to cis 3 in my work) fused downstream of the 
Col2a1 minimal promoter (-309 - +308 base pairs relative to the mouse Col2a1 transcriptional 
start site), i.e, the proximal promoter, first exon (with the translation initiation site mutated into 
CTG), as well as 70p of the first intron (not including enhancer sequences).  They also 
included a splice donor and splice acceptor site immediately upstream and downstream of the 
4xA1 sequence respectively. For these purposes, and with the help of Hiro Nakamura at the 
KIR, this ColII4xA1 sequence was cloned upstream of the CreERT2 fusion gene, IRES 
sequence, the firefly luciferase reporter gene and polyA DNA sequences (Figure 35A). The 
firefly luciferase gene serves as a reporter gene to locate the expression of CreERT2 by in vivo 
bioluminescence imaging while the IRES (internal ribosomal entry site) sequence ensures the 
transcription of bi-cistronic mRNA in which two proteins are translated from one mRNA 
sequence. This construct was named ‘ColII4xA1Cre’ (Methods section 5 construct 17). 
 
To generate a transgenic mouse line, this sequence was microinjected into fertilised oocytes 
as described earlier and positives identified via real-time PCR.  A positive expressor was 
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selected by detecting transgene expression through whole animal imaging. The Kodak imaging 
system was used to detect any bioluminescence  (Methods section 7.2.2.2). Upon injection of 
transgenic mice synthesising luciferase with the substrate luciferin, a reaction occurs in which 
light that is emitted from luciferase-producing live cells is captured as light photons and 
photographed by this machine. This mouse was then bred into a homozygous line named line 
39 after the founder. The light emission from this transgenic line was detected as a black 
pseudo-colour and confined to cartilaginous regions as expected. Figure 35B displays an 
example of a ‘ColII4xA1Cre’ mouse in which light is detected in the footpads, paws, knees as 
well as the segmented tail. Light emission is not detected in all other known cartilaginous 
regions due to the effect that mouse fur has on blocking this. Black fur blocks weak signal from 
internal organs or unexposed cartilages and bones 
 
Although the spatial and temporal characterisation of the pattern of CreERT2 expression was 
achievable via the use of the Kodak imaging system, examining functionality of the Cre 
recombinase required a different system. To do this, we used the global double-fluorescent 
Cre reporter mouse (Muzumdar et al., 2007).  
 
Upon crossing a homozygous female ‘mT/mG’ global double-fluorescent reporter mouse with a 
heterozygous male mouse from line 39 (ColII4xA1Cre), the intraperitoneal injection of the 
pregnant mothers or F1 progeny with tamoxifen would theoretically lead to the Cre-producing 
cells (chondrocytes) in half the F1 progeny to be labelled with bright green membrane-bound 
fluorescence. All other cells should be labelled with bright red membrane-bound fluorescence. 
The localization of fluorescent proteins to the cell membrane enables cell morphology to be 
outlined with fine resolution. 
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Figure 35: Bioluminescence imaging of luciferase activity in an adult transgenic mouse 
from the ColII4xA1Cre transgenic line. A) Diagram of the ColII4xA1Cre transgene. B) Dorsal 
view of an image of two representative ColII4xA1Cre adult transgenic mouse showing 
luminescence/luciferase activity (black regions) in cartilaginous areas such as the knees, the 
tail, the foot pads and the paws.   
 
To assess whether what is expected is in fact true, the pregnant mother in which half the F1 
progeny were double transgenic ‘mT/mG’/ColII4xA1Cre’ while the other half were ‘mT/mG’ 
single trangenics was injected with 4 doses of 5mg tamoxifen (20mg in total) on the final 4 
days of gestation (E15.5-E19.5). The hips and knees of the F1 progeny were then snap frozen 
1 or 2 weeks after the final tamoxifen injections (at postnatal day 7 for one litter and at 
postnatal day 14 for another litter). Figure 36 demonstrates the hips of sacrificed pups at 
postnatal day 7 (P7 - 1 week after the final dose of tamoxifen was injected) while Figure 37 
demonstrates the hip and knees of sacrificed pups at postnatal day 14 (P14 - 2 weeks after the 
final dose of tamoxifen was injected). In both cases, there has been a conversion from red-
membrane bound fluorescence to green that is specific to the cartilage of the 
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‘mT/mG’/ColII4xA1Cre’ double transgenics as demonstrated by the negative controls in which 
none of the cells underwent conversion (Figure 36 D1-3 and Figure 37 E1-3 and F1-3). Figure 
36 D1-3 and Figure 37 E1-3 show hip cartilage 1 week after the final tamoxifen injection and 
knee cartilage 2 weeks after the final tamoxifen injection respectively of mTmG single 
transgenics. There was no conversion in any of the chondrocytes. Figure 37 F1-3 shows 
muscle from one of the P14 mT/mG’/ColII4xA1Cre’ double transgenics in which none of the 
cells have undergone conversion.  The labelling in the hips from the ‘mT/mG’/ColII4xA1Cre’ 
double transgenics at the two timepoints was mosaic but also mutually exclusive (Figure 36 
A1-3, B1-3 and C1-3 for P7 double transgenics and Figure 37 A1-3 and B1-3 for P14 double 
transgenics). The mG labelling was present throughout the different zones of the hip articular 
cartilage ranging from the terminal cells on the surface to the deeper hypertrophic cells. The 
deeper hypertrophic chondrocytes were identified by their size and location adjacent to the 
autofluorescing bone marrow.  At a higher magnification, it was possible to see that the 
fluorescence was targeted to the membranes of the cells. The labelling in the knees from the 
P14 ‘mT/mG’/ColII4xA1Cre’ double transgenics was also mosaic and mutually exclusive. Like 
the hips, mG labelling was present in the hyaline cartilage of the articular cartilage throughout 
the terminal chondrocytes of the articular cartilage as well as the fibrocartilage of the meniscus. 
However the labelling did not seem to extend below the tidemark to the hypertrophic cells of 
the articular cartilage. In both the knees and the hips, the bone marrow showed 
autofluorescence as the fluorescence overlapped from both the green and red channels and 
was not targeted to the membranes of any cells. There are no knee images for the 
‘mT/mG’/ColII4xA1Cre’ double transgenics at the ‘1 week’ timepoint due to the unfortunate 
fragmentation of the sections.  
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Figure 36 (next page): Ubiquitous mT and mG labelling of fixed hip sections in 
‘mT/mG’/ColII4xA1Cre’ double transgenic mice (A1-3, B1-3 and C1-3) and an ‘mT/mG’ 
single transgenic (D1-3) post Cre-mediated recombination (1 week after final injection of 
tamoxifen).  A1-D1 are bright field confocal images, A2-D2 are mT labelled confocal images 
while A3-D3 are mG labelled confocal images. The 3 images on each row are the same image 
captured using different filters.  All images are at 10x magnification except for C1-3, which are 
at 20x magnification. AC (articular cartilage), BM (bone marrow), HC (hypertrophic 
chondrocytes), TC (terminal chondrocytes). 
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Figure 37 (next 2 pages): Ubiquitous mT and mG labelling of fixed hip (A1-3, B1-3), knee 
(C1-3, D1-3) and muscle (F1-3) sections in ‘mT/mG’/ColII4xA1Cre’ double transgenic 
mice and hip sections of an ‘mT/mG’ single transgenic (E1-3) post Cre-mediated 
recombination (2 week after final injection of tamoxifen).  A1-E1 are bright field confocal 
images, A2-E2 are mT labelled confocal images while A3-E3 are mG labelled confocal images. 
The 3 images on each row are the same image captured using different filters. All images are 
at 10x magnification except for E1-3, which are at 20x magnification. AC (articular cartilage), 
HC (hypertrophic chondrocytes), M (meniscus), MU (muscle), TC (terminal chondrocytes). 
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2.3 Discussion 
 
Aggrecan is a major ECM protein of both growth plate and articular cartilage in long bones and 
other cartilage tissues in the body. In articular cartilage, and particularly in adults, aggrecan is 
expressed more robustly than collagen type II. This was shown through a previous study of 
mouse knee joints in which endogenous Col2a1 mRNA was detected in the growth plate by in 
situ hybridization but not in articular cartilage or in the meniscus of adult mice ranging from 7 to 
10 months of age. In addition to this, aggrecan mRNA was detected in the articular, growth 
plate and meniscus cartilage of these adult mice, indicating that the aggrecan gene maintains 
its expression in articular cartilage of adult mice at a time when Col2a1 RNA is no longer 
evident (Chambers et al., 2002). So although collagen type II is expressed specifically in 
cartilage, it is switched off in adult mice.   
 
For this reason, the inducible cartilage-specific Cre recombinase transgenic mice lines that 
have already been generated using the Col2a1 promoter have certain limitations when 
analyzing OA models.  Allthough inducible Cre recombinase activity was detected in the 
cartilage of postnatal animals in these lines, they each had their own limitations. In one of 
these, in which expression of Cre recombinase is under control of both the type II collagen 
promoter (3kb promoter and 3kb first intron of Col2a1 (Zhou et al., 1995)) to allow cartilage-
specific expression and a doxycycline response element to permit temporal control of 
expression, inducible Cre recombinase activity was observed in articular and growth plate 
cartilage of 1-month-old mice but no longer at later timepoints (Grover and Roughley, 2006). In 
a second transgenic mouse, in which CreERT1 expression was driven by a minimal promoter 
and an enhancer element of Col2a1 (Zhou et al., 1995), tamoxifen-induced Cre recombinase 
activity was detected in the articular cartilage of mice 3 weeks post-natally, but this activity 
gradually decreased with age and was no longer detected in 3-month-old animals (Nakamura 
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et al., 2006). In a third transgenic line (Chen et al., 2007; Zhu et al., 2008a), in which promoter 
and enhancer elements of Col2a1 were directing expression of CreERT2, efficient tamoxifen-
induced Cre recombination activity was shown in articular chondrocytes of adult 6-month-old 
animals, but the Cre recombinase activity was much less efficient in growth plate cartilage (Zhu 
et al., 2008b). It has been suggested that the discrepancy between the expression of Col2a1 
mRNA in adult mice and that of the Col2a1-CreERT2 transgene in the third transgenic mice line 
might be a consequence of the transgene integration site. It would therefore be challenging to 
use these models for exploring osteoarthritis pathogenesis since it is a disease only affecting 
adult/aging mice.   
 
The promoter of the aggrecan gene was selected here to drive cartilage specific expression of 
the CreERT2  fusion protein due to aggrecan being the most abundant proteoglycan in the ECM 
of cartilage as well as its continuous expression throughout adulthood. Another group 
generated an aggrecan-CreERT2 mice, in which CreERT2 expression very closely paralleled 
expression of the endogenous aggrecan gene. In these mice, a Cre-ERT2 cassette was 
introduced by homologous recombination into the 3’UTR of the aggrecan gene. The group 
used a Cre reporter line to localize the expression of the CreERT2 transgene and validate the 
activity of the recombinase. They found the expression of the CreERT2 transgene to be highly 
specific and efficient in postnatal mice at 6 and 12 months of age in articular chondrocytes, in 
growth plate chondrocytes, and in fibrocartilage cells of the meniscus and of the nucleus 
pulposus and annulus fibrosis of intervertebral disks. The excision was also very efficient at 
different times during embryonic development and during the earlier postnatal growth period 
(Henry et al., 2009). 
 
For our purposes, I used an aggrecan promoter approach as opposed to the knockin 
mechanism used by Henry et al. Although the work I carried out to identify the regulatory 
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region(s) responsible for endogenous aggrecan regulation in chondrocytes led to the discovery 
of a reproducible cartilage-specific "20kb sequence that was active in developing embryos, 
this sequence was not as robust in adults. As discussed in the previous results chapter, !-
galactosidase expression driven by the "20kb regulatory sequence in line 12 was only very 
weakly detected in the articular cartilage of the hips and the growth plate cartilage of the tibia 
as well as the fibrocartilage of the intervertebral discs of the tail. For the former 2 tissues, the 
level of expression was random, inconsistent, extremely low and only present within a few 
chondrocytes. There seemed to be no expression in the articular cartilage of the knees either. 
For this reason, we opted to use the established A1 mouse sequence (Han and Lefebvre, 
2008), which was equivelant to the cis 3 human sequence in my work. Since a single copy of 
the A1 sequence only weakly activated the Agc1 -596 - +90bp minimal promoter (pAgc1) and 
Col2a1  -86 - +6bp minimal promoter (pCol2), we obtained the multimerised sequence in which 
4xA1 copies were cloned downstream of a lengthened Col2a1 minimal promoter (-309 - 
+308bp). This sequence was shown to drive gene expression in transgenic mice with the 
characteristic spatial and temporal pattern of aggrecan. In particular, reporter gene expression 
was revealed to be tissue-specific with expression found in all craniofacial, axial and 
appendicular cartilage elements but lacking in noncartilaginous tissues, prechondrocytes, the 
perichondrium and presumptive joints. Embryonic sections showed expression in differentiated 
articular and growth plate chondrocytes as well as in notochord-derived nucleus pulposes 
cells. Importantly, when tested postnatally, the sequence was able to drive high reporter gene 
expression in all growth plate and articular cartilage structures of actively growing 2-week old 
pups. This remained true for the same structures in 6-month-old adult mice.  
 
This colII4xA1 sequence was cloned upstream of the CreERT2 fusion protein, an IRES 
sequence, the firefly luciferase reporter gene as well as a mouse polyA signal. The IRES 
sequence was used to allow for the production of two proteins, CreERT2 and firefly luciferase, 
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out of one mRNA sequence. Firefly luciferase catalyzes the bioluminescent oxidation of the 
substrate luciferin in the presence of ATP, magnesium and oxygen. The firefly luciferase used 
was that of the North American firefly Photinus pyralis. The advantages of using the firefly 
luciferase as a reporter gene are the high sensitivity in detection of expression of the gene, the 
absence of luciferase activity inside most cell types, the wide dynamic range, rapidity and low 
costs. Also, the protein does not require any posttranslational modification to be enzymatically 
active and is not toxic in high concentrations in vivo (de Wet et al., 1987). For these purposes, 
the use of this reporter gene allowed me to carry out genotyping and pinpoint the location of 
CreERT2 expression at different ages and under different conditions e.g injury in the 
ColII4xA1Cre mice (Chapter 3 ‘Results’). 
 
The bioluminescent images of the transgenic mice from the ColII4xA1Cre line (line 39) showed 
enzyme activity within some cartilaginous elements such as the cartilage of the tail, foot pads, 
paws and knees (Figure 35B). The remaining cartilageous elements of the axial and 
appendicular skeleton did not reveal enzyme activity due to the presence of fur around these 
regions. As described in the methods section, the fur was only shaved in the knee/leg area as 
it was an important region of interest due to the future applications of this conditional/inducible 
model for investigating the roles of genes within wildtype and OA-induced knees (Chapter 3 
‘Results’).   
 
To test for the functionality, specificity and potential leakiness of the CreERT2  fusion protein 
and establish a protocol for activation of cartilage-specific Cre in the ColII4xA1Cre mouse line, 
the global double fluorescent Cre reporter mouse was used (Muzumdar et al., 2007). The 
advantages of using this mouse model are that it allows for direct visualization of both 
recombined and nonrecombined cells at a single-cell resolution, offering an internal control for 
phenotypic analysis of Cre-induced mosaic mutants. All this without the need for assaying for 
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enzymatic activity or antibody staining. However, one of the potential drawbacks of the double-
fluorescent system is the possible bleedthrough between the red and green fluorescent 
channels. A cell that is labeled using the red channel filter may also be labeled using the green 
channel filter. Also, some tissues autofluoresce and it is important to take this into 
consideration. Nevertheless, if the mT and mG labeled cells do not overlap, it is safe to say 
that there is minimal bleethrough between the red and green fluorescent channels. Also, 
because the fluorescent proteins are membrane-targetted, it is possible to rule out 
autofluorescence that is not due to mT/mG expression by visualizing the cells at higher 
magnifications.  
 
In theory, Cre-mediated exision should occur within 24 hours after administration of Tamoxifen 
to the mouse. However, it is important to allow for a certain amount of time between Cre 
induction and analysis. This is to allow for the turnover of mT in cells that have undergone Cre-
mediated exision. Examining tissues in a relatively short time interval after Cre induction would 
reveal double labeled cells (these cells appear yellow) due to the rapid onset of mG labeling 
and the perdurance of mT mRNA and protein. (Muzumdar et al., 2007) generated mosaic mice 
with the actin-CreER line (Muzumdar et al., 2007). The injection of 2 mg of TM at P7 followed 
by dissection at P21 revealed a mosaic and mutually exclusive pattern of mT and mG labeling 
in multiple tissues. They concluded that dissection 2 weeks after recombination induction with 
actin-CreER was sufficient to observe minimal numbers of double-labeled cells in most tissues 
examined. Because the rate of mT loss varies from tissue to tissue based on cell type-specific 
mRNA and protein turnover properties, I chose to analyse hips and knees 1 and 2 weeks after 
the final administration of Tamoxifen (20mg in total). 
 
Figure 36 & Figure 37 show ubiquitous mT and mG labelling of fixed hip and knee sections in 
‘mT/mG’/ColII4xA1Cre’ double transgenic mice and ‘mT/mG’ single transgenic  (control) post 
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cre-mediated recombination 1 week (Figure 36) and 2 weeks (Figure 37) after final injection of 
tamoxifen. For both the hip and the knee articular cartilage at both timepoints, there has been 
a conversion from red-membrane bound fluorescence to green that is specific to the 
chondrocytes of the ‘mT/mG’/ColII4xA1Cre’ double transgenics as demonstrated by the 
negative controls in which none of the cells underwent conversion. The hip sections of the 1 
and 2 week timepoints revealed conversion in the terminal and hypertrophic chondrocytes 
whereas the knee section of the 2 week timepoint (no one week timepoint due to deterioration 
of sections) revealed conversion in the superficial and deeper layers of the menisci as well as 
the superficial chondrocytes of the uncalcified articular cartilage above the tidemark. This was 
to be expected as the same was noted in the Agc1tm(IRES-creERT2)/+ mice produced by Henry et 
al. By in situ hybridization, they found that the mRNA expression pattern of aggrecan was 
limited to the uncalcified articular cartilage above the tidemark (Henry et al., 2009). The two 
negative controls used were a) the cartilaginous tissues of the mTmG single transgenics 
whereby the lack of conversion from mT to mG fluorescence indicated that this conversion 
occurs indeed due to the activity of the Cre recombinase in the cells as opposed to leakiness 
in the system and b) non cartilaginouse tissue (muscle) of the ‘mT/mG’/ColII4xA1Cre’ double 
transgenics whereby the lack of conversion from mT to mG fluorescence indicated that the Cre 
recombinase was produced specifically in chondrocytes.  The labelling in the hips and the 
knees from the ‘mT/mG’/ColII4xA1Cre’ double transgenics at the two timepoints was 
membrane-targeted (indicating real fluorescence as opposed to autofluorescence), mosaic 
(individual chondrocytes showed either green or red fluorescence) and mutually exclusive 
(chondrocytes were not doubly labeled which would have appeared yellow). This means that 
the chondrocytes examined required as little as 1 week to switch on mG expression and 
labeling and turnover the mT mRNA and protein. The mosaic pattern in both the knees and 
hips at both timepoints indicates that the ColII4xA1 promoter is active at different times across 
individual chondrocytes, which possibly reflects the way the endogenous aggrecan promoter 
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regulates aggrecan gene expression. Aggrecan may not be expressed continually in every cell 
but rather, as and when it is needed to maintain the ECM.  
 
To take this model further, it is important to perform these experiments on mice at 1, 3 and 6 
months of age. Although the promoter was shown to be active at 6 months of age (Han and 
Lefebvre, 2008), it is necessary to verify this in line 39. Also, in addititon to articular cartilage, it 
would be useful to test for conversion within the hyaline cartilage of the growth plate. For these 
purposes, Rosa26 !-galactosidase reporter mice will be used in order to ensure high quality 
knee sections. The visualisation of the membrane targetted mT and mG polypeptides in the 
cartilage of knees requires them to be frozen and eventually cut without decalcification. This 
can lead to the fragmentation of sections. However, the visualisation of !-galactosidase in 
knees does not require them to be frozen and they can be decalcified and paraffin embedded. 
Assuming the expression and activity of CreERT2 in line 39 remains the same at older ages 
and in other cartilaginous tissues (growth plate and intervertebral discs), this model should 
provide a very valuable tool to analyze the role of specific proteins in the maintenance of 
articular cartilage, growth plate and intervertebral disks at different timepoints postnatally in 
intact animals. These proteins include regulatory molecules such as key transcription factors, 
signaling molecules, and ECM proteins. The characterization of mice harboring the 
ColII4xA1Cre transgene in combination with conditional alleles for these proposed proteins will 
give rise to new rational models for human degenerative cartilage diseases and will enable the 
dissection of the in vivo mechanisms that govern the renewal, stability, and integrity of the 
complex, multicomponent ECM of different cartilages. 
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Chapter 3: Induction of osteoarthritis in the knees of line 
39 (‘ColII4xA1Cre’) and line 12 (‘!AGG20’) 
3.1 Background 
In a bid to define the biological mechanisms through which mechanical stress leads to the 
development of OA, experimental mouse models have been developed whereby knee joint 
instability can be induced through different methods.  One of these methods is the 
destabilization of the medial meniscus (DMM) through surgery (Glasson et al., 2007) while 
another is the axial loading of the mouse tibias (De Souza et al., 2005).  
 
The DMM model in mice was developed due to the great ease and reproducibility with which it 
could be performed in guinea pigs. Another advantage of this model is the relatively slow 
speed with which OA develops in operated mice knees (closer resemblance to the slow 
development of OA in the older human population).  It has been reported that, following 
surgery, the mouse knees develop mild to moderate OA with lesions primarily located on the 
anterior-central weight bearing area of the medial femoral chondyle as well as the medial tibial 
plateau that increase in severity over time.  Normally, there is no posterior erosion of the tibial 
plateaus and chondrogenesis is negligible (Glasson et al., 2007).  Figure 38 illustrates a 
diagram of the right knee of a mouse. The medial meniscotibilal ligament (MMTL), which 
anchors the medial meniscus (MM) to the tibial plateau, is transected in order to generate the 
destabilisation of the medial meniscus (DMM).  
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Figure 38: Basic anatomy of the knee. The main ligaments of the knee are: The ACL 
(Anterior Cruciate Ligament). It runs from the anterior tibia to the posterior femur and it keeps 
your knee from anteriorly translating: The PCL (Posterior Cruciate Ligament) runs posterior 
tibia to anterior femur and it controls the posterior translantion; The LCL (Lateral Collateral 
Ligament); the MCL(Medial Collateral Ligament) run on the lateral and medial side respectively 
of the tibia and femur; the MMTL (medial meniscotibilal ligament) which anchors the medial 
meniscus (MM) to the tibial plateau and the LMTL (lateral meniscotibilal ligament). 
(http://www.ncssm.edu/library/dirt/Valerie%20Todd/Basic%20Anatomy.html). 
 
 
Another model, the non-invasive axial loading of mouse tibias, is one which enables the study 
of how loading modulates (re)modelling of the knee joint. The mechanisms that initiate and 
coordinate these events can also be measured. The model is achieved by applying axial 
compressive loads to the mouse tibia through natural sites of articulation. The modifications 
that occur in cancellous and cortical bone can then be quantified, in response to controlled 
exogenous loading under conditions of continual use or disuse.  
 
PhD Thesis                                                                                                                          Andrea Layyous     
  
 220 
It has been shown that short periods of externally applied dynamic loading of the mouse tibia 
for 2 weeks (on alternate days) is an effective means of promoting adaptive modification in the 
cortical bone architecture and variation in trabecular structure in the proximal tibia. It induces 
periosteal formation at all diaphyseal sites within the central third of the tibia. In contrast to this 
periosteal response to loading, the load-induced endosteal formation is less widespread, 
spreading only distal to the mid-shaft.  Consequently, this model of loading promotes radial 
expansion along a segment of the tibial mid-shaft that is coupled to marked increases in 
cortical thickness mostly at, and distal to the mid-shaft. The changes in endosteal, periosteal 
and trabecular bone are consistent with a regionalised osteogenic response (De Souza et al., 
2005).  
 
As opposed to characterising the biological components that can lead to the development of 
OA, the application of the above-described models to the transgenic lines ‘!AGG20’ and 
‘ColII4xA1Cre’ would enable us to further understand/define the response that either promoter 
sequence possibly has to injury.  
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3.2 Results  
 
3.2.1 DMM of line 12 (!AGG20 transgenics) 
DMM was peformed on transgenic mice from line 12 based on the described method in 
Results sections 8.1 & 8.1.1. Knees were then analysed based on the described method in 
Results sections 8.1.1.  At 4 weeks post-operatively, the whole mount X-gal staining of the 
right operated knees in all 6 of the sacrificed animals showed localised blue staining on the 
medial side of the knee. However, the left contralateral control knees of these mice showed no 
staining (Figure 39A&B). At 8 weeks post-operatively, the whole mount X-gal staining of both 
right operated knees and control left unoperated knees showed no staining (Figure 39C&D). 
 
For histological analysis of reporter gene expression, all knees (operated and unoperated) 
from both the 4 and 8-week groups were analysed microscopically and operated knees with 
the highest score (indicating a more biologically aggressive disease) based on The OARSI 
Osteoarthritis Cartilage Histopathology scoring system were photographed alongside the 
contralateral unoperated knees and are shown below in Figure 40 A-E.  Figure 40 A-E shows 
representative images corresponding to the sections with the maximum score (highest 
grade/stage) for the operated right knees of the 4 and 8-week groups as well as their 
contralateral control left knees.  The histological analysis of the 4-week post-operative group 
revealed low levels of OA in the left unoperated control knees (grade 1, stage 1) (see Figure 
40 A-C).  At 8 weeks, the scores were similar for the knees that had not undergone surgery 
(also grade 1, stage 1) (see Figure 40 A-C). Erosion and free cells were not observed in these 
control knees.  
 
The right knees, which had undergone the DMM surgery, had significantly more OA than the 
left control knee and increased scores were observed. The histological analysis of the 4-week 
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post-operative group revealed mild-moderate levels of OA (grade 3.5, stage 3) (see Figure 40 
A-C).  At 8 weeks, there was a progression in the disease from mild-moderate to moderate 
(grade 4.5, stage 3) (see Figure 40 A-C). Lesions were most apparent on the medial side of 
the joint and mainly on the tibia plateau. Safranin O staining showed severe loss of 
proteoglycans, fibrillation and erosion of the tibial plateau cartilage. Chondrogenesis, patellar 
dislocation, free cells in the synovial cavity and ectopic bone formation are not usually 
observed in this model. 
 
Figure 39: Wholemount operated + unoperated knees from line 12 (!AGG20 line) 
expressing the !AGG20 transgene (blue staining) only on the medial side of right 
operated knees 4 weeks post-surgery (black arrows). A and B) Paired operated and 
contralateral knees from mice sacrificed 4 weeks after DMM. C and D) Paired operated and 
contralateral knees from mice sacrificed 8 weeks after DMM. L and R represent the Left 
unoperated and Right operated contralateral knees of a mouse. F (femur), PA (Patella), TI 
(tibia).  
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Figure 40 (A): Coronal sections of representative line 12 (!AGG20) operated (DMM) right 
knees (R) and contralateral unoperated left knees (L) 4 and 8 weeks after surgery that 
have been stained overnight with X-gal. Sections are of whole knees counterstained with 
safranin O for proteoglycans (bright red) and counterstained with ‘Haematoxylin and Eosin’ at 
4x magnification. A consistent feature of the DMM model was loss of Safranin-O, fibrillation 
and cartilage loss on the medial tibial plateau (black arrow) and medial femoral condyle (blue 
arrow). Blue boxed regions represent the lateral articular cartilage of each of the knees 
(magnified in Figure 40B), green boxed regions represent the medial articular cartilage of each 
of the knees (magnified in Figure 40C), yellow boxed regions represent the lateral tibial growth 
plate of each of the knees (magnified in Figure 40D), orange boxed regions represent the 
medial tibial growth plate of each of the knees (magnified in Figure 40E). 
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Figure 40 (B): High magnifications of coronal sections of the knees in figure 40A above 
showing the lateral side of articular cartilage.  The sections are of representative line 12 
(!AGG20) operated (DMM) right knees (R) and contralateral unoperated left knees (L) 4 and 8 
weeks after surgery that have been stained overnight with X-gal. Black arrows point to blue 
stained cells that are positive for !-galactosidase expression. Sections are stained with 
safranin O for proteoglycans (bright red) and counterstained with ‘Haematoxylin and Eosin’ at 
20x magnification. 40X magnifications of boxed regions are also shown. 
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Figure 40 (C): High magnifications of coronal sections of the knees in figure 40A above 
showing the medial side of articular cartilage. The sections are of representative line 12 
(!AGG20) operated (DMM) right knees (R) and contralateral unoperated left knees (L) 4 and 8 
weeks after surgery that have been stained overnight with X-gal. Black arrows point to blue 
stained cells that are positive for !-galactosidase expression. Sections are stained with 
safranin O for proteoglycans (bright red) and counterstained with ‘Haematoxylin and Eosin’ at 
20x magnification. 40X magnifications of boxed regions are also shown. 
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Figure 40 (D) (next page): High magnifications of coronal sections of the knees in figure 
40A above showing the lateral side of the tibial growth plate.  The sections are of 
representative line 12 (!AGG20) operated (DMM) right knees (R) and contralateral unoperated 
left knees (L) 4 and 8 weeks after surgery that have been stained overnight with X-gal. Black 
arrows point to blue stained cells that are positive for !-galactosidase expression. Sections are 
stained with safranin O for proteoglycans (bright red) and counterstained with ‘Haematoxylin 
and Eosin’ at 20x magnification. 40X magnifications of boxed regions are also shown. 
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Figure 40 (E) (next page): High magnifications of coronal sections of the knees in figure 
40A above showing the medial side of the tibial growth plate.  The sections are of 
representative line 12 (!AGG20) operated (DMM) right knees (R) and contralateral unoperated 
left knees (L) 4 and 8 weeks after surgery that have been stained overnight with X-gal. Black 
arrows point to blue stained cells that are positive for !-galactosidase expression. Sections are 
stained with safranin O for proteoglycans (bright red) and counterstained with ‘Haematoxylin 
and Eosin’ at 20x magnification. 40X magnifications of boxed regions are also shown. 
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3.2.2 Axial Loading of line 12 (!AGG20 transgenics) 
 
‘Non-invasive axial loading of mice tibias’ was peformed on transgenic mice from line 12 based 
on the described method in Results sections 8.2 & 8.2.1. Knees were then analysed based on 
the described method in Results sections 8.2.1. Unlike the operated knees of the line 12 
(!AGG20 transgenics) from the 4 week post-operative group, there was no blue X-gal staining 
in the right loaded and left unloaded knees in all 12 of the sacrificed animals that could be 
visualised macroscopically.   
 
For histological analysis of reporter gene expression, all knees (loaded and unloaded) were 
analysed microscopically and loaded right knees with the highest score (indicating a more 
biologically aggressive disease) based on The OARSI Osteoarthritis Cartilage Histopathology 
scoring system were photographed alongside the contralateral unloaded left knees and are 
shown below in Figure 41 A-E. !-galactosidase antibody staining was also performed for 
comparison.  Figure 41 A-E shows representative images corresponding to the sections with 
the maximum score (highest grade/stage) for the loaded as well as their contralateral control 
knees.  Also shown are the !-galactosidase stained successive sections. The histological 
analysis of the knees revealed no signs of OA in the unloaded control knees (grade 0, stage 0) 
(Figure 41 A-C).   
 
The right knees, which had undergone the non-invasive axial loading, had very mild signs of 
OA development in the lateral femoral articular cartilage (grade 1, stage 1). 
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Figure 41 (A): Coronal sections of a representative line 12 (!AGG20) loaded right knee 
(A2) and contralateral unloaded left knee (A1) that have been stained overnight with X-
gal and counterstained with eosin or the !-galactosidase antibody. A1+A2(a) 4x 
magnification of whole knee counterstained with eosin A1+A2(b) 4x magnification of whole 
knee stained with !-galactosidase antibody (brown staining). A consistent feature of the axial 
loading model was the loss of cartilage on the lateral femoral condyle (black arrows). Blue 
boxed regions represent the lateral articular cartilage of each of the knees (magnified in Figure 
41B), green boxed regions represent the medial articular cartilage of each of the knees 
(magnified in Figure 41C), yellow boxed regions represent the lateral tibial growth plate of each 
of the knees (magnified in Figure 41D), Blue boxed regions represent the medial tibial growth 
plate of each of the knees (magnified in Figure 41E). 
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Figure 41 (B): High magnifications of coronal sections of the knees in figure 41A above 
showing the lateral side of articular cartilage. The sections are of a representative line 12 
(!AGG20) loaded right knee (A2) and contralateral unloaded left knee (A1) that have been 
stained overnight with X-gal and counterstained with eosin or the !-galactosidase antibody. 
A1+A2(c) 20x magnification counterstained with eosin A1+A2(d) 20x magnification of the knee 
stained with !-galactosidase antibody (brown staining). Purple arrows point to brown cells 
positive for !-galactosidase antibody staining indicating expression of !-galactosidase. 
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Figure 41 (C): High magnifications of coronal sections of the knees in figure 41A above 
showing the medial side of articular cartilage. The sections are of a representative line 12 
(!AGG20) loaded right knee (A2) and contralateral unloaded left knee (A1) that have been 
stained overnight with X-gal and counterstained with eosin or the !-galactosidase antibody. 
A1+A2(e) 20x magnification counterstained with eosin A1+A2(f) 20x magnification  stained 
with !-galactosidase antibody (brown staining). Purple arrows point to brown cells positive for 
!-galactosidase antibody staining indicating expression of !-galactosidase. 
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Figure 41 (D): High magnifications of coronal sections of the knees in figure 41A above 
showing the lateral side of the tibial growth plate. The sections are of a representative line 
12 (!AGG20) loaded right knee (A2) and contralateral unloaded left knee (A1) that have been 
stained overnight with X-gal and counterstained with eosin or the !-galactosidase antibody. 
A1+A2(g) 20x magnification counterstained with eosin A1+A2(h) 20x magnification stained 
with !-galactosidase antibody (brown staining). Purple arrows point to brown cells positive for 
!-galactosidase antibody staining indicating expression of !-galactosidase. Black arrows point 
to blue cells positive for X-gal staining indicating expression of !-galactosidase. 
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Figure 41 (E): High magnifications of coronal sections of the knees in figure 41A above 
showing the medial side of the tibial growth plate. The sections are of a representative line 
12 (!AGG20) loaded right knee (A2) and contralateral unloaded left knee (A1) that have been 
stained overnight with X-gal and counterstained with eosin or the !-galactosidase antibody. 
A1+A2(I) 20x magnification counterstained with eosin A1+A2(J) 20x magnification stained with 
!-galactosidase antibody (brown staining). Purple arrows point to brown cells positive for !-
galactosidase antibody staining indicating expression of !-galactosidase. Black arrows point to 
blue cells positive for X-gal staining indicating expression of !-galactosidase. 
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3.2.3 DMM of line 39 (ColII4xA1Cre transgenics) 
 
DMM was peformed on 5 transgenic mice from line 39 and one wild-type littermate (control) 
based on the described method in Methods sections 8.1 & 8.1.2. Knees were then analysed 
based on the described method in Methods section 7.2.2.2.  Figure 41A shows bioluminescent 
images of a representative colII4xA1 mouse before surgery (week 0) and 1,2,3,4 and 8 weeks 
post-operatively. The luminescence emmited by the knees of each mouse was visualized as 
an orange pseudo-colour and so the luciferase/ColII4xA1Cre promoter activity was measured 
by collecting pseudo-colour intensity values for a defined region of interest (ROI) occupying the 
whole knee (identified with corresponding X-ray images). This was done for all 5 mice and the 
mean pseudo-colour intensity values for the left and right knees for each week were 
calculated. A comparison of the mean pseudo-colour (reflecting luciferase/promoter activity) 
between the right operated knees (RK) and the contralateral left unoperated knees (LK) before 
surgery (0 weeks) and at 1,2,3,4 and 8 weeks post surgery was performed by subtracting the 
pseudo-colour intensity values of the left unoperated knees from the right operated knees (RK-
LK) (Figure 41B).  The mean pseudo-colour values (reflecting luciferase/promoter activity) of 
other cartilaginous tissues including the left ankles (LA), the left footpads (LF) and the left tibias 
(LTb) at 0 weeks (before surgery) and at 1,2,3,4 and 8 weeks were also collected alongside 
the left knee values and are depicted in the graph in Figure 41C. The same is shown for the 
right side in the graph in Figure 41D. The graphs in Figure 41C+D show that while the mean 
pseudo-colour values of the left and right ankles, footpad and tibias vary from week to week, 
this is most probably due to experimental limitations as opposed to differences in promoter 
activity since the pattern of variation from week to week is extremely similar for all these 
examines regions. However, for the right knees but more so for the left knees, the pattern of 
mean pseudo-colour value variation from week to week is different to that of all the other 
examined regions indicating that this is most likely due to variations in promoter activity as 
opposed to experimental limitations.   
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Before surgery and at 1 week post surgery, the pseudo-colour intensity/luciferase activity in the 
left unoperated knees was higher than the right operated knees (negative values in Figure 
41B). At these timepoints, the right operated knees showed no activation or repression of the 
promoter since the mean pseudo-colour intensity values were similar to those of the right 
ankles, tibias and footpads. However, the pseudo-colour intensity values of the left unoperated 
knees were lower than the average pseudo-colour intensity values of the left ankles, footpads 
and tibias. Around 2-3 weeks post-surgery, the difference in mean pseudo-colour intensity 
values between the right operated knees and left unoperated knees (RK-LK) were positive 
(Figure 41B). This was due to a repression in promoter/luciferase activity in the left unoperated 
knees as opposed to an increase in promoter activity in the right operated knees. At 4 weeks, 
the promoter activity of the left unoperated knees increased and the difference in mean 
pseudo-colour activity between right and left knees (RK-LK) became negative again (Figure 
41B). Up until this point, the differences in luciferase activity between the right operated knees 
and left unoperated knees was due mostly to variations in promoter activity in the left 
unoperated knees. At 8 weeks however, the luciferase/promoter activity in both the left and 
right knees was activated compared to all other regions examined and there was no difference 
in pseudo-colour intensity/luciferase activity between them. The wild-type littermate showed no 
orange pseudo-colour/luciferase activity at any time point. 
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Figure 42: Results of bioluminescence imaging of luciferase activity in adult transgenic 
mice from the ColII4xA1Cre transgenic line before and after DMM surgery A) Dorsal 
images from a representative adult transgenic mouse before surgery (week 0) and 1,2,3,4 and 
8 weeks after DMM showing luminescence/luciferase activity in cartilaginous areas including 
the knees (orange pseudo-colour). B) Graph depicting the difference in mean measured 
pseudo-colour intensity (luciferase activity) ±s.d between DMM right operated knees (RK) and 
contralateral left unoperated knees (LK) at several timepoints. C) Graph depicting the mean 
measured pseudo-colour intensity (luciferase activity) ±s.d of the left knees (LK), left ankles 
(LA), left footpads (LF) and left Tibias (LTb) at several timepoints. D) Graph depicting the mean 
measured pseudo-colour intensity (luciferase activity) ±s.d of the right operated knees (RK), 
right ankles (RA), right footpads (RF) and right tibias (RTb) at several timepoints. Luciferase 
activity was measured for a set region of interest (ROI) on both the left and right knees, ankles, 
footpads and tibias by retrieving pseudo-colour intensity values (arbitrary units). 5 mice were 
used for weeks 0-4 and 3 mice were used for week 8. 
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3.3 Discussion  
 
 
The pathophysiology of OA can be further elucidated by murine OA models as several of the 
biochemical features observed in murine OA models, such as matrix proteoglycan depletion by 
extracellular proteinases, are similar to changes found in human OA cartilage. In this chapter, I 
used two of these models to elucidate the response that the regulatory fragments in the 
‘!AGG20’ and ‘ColII4xA1Cre’ transgenic lines 12 and 39 respectively have when subjected to 
injury. I did this since both regulatory regions in theory drive an ‘aggrecan type’ expression and 
aggrecan is one of the major components of cartilage whose degradation/dysregulation is 
indicative of cartilage extracellular matrix destruction!" 
 
3.3.1 Transgene regulation in !AGG20 transgenics after DMM 
Previous studies on aggrecan gene expression levels from OA joints have been quite varied 
possibly due to the differences in stages and grades of OA at which point these levels were 
analysed. For our purposes, we used both the ‘axial loading of mouse tibias’ model and the 
‘DMM surgery’ model to induce OA in mouse knees from line 12.  
 
The DMM model was selected, as it is an established and reliable technique in the institute.  It 
is well known that this particular model of cartilage degradation is characterized by initial 
aggrecan depletion of intact cartilage followed by fibrillation, clefting and subsequent loss of 
cartilage down to the tidemark. This depletion is due to the increased activity of several 
proteinases, in particular the aggrecanase ADAMTS5 (Glasson et al., 2005).  Since the 
transgenic product driven by the !AGG20 fragment in line 12 is the !-galactosidase protein as 
opposed to the aggrecan protein and hence not degraded by aggrecanases, it is possible to 
hypothesise that the differing levels of !-galactosidase protein in the chondrocytes is a 
reflection of the varied regulation of the transgene at a transcriptional rather than post-
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translational level.  Unfortunately, it is not possible to assume that the level of !-galactosidase 
protein within a chondrocyte corresponds to the level of !-galactosidase mRNA within that 
chondrocyte at a particular timepoint. This is due to the relative high stability of the !-
galactosidase protein. One group showed that !-galactosidase activity decays with a half-life of 
approximately 13 hours (Jacobsen and Willumsen, 1995) while another estimated a maximum 
half life of 24-48 hours (Smith et al., 1995). 
 
DMM was performed on 8 week old line 12 mice and the operated as well as control 
contralateral knee analysed 4 and 8 weeks post-operatively. In the 4 week post-operative 
group, several points could be made: a) in the whole mount X-gal stained knees, blue staining 
was only found macroscopically in the medial injured side of the operated knee; b) the 
expression of the transgene was significantly higher in the medial and lateral tibial growth 
plates of the operated knee when compared to the same compartments within the contralateral 
non-operated knee; c) the expression of the transgene was higher in the medial and lateral 
articular cartilage of the operated knee when compared to the the entire articular cartilage of 
the contralateral non-operated knee, both of which had similar levels of expression ; d) the 
overall transgene expression in the articular cartilage and the tibial growth plates of the 
contralateral non-operated knee was higher than that in the naïve (pre-operative) knee (Figure 
32). In the 8 week post-operative group however, the other points to be made are:  a) in the 
whole mount X-gal stained knees, there was no blue staining to be found macroscopically in 
the operated or contralateral knee; b) the overall expression of the transgene decreased in the 
lateral and medial tibial growth plates of the operated knee compared to its expression in these 
compartments in the 4 week post-operative knee; c) the overall expression of the transgene 
decreased in the articular cartilage of the operated knee compared to its expression in the 4 
week post-operative knee but was still higher than the expression in the contralateral knee; d) 
the level of transgene expression in all compartments of the contralateral knee remain at a 
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similar level to the level of expression within the corresponding compartments of the 
contralateral knee in the 4 week post-operative group.  
 
The various studies that have focused on the analysis of gene expression in OA versus control 
articular cartilage somewhat support the results discussed above. The increase in transgene 
expression seen in the articular cartilage of the operated knee in comparison with the 
contralateral unoperated knee at 4 weeks  has also been demonstrated in a canine model of 
osteoarthritis. In this particular study by Matyas et al, northern blot analysis revealed that 
expression of aggrecan in canines was 2 times higher in the articular cartilage of the knees/OA 
joints produced by anterior cruciate ligament transaction compared to the unoperated 
contralateral knee joints. The operated knee joints were analysed 10 weeks after surgery, 
which in dogs, corresponds to early experimental OA.  The group suggested that while both 
the aggrecan mRNA and type II collagen mRNA are elevated (8 fold for type II collagen), the 
disproportionate levels of synthesis of both mRNAs in this early phase of OA in this animal 
model is a metabolic characteristic of early OA that may contribute to its pathogenesis (Matyas 
et al., 1995). An additional gene expression analysis was performed by Annika Burleigh at the 
KIR (PhD student) in which the mRNA levels within the articular cartilage of surgically induced 
mouse knees (by DMM) were compared with that of naive, sham and contralateral non-
operated knees. It was shown that aggrecan is down regulated initially post DMM surgery 
(6hrs-7days) however by two weeks it was upregulated 1.8 fold above naive and sham limbs.  
This rose to 12.84 fold at 4wks (personal commmunication).  
 
The upregulation of LacZ expression in the articular cartilage of the operated line 12 knees 
was localised to the medial compartment, which corresponds to the site of injury (more lesions 
and signs of deterioration at the medial side of the joint).  Also, it was clear when analysing 
operated joints from different mice that the upregulation of the transgene was much less 
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marked in operated joints that had lower scores.  It is possible therefore that the increase in 
!AGG20 promoter activity is proportional to the amount of damage found within the articular 
cartilage at this particular timepoint.    
 
The expression of the transgene was also significantly higher in the medial and lateral tibial 
growth plates of the operated knee when compared to the same compartments within the 
contralateral non-operated knee. This was true for the whole depth of the growth plate but the 
most intense blue staining was found in the deeper zones containing the hypertrophic 
chondrocytes. As with the expression of the transgene in articular cartilage, the level of LacZ 
expression in the tibial growth plate was also proportionate to the amount of damage found 
within the joint at this time point. These growth plate results challenge the notion that 
abnormalities in the growth plate are not related to nor have a role in the development of OA. 
This notion was proposed by Chambers et al who showed via insitu hybridization that both 
CBA and STR/ort mice (spontaneously develop OA) had similar patterns of expression of 
aggrecan in the growth plate (Chambers et al., 2002). This difference could be due to the fact 
that the STR/ort mice have different mechanisms by which they develop OA than mice that 
have undergone surgery or axial loading.  
 
The decrease in the expression of the transgene in the articular cartilage of the operated knee 
at 8 weeks, compared to its expression in the articular cartilage at 4 weeks post-operatively 
also corresponds to some recent studies performed by Brew et al (2010). These experiments 
focused on the gene expression in the knees of patients with OA that had undergone knee 
replacements (aged 60-84), which was analysed by quantifying the RNA extracted from the 
articular cartilage of these knees by PCR. The expression of aggrecan was reduced in OA 
cartilage in comparison with control tissue (4 fourfold lower) and interestingly the expression of 
Sox9, the well-known transcriptional regulator of aggrecan, was even more greatly reduced in 
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OA cartilage in comparison with control tissue (38-fold lower). Both genes were downregulated 
at the intact as well as the damaged sites within the articular cartilage. The gene expression 
profiles at both the damaged and intact sites of cartilage on an OA joint were similar to each 
other and significantly different from those of age-matched controls (Brew et al.). 
 
 It is important to note that, unlike the gene expression analysis performed by Matyas et al 
which focused on early experimental OA, the analysis performed by Brew et al (2010) provides 
an assessment of gene expression in cartilage late in the OA process at joint replacement. The 
differences in gene expression at both experimental OA timepoints may thus reflect a pattern 
of failed remodelling of the joint, which at the late stage shows abnormal matrix production 
(aggrecan), and potentially enhanced matrix turnover.  The pattern of LacZ staining in the 
operated knee shows that its expression is elevated initially at 4 weeks, when the joint has 
mild-moderate OA (early experimental OA), and suppressed at the later 8-week timepoint, 
when the joint develops a more moderate phenotype. This moderate phenotype has not 
reached a stage that is late in the OA process but is obviously more developed than the mild-
moderate OA present in the operated knees of the 4-week timepoint. This is probably why the 
expression of the transgene is reduced but has not reached below the control contralateral 
knee as is true for the Brew et al (2010) study.  The expression of aggrecan may change 
during progression of OA from initial enhancement, to later suppression. 
 
At the 8-week timepoint, there is also a decrease in the protein levels within the medial and 
lateral condensed tibial growth plate, in which it is more difficult to assign cells to different 
zones, when comparing it to the transgene expression in the tibial growth plate at 4 weeks 
post-operatively. This reflects the dysregulation of transgene expression that occurs within the 
articular cartilage between the two timepoints and further supports the idea that the growth 
plate may play a role in the development of OA. 
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Another important point to make is that the overall transgene expression in the articular 
cartilage and the tibial growth plates of the contralateral non-operated knee was slightly higher 
than that in the naïve knee. This was also shown by A Burleigh (KIR), who found that although 
no significant difference was found in the sham limb compared to naive, some up regulation 
was also seen in the contralateral non-operated limb.  Aggrecan was 8.59 fold above naive in 
the contralateral limb 4 weeks post DMM (unpublished data).  This is possibly due to the fact 
that the contralateral limb revealed very low levels of OA (grade 1, stage 1). 
 
All operated knees from the 4-week post-operative group showed very similar X-gal staining 
patterns, as was also the case for the knees from the 8-week post-operative group.  This was 
also true for the control contralateral knees of both groups. 
3.3.2 Transgene regulation in !AGG20 transgenic after Axial Loading 
 
The ‘axial loading of mice tibia’ model was selected as it involves simple and non-invasive in 
vivo repetitions of loads on mice tibial plateaus on alternate days for 2 weeks that eventually 
lead to the development of lesions within the articular cartilage of the loaded joint. This 
particular model is characterized by significant load magnitude-related increases in cortical 
bone formation. Also, Micro-CT scans show that loading significantly increases trabecular bone 
volume in 8 week old mice, but modifies trabecular organization with decreases in trabecular 
bone volume in 12 and 20 week old mice (De Souza et al., 2005).  The axial loading was 
performed on 8-week-old mice and the loaded as well as control contralateral knee analysed 
after the final loading 2 weeks later. The loaded and contralateral knee sections were also 
stained with the !-galactosidase antibody.  
 
At first glance, when looking at the eosin counterstained sections, it appears that, like the 
naïve knee, there is no !-galactosidase activity (no blue staining) within the articular 
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chondrocytes in either the lateral or medial compartments of the loaded and contralateral 
unloaded knee. However, staining with the !-galactosidase antibody actually revealed that a 
significant proportion of the articular chondrocytes down to the tidemark stained positive.  LacZ 
reporter gene detection by antibody staining of the !-galactosidase protein is a much more 
sensitive way of detection than an enzymatic assay using the X-gal substrate. This is because 
the amount of !-galactosidase protein present within each cell must reach a certain threshold 
before it can efficiently process the substrate. However, antibody staining can detect minute 
quantities of the protein.  Nevertheless, the medial and lateral articular cartilages in both 
loaded versus control knees revealed no visible quantitative difference in !-galactosidase 
antibody staining.  
 
This model is an early model of OA and as such is better compared to the DMM model at the 
earlier timepoint of 4 weeks post-operatively.  It is interesting that the more invasive DMM 
model, which caused a lot more damage to the articular cartilage, led to higher reporter gene 
expression in operated knees overall. It is possible to make this comparison as the !-
galactosidase protein was detected in the DMM operated knees by the less sensitive detection 
method of an enzymatic assay. Even the articular chondrocytes of the contralateral knees, 
which also have some blue staining, seem to have a higher expression of LacZ when 
compared to the loaded knees and their controls. This is possibly due to the fact that they have 
developing OA as well that may be slightly more advanced than the loaded knee. This further 
supports the notion that more deteriorated articular cartilage in eary experimental OA is 
associated with higher levels of reporter gene expression.  
 
In the same way that the expression of the transgene was higher in the medial and lateral tibial 
growth plates of the DMM operated knee compared to the control non-operated knee, there 
was also an increase in transgene expression in the medial and lateral growth plates of the 
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loaded knee versus the control knee as indicated by the blue staining and !-galactosidase 
antibody staining. This was true for the whole depth of the growth plate but the darkest blue 
stained and antibody stained cells were found in the deep zone containing the hypertrophic 
cells. Although there was a clear difference in the expression of the transgene between the 
loaded growth plate and the contralateral unloaded growth plate, the overall expression in 
either knee was lower than the 4 and 8 week postoperative DMM operated knee and 
contralateral knee since fewer chondrocytes were stained. The activity of the !AGG20 
promoter could be a function of the length of time that the knee was loaded and the extent of 
the loading itself. The DMM operated knees have the most developed signs of OA as the 
instability caused by severing the medial meniscus leads to increased loading on the joint. The 
contralateral knee to the DMM operated knee has increased loading, as the mouse must rely 
more on it for movement. Also the DMM operated and contralateral knees were analysed 4 
and 8 weeks post-operatively. In contrast to this, the axial loaded knee was loaded a total of 6 
times for 2 weeks only. The loading must be less invasive as is demonstrated by the extent of 
damage found within the articular cartilage. The transgene expression pattern in the 
contralateral unloaded knee bears the closest similarity to the naïve knee. The hypothesis that 
the response of the !AGG20 promoter, which in theory should mimic the activity of the 
aggrecan promoter, in the chondrocytes of the growth plate is related to the loading of the 
knees is further supported by the fact that STR/ort mice, which develop OA by a completely 
different mechanism that is not related to loading and more a result of genetics, had similar 
patterns of expression of aggrecan in the growth plate (Chambers et al., 2002). The increased 
expression of aggrecan in the growth plate may have a protective role as it is unusual that the 
axial loading model only leads to lesions in the lateral femoral articular cartilage and not the 
lateral tibial articular cartilage. It is possible that as OA develops, the growth plate becomes 
less protective due to suppression in aggrecan gene activity.  
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On a final note, the response that the !AGG20 transgene has to the induction of injury in 
transgenic mice could be due to particular sites found within the 3’ end of cis 5. The expression 
of aggrecan can be modulated by mechanical forces, cytokines, and other serum factors. 
There are two NF-kB sites in the promoter that may confer responsiveness to cytokines. This 
is suggested by the overlapping NF-kB and STAT binding sites at!+362 - +375bp relative to 
the aggrecan TSS and the fact that NF-kB is often activated by cytokines such as tumor 
necrosis factor. There are also four SSREs (one in the promoter and three in the 5’UTR within 
cis 5), which are potential sites for regulating aggrecan gene expression by shear stresses.  
 
All the loaded knees showed very similar X-gal staining as well as !-galactosidase antibody 
staining patterns.  This was also true for the control contralateral unloaded knees. 
 
3.3.3 DMM of line 39 (ColII4xA1Cre transgenics) 
DMM was performed on 5 8-week-old line 39 mice and the operated as well as control 
contralateral knees analysed by whole-mount bioluminescence imaging before surgery (week 
0) and at 1,2,3,4 and 8 weeks post-operatively. The purpose of this study was to establish 
whether this promoter remains active and able to deliver Cre recombinase gene expression 
after the induction of OA and whether it is upregulated or downregulated within the injured 
cartilage of the right operated knee compared with the contralateral left unoperated knee. The 
luminescence emmited by the knees of each mouse was visualized as an orange pseudo-
colour and so the luciferase/ColII4xA1Cre promoter activity was measured by collecting 
pseudo-colour intensity values for a defined region of interest (ROI) occupying the whole knee. 
The comparison between the ColII4xA1Cre promoter activity in the cartilages of the right and 
left knees at each timepoint was done by subtracting the mean pseudo-colour intensity values 
of the left unoperated knees from the right operated knees (Figure 41B). A value of 0 would 
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indicate no difference in promoter activity between both knees. A positive value would either 
indicate higher promoter activity in the right operated knees compared with the left unoperated 
knees or lower promoter activity in the left unoperated knees compared to the right operated 
knees. A negative value, on the other hand, would either indicate higher promoter activity in 
the left unoperated knees compared with the right operated knees or lower promoter activity in 
the right operated knee compared with the left unoperated knee. In order to verify the cause of 
the differences in mean pseudo-colour intensity values/promoter activity between the 
contralateral knees, the mean pseudo-colour values (reflecting luciferase/promoter activity) of 
the left and right ankles, footpads and tibias were also collected (Figure 41C+D). This was 
achievable since the variations in mean pseudo-colour values across these regions from week 
to week followed a similar pattern indicating that these variations were due to experimental 
limitations such as the luciferin substrate on the day, the time it takes for the mice to be 
anaesthetised and any slight changes in the weight of the mice.  
 
Interestingly, it was the left unoperated knees as opposed to the right operated knees that 
showed variation in promoter activity until 4 weeks post surgery. The activity of the promoter 
increased slightly 1 week post surgery but then decreased 2-3 weeks post surgery.  The initial 
increase was probably due to the mouse using its left unoperated knee more due to the injury 
in the right operated knee. By 8 weeks, however, the promoter activity in both the left 
unoperated knees and right operated knees had risen by a similar amount. This somewhat 
mimics the DMM study performed on the !AGG20 transgenics in that the activity of the 
promoter in both the right operated knees and the left unoperated knees was higher at 8 
weeks compared with the naïve knee. However, in the case of the !AGG20 transgenics, there 
was a difference in promoter activity between the two contralateral knees (promoter activity 
was higher in the right operated knees) and unlike the ColII4xA1Cre transgenics, the overall 
promoter activity in the operated knees was lower at 8 weeks compared to 4 weeks post 
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surgery. Using the ColII4xA1Cre promoter would be potentially useful for delivery of Cre 
recombinase to the joint since its activity is not reduced in the early stages of experimental OA. 
Instead, it is upregulated by early-middle stages of OA development.   
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Conclusions 
 
Using mouse transgenic experiments, an approximately 20kb sequence (between -20,054bp 
and +375bp relative to the aggrecan transcriptional start site including a deleted 92 base pair 
sequence between -62bp and +25bp) was demonstrated to have chondrocyte specific 
regulatory activities in vivo. The regulatory activity of this sequence begins at E13.5 (Figure 
30.1D) where reporter gene expression can be found in the developing cartilages of the long 
bones of the hind and forelimbs. At E14.5, this sequence can drive reporter gene expression in 
the developing cartilage of the long bones of the fore and hind limbs, the ribs, the scapulae, 
the digits and some craniofacial cartilages (meckel’s cartilage) but this does not extend to the 
vertebral cartilage (gene expression is expected at this stage of development) (Figure 17 and 
Figure 30.1A&B).  At E16.5, the "20kb sequence can drive gene expression in all the 
anatomical regions mentioned above but with a much higher intensity. Also, the gene 
expression at this stage of development extends to include more facial cartilages such as the 
nasal cartilage, the cartilage of the ear and the cartilage of the eye socket as well as the 
vertebral bodies and intervertebral disc. However, there is no expression in the 
chondrocranium, which is expected at this stage of development (Figure 19). Furthermore, the 
promoter activity of this "20kb sequence is extremely weak in the adult transgenic line 
harbouring this DNA sequence and is limited to the intervertebral discs and growth plate of the 
tail and a few randomly scattered chondrocytes in other cartilaginous structures of the hip and 
the knee (Figure 30.2 and 31). 
 
Progressive deletions to this "20kb sequence have enabled us to hypothesise the roles of 
different potential cis-regulatory elements that were selected due to the assumption that 
regulatory elements lie within sequences that have high evolutionary identity across species. 
The minimal promoter/cis 5, which corresponds to the sequence from -452bp to +375bp 
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relative to the start site, seems to be inactive on its own in vivo. Cis 3 (-10.9 to -10.2kb), which 
corresponds to the mouse enhancer sequence A1 identified by Han and Lefebvre during the 
course of this study (Han and Lefebvre, 2008), has been shown to have 3 binding sites for L-
sox5/sox6 dimers and one binding site for a sox9 dimer. These transcriptional activators may 
recruit different coactivators such as HATs to drive transcription of aggrecan. We hypothesise 
that cis 4 (-3.8 to -3.7kb) could be a silencer element with a binding site(s) for repressors that 
can recruit corepressors such as HDACs and HMTs in order to inhibit the transcription of 
aggrecan. We also hypothesise that cis 1 and/or 2 (-20 to -19.7kb and -14.5 to -14.4kb 
respectively), have binding sites for transcriptional activators that can potentially recruit tissue-
specific cofactors that function alongside the positive cofactors recruited by cis 3 to counteract 
the transcriptional inhibition caused by cis 4. We also investigated the role of cis 6, a 3kb 
sequence present within the first intron of the gene (+5kb to +8kb). When fused downstream of 
the "20kb sequence, it downregulated the activity of the overall promoter. It could possibly be 
a silencer element that inhibits the transcription of the gene. See Figure 43 for proposed roles 
of cis 1-6. 
 
 Figure 43: Proposed action of ‘cis-regulatory elements’ cis  1-6. Green boxes represent 
potential enhancer elements while the red boxes represent potential silencer elements. The 
white box represents the basal promoter. The ‘cis-regulatory elements’ with question marks are 
those that are still speculative. 
 
The absent 92 base pair sequence within the "20kb sequence described above contains an 
overlapping SP-1/AP-2 binding site that potentially recruits general positive cofactors to aid in 
the assembly of the preinitiation complex. It is possible that positve cofactors recruited by cis 1 
and/or 2 may compensate for the deleted 92 base pair sequence. Nevertheless, the presence 
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of this 92 base pair sequence may be essential to drive full endogenous expression of 
aggrecan within humans. It is possible that all the positive cofactors that are potentially 
recruited via the transcription factors that bind to putative binding sites within cis 1 and/or 2, cis 
3 and the minimal promoter (including the deleted 92 base pair sequence) are necessary to 
confer full endogenous aggrecan expression and counteract the negative regulatory effects of 
repressors and corepressors. Figure 44 shows a schematic diagram of the hypothesised 
regulation of the human aggrecan gene based on data presented in this thesis.  
 
The full endogenous pattern of expression in embryos/adults harbouring the "20kb sequence  
including the deleted 92 base pair sequence may require the presence of the missing 92 base 
pair sequence and/or the additional presence of other potential cis-regulatory sequences such 
as insulator elements. The major difference in the embryonic and adult expression pattern 
driven by this sequence is either due to the inactivation of the promoter in the adult transgenic 
mouse line due to epigenetic modifications or possibly a difference in regulation of the 
aggrecan gene developmentally and post-natally. It is likely that the missing 92 base pairs are 
crucial for adult-specific regulation of the gene.  
 
I also conclude that the conditional/inducible cartilage-specific transgenic mouse that was 
created using the cartilage specific promoter ColII4xA1 from Han and Lefebvre (2008) fused to 
the CreERT2 gene has proved to be functional, tissue specific (Cre recombinase only present in 
chondrocytes) and not leaky (no Cre recombinase activity prior to induction with tamoxifen) at 
post-natal ages P7 and P14.   
 
Finally, the "20kb promoter discussed in the transgenic line that was created is activated in 
knee articular chondrocytes as well as tibial growth plate chondrocytes with the induction of OA 
in the knee through different models of injury (DMM and axial loading of the mouse tibias). This 
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activation seems to be proportionate to the extent of tissue damage in these knees. The 
response of the ColII4xA1 promoter in chondrocytes of mouse knees to OA induction through 
DMM, however, is somewhat different. This promoter is less responsive to injury and its activity 
does not seem to be proportionate to the extent of tissue damage and cartilage loss in mouse 
knees. It is possible that, unlike the ColII4xA1 promoter containing only cis 3 and the mouse 
aggrecan minimal promoter, the "20kb promoter reacts more to OA due to it containing other 
cis-regulatory elements such as cis 1 and/or 2 that could possibly be more responsive to 
cellular signalling cascades brought on by injury. 
 
 
Figure 44: Schematic of hypothesised human aggrecan gene regulation. The ultimate 
purpose of DNA-binding activators is to mediate Pol II recruitment and function. In this case, 
Pol II along with the preinitiation complex is recruited and bound to cis 5/the minimal promoter. 
Cis 3 has 3 known binding sites for L-sox5/sox6 dimers (dark green) and one binding site for a 
sox9 dimer (turqoise). The effects of the L-sox6/sox5 and sox9 activators on Pol II are 
hypothetically indirect and may involve several interactions with diverse cofactors that modify 
chromatin structure and ease the recruitment of Pol II and general initiation factors (ATP-
dependent factors, HATs shown in orange). Cis 4 may contain binding sites for repressor(s) 
that can recruit negative cofactors (HMTs and HDACs shown in indigo) that also modify 
chromatin structure to inhibit the initiation of transcription. Cis 1 and/or 2 may contain binding 
sites for activator(s) that can recruit cofactors that act at the level of DNA (shaded blue) such 
as cell specific factors (X). Cis 5/ minimal promoter may also recruit general positive cofactors 
such as PC3 and PC4 via positive activators. The absent 92 base pairs in the "20kb sequence 
may have binding sites for such activators.  
 
PhD Thesis                                                                                                                          Andrea Layyous     
  
 256 
Future Work 
 
Although the work presented here has demonstrated a role for the "20kb sequence in human 
aggrecan gene regulation, the reporter gene expression driven by this promoter sequence did 
not exactly match the endogenous pattern of aggrecan gene expression embryonically and 
post-natally. Since a possibly crucial 92 base pair sequence present endogenously within the 
minimal promoter of the gene is absent in the investigated "20kb sequence, it will be extremely 
important to investigate its activity in context of the entire 20kb sequence. To do this, 
transgenic embryos harbouring the "20kb sequence including the 92 base pair sequence will 
be created as well as transgenic lines to monitor the expression driven by the complete 
sequence post-natally. Also, in order to establish whether the reduced post-natal expression 
driven by the "20kb sequence lacking the 92 base pair sequence in transgenic line 12 is due to 
the absence of the 92 base pairs as opposed to a positional artefact caused by the location of 
the promoter within the genome, more transgenic lines containing this sequence will be 
created and compared to the transgenic lines containing the "20kb sequence that includes the 
92 base pair sequence.  If the results of these experiments show a role for the 92 base pair 
sequence, it will be important to establish the trans-acting factors that bind to this sequence 
(potentially SP-1/AP-2) via EMSA studies (common affinity electrophoresis technique used to 
study protein-DNA interactions) and verify whether these transacting factors interact with any 
of the sox proteins that bind to the enhancer sequence cis 3. This could be done using ChIP 
analysis (method that gives a picture of the protein-DNA interactions that occur inside the 
nucleus of livings cells).   
 
Also, the hypothesized activities of cis 1,2 and 4 will be verified further by creating more 
combinations of these different potential cis-regulatory elements alongside cis 3 and the 
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minimal promoter and investigating their effect on overall reporter gene activity in transgenic 
embryos.  
 
Furthermore, in order to investigate the efficiency of line 39 containing ColII4xA1Cre in a 
quantitative manner, the line will be crossed to Rosa26 !-galactosidase reporter mice as 
opposed to the global fluorescence reporter mouse used. The visualisation of the membrane 
targetted mT and mG polypeptides in the cartilage of knees requires them to be frozen and 
eventually cut without decalcification. This can lead to the fragmentation of sections. However, 
the visualisation of !-galactosidase in knees does not require them to be frozen and they can 
be decalcified, paraffin embedded and cut into high quality knee sections.  The Cre 
recombinase will eventually be activated in the progeny by injection with tamoxifen at 1,3 and 6 
months of age. The activity of the promoter at these different ages will be monitered as well as 
the efficiency of recombination (can be measured by counting X-gal positive stained cells).  
 
If the results of the above experiments show significant chondrocyte-specific conversion into X-
gal positive stained cells in the cartilages of mice at all the ages inspected with no leakiness, 
line 39 will be crossed with a number of different floxed transgenic mice. It can be mated to 
mice in which a particular gene of interest is floxed (loss of function) or in which a stop 
sequence inhibiting the transcription of a gene is floxed (gain of function). For example, it can 
be mated to a transgenic mouse in which Timp3 or FGF-2 are floxed. DMM will eventually be 
performed on the knees of the F1 progeny. Tamoxifen can be given to these mice directly 
before or even after the onset of OA.  
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